{"text": "Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib ( MLN9708 ) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant .", "paragraph": "<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>Ib</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Oral</i></b> <b style='color:DodgerBlue;'><i>Proteasome</i></b> <b style='color:DodgerBlue;'><i>Inhibitor</i></b> <b style='color:MediumOrchid;'><i>Ixazomib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MLN9708</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Advanced</i></b> <b style='color:DodgerBlue;'><i>ER+</i></b> <b style='color:DodgerBlue;'><i>Breast</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>Progressing</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### background <b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### methods This is a single-center phase Ib study with a 3+3 design of <b style='color:Tomato;'><i>fulvestrant</i></b> and the proteasome inhibitor <b style='color:Tomato;'><i>ixazomib</i></b> (MLN9708) in patients with advanced ER+ breast cancer that was progressing on <b style='color:Tomato;'><i>fulvestrant</i></b>. A dose-escalation design allowed establishment of the <b style='color:Tomato;'><i>ixazomib</i></b> maximum tolerated dose (MTD). Secondary objectives included progression-free survival, pharmacokinetics, and tumor molecular analyses. ### results Among nine evaluable subjects, treatment was well-tolerated without dose-limiting toxicities The MTD of <b style='color:Tomato;'><i>ixazomib</i></b> was 4 mg in combination with <b style='color:Tomato;'><i>fulvestrant</i></b>. Plasma concentrations of the active form of <b style='color:Tomato;'><i>ixazomib</i></b> (MLN2238) in the 4-mg dose cohort had a median (range) Cmax of 155 (122-171) ng/mL; Tmax of 1 (1-1.5) h; terminal elimination half-life of 66.6 (57.3-102.6) hr after initial dose; AUC of 5,025 (4,160-5,345) ng*h/mL. One partial response was observed, and median progression-free survival was 51\u2009days (range 47-137). ### conclusion This drug combination has a favorable safety profile and anti-tumor activity in patients with <b style='color:Tomato;'><i>fulvestrant</i></b>-resistant advanced ER+ breast cancer that justifies future testing.", "tokens": [{"text": "Phase", "start": 0, "end": 5, "id": 0, "ws": true}, {"text": "Ib", "start": 6, "end": 8, "id": 1, "ws": true}, {"text": "Study", "start": 9, "end": 14, "id": 2, "ws": true}, {"text": "of", "start": 15, "end": 17, "id": 3, "ws": true}, {"text": "the", "start": 18, "end": 21, "id": 4, "ws": true}, {"text": "Oral", "start": 22, "end": 26, "id": 5, "ws": true}, {"text": "Proteasome", "start": 27, "end": 37, "id": 6, "ws": true}, {"text": "Inhibitor", "start": 38, "end": 47, "id": 7, "ws": true}, {"text": "Ixazomib", "start": 48, "end": 56, "id": 8, "ws": true}, {"text": "(", "start": 57, "end": 58, "id": 9, "ws": true}, {"text": "MLN9708", "start": 59, "end": 66, "id": 10, "ws": true}, {"text": ")", "start": 67, "end": 68, "id": 11, "ws": true}, {"text": "and", "start": 69, "end": 72, "id": 12, "ws": true}, {"text": "Fulvestrant", "start": 73, "end": 84, "id": 13, "ws": true}, {"text": "in", "start": 85, "end": 87, "id": 14, "ws": true}, {"text": "Advanced", "start": 88, "end": 96, "id": 15, "ws": true}, {"text": "ER+", "start": 97, "end": 100, "id": 16, "ws": true}, {"text": "Breast", "start": 101, "end": 107, "id": 17, "ws": true}, {"text": "Cancer", "start": 108, "end": 114, "id": 18, "ws": true}, {"text": "Progressing", "start": 115, "end": 126, "id": 19, "ws": true}, {"text": "on", "start": 127, "end": 129, "id": 20, "ws": true}, {"text": "Fulvestrant", "start": 130, "end": 141, "id": 21, "ws": true}, {"text": ".", "start": 142, "end": 143, "id": 22, "ws": false}], "spans": [{"start": 48, "end": 56, "token_start": 8, "token_end": 8, "label": "DRUG"}, {"start": 73, "end": 84, "token_start": 13, "token_end": 13, "label": "DRUG"}, {"start": 130, "end": 141, "token_start": 21, "token_end": 21, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/33641211/", "_input_hash": -1014334224, "_task_hash": 1740062343, "_session_id": "drug_drug_pilot_shared2b-hagit", "_view_id": "blocks", "relations": [{"head": 8, "child": 13, "head_span": {"start": 48, "end": 56, "token_start": 8, "token_end": 8, "label": "DRUG"}, "child_span": {"start": 73, "end": 84, "token_start": 13, "token_end": 13, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Pharmacokinetic studies showed that chronic lymphocytic leukemia involving more than 80 % of the bone marrow at study start was associated with lower trough concentrations of alemtuzumab and rituximab , and that higher trough serum concentrations of alemtuzumab were associated with complete bone marrow clearance .", "paragraph": "<h3><u>A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.</u></h3>This study assessed the safety and preliminary efficacy of escalated dose subcutaneous <b style='color:Tomato;'><i>alemtuzumab</i></b> in combination with <b style='color:Tomato;'><i>rituximab</i></b> in chronic lymphocytic leukemia. Twenty-eight patients with relapsed refractory chronic lymphocytic leukemia were treated on four dosing cohorts of weekly <b style='color:Tomato;'><i>rituximab</i></b> at 375 mg/m(2) and <b style='color:Tomato;'><i>alemtuzumab</i></b> doses that started at 30 mg three times per week and escalated to weekly dosing over four weeks, culminating with 90 mg weekly. One dose limiting toxicity of a <b style='color:Tomato;'><i>rituximab</i></b> infusion reaction was seen in cohort 2, but the regimen was otherwise well tolerated without evidence of differential toxicity by cohort. The overall response rate by National Cancer Institute-Working Group criteria was 61%, and the rate of complete bone marrow response was 43%, most of whom were negative for minimal residual disease. The addition of CT scan evaluation per International Workshop on Chronic Lymphocytic Leukemia 2008 criteria reduced the overall response rate to 14%. Median overall survival was 35 months, with 12 patients able to proceed to stem cell transplantation. <b style='color:DodgerBlue;'><i>Pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>lymphocytic</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>involving</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>start</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>clearance</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We conclude that escalated subcutaneous doses of <b style='color:Tomato;'><i>alemtuzumab</i></b> given weekly are well tolerated and result in excellent bone marrow clearance of chronic lymphocytic leukemia, helping patients to proceed to stem cell transplantation. This study is registered at ClinicalTrials.gov (Identifier:00330252).", "tokens": [{"text": "Pharmacokinetic", "start": 0, "end": 15, "id": 0, "ws": true}, {"text": "studies", "start": 16, "end": 23, "id": 1, "ws": true}, {"text": "showed", "start": 24, "end": 30, "id": 2, "ws": true}, {"text": "that", "start": 31, "end": 35, "id": 3, "ws": true}, {"text": "chronic", "start": 36, "end": 43, "id": 4, "ws": true}, {"text": "lymphocytic", "start": 44, "end": 55, "id": 5, "ws": true}, {"text": "leukemia", "start": 56, "end": 64, "id": 6, "ws": true}, {"text": "involving", "start": 65, "end": 74, "id": 7, "ws": true}, {"text": "more", "start": 75, "end": 79, "id": 8, "ws": true}, {"text": "than", "start": 80, "end": 84, "id": 9, "ws": true}, {"text": "80", "start": 85, "end": 87, "id": 10, "ws": true}, {"text": "%", "start": 88, "end": 89, "id": 11, "ws": true}, {"text": "of", "start": 90, "end": 92, "id": 12, "ws": true}, {"text": "the", "start": 93, "end": 96, "id": 13, "ws": true}, {"text": "bone", "start": 97, "end": 101, "id": 14, "ws": true}, {"text": "marrow", "start": 102, "end": 108, "id": 15, "ws": true}, {"text": "at", "start": 109, "end": 111, "id": 16, "ws": true}, {"text": "study", "start": 112, "end": 117, "id": 17, "ws": true}, {"text": "start", "start": 118, "end": 123, "id": 18, "ws": true}, {"text": "was", "start": 124, "end": 127, "id": 19, "ws": true}, {"text": "associated", "start": 128, "end": 138, "id": 20, "ws": true}, {"text": "with", "start": 139, "end": 143, "id": 21, "ws": true}, {"text": "lower", "start": 144, "end": 149, "id": 22, "ws": true}, {"text": "trough", "start": 150, "end": 156, "id": 23, "ws": true}, {"text": "concentrations", "start": 157, "end": 171, "id": 24, "ws": true}, {"text": "of", "start": 172, "end": 174, "id": 25, "ws": true}, {"text": "alemtuzumab", "start": 175, "end": 186, "id": 26, "ws": true}, {"text": "and", "start": 187, "end": 190, "id": 27, "ws": true}, {"text": "rituximab", "start": 191, "end": 200, "id": 28, "ws": true}, {"text": ",", "start": 201, "end": 202, "id": 29, "ws": true}, {"text": "and", "start": 203, "end": 206, "id": 30, "ws": true}, {"text": "that", "start": 207, "end": 211, "id": 31, "ws": true}, {"text": "higher", "start": 212, "end": 218, "id": 32, "ws": true}, {"text": "trough", "start": 219, "end": 225, "id": 33, "ws": true}, {"text": "serum", "start": 226, "end": 231, "id": 34, "ws": true}, {"text": "concentrations", "start": 232, "end": 246, "id": 35, "ws": true}, {"text": "of", "start": 247, "end": 249, "id": 36, "ws": true}, {"text": "alemtuzumab", "start": 250, "end": 261, "id": 37, "ws": true}, {"text": "were", "start": 262, "end": 266, "id": 38, "ws": true}, {"text": "associated", "start": 267, "end": 277, "id": 39, "ws": true}, {"text": "with", "start": 278, "end": 282, "id": 40, "ws": true}, {"text": "complete", "start": 283, "end": 291, "id": 41, "ws": true}, {"text": "bone", "start": 292, "end": 296, "id": 42, "ws": true}, {"text": "marrow", "start": 297, "end": 303, "id": 43, "ws": true}, {"text": "clearance", "start": 304, "end": 313, "id": 44, "ws": true}, {"text": ".", "start": 314, "end": 315, "id": 45, "ws": false}], "spans": [{"start": 175, "end": 186, "token_start": 26, "token_end": 26, "label": "DRUG"}, {"start": 191, "end": 200, "token_start": 28, "token_end": 28, "label": "DRUG"}, {"start": 250, "end": 261, "token_start": 37, "token_end": 37, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/23645694/", "_input_hash": -1128840740, "_task_hash": -278706627, "_session_id": "drug_drug_pilot_shared2b-hagit", "_view_id": "blocks", "relations": [{"head": 26, "child": 28, "head_span": {"start": 175, "end": 186, "token_start": 26, "token_end": 26, "label": "DRUG"}, "child_span": {"start": 191, "end": 200, "token_start": 28, "token_end": 28, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with bevacizumab ( 5 mg/kg body weight i.v . every 21 days ) and oral capecitabine ( 950 mg/m(2 ) twice daily for 14 days followed by 7 days of rest ) in 2006 - 2008 .", "paragraph": "<h3><u>Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.</u></h3>No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended <b style='color:Tomato;'><i>mitotane</i></b> as monotherapy or combined with <b style='color:Tomato;'><i>etoposide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b> and cisplatin or with <b style='color:Tomato;'><i>streptozotocin</i></b> as first-line systemic therapy. However, there is no evidence for any therapy beneficial in patients failing these therapies. Therefore, we evaluated the effects of the anti-VEGF antibody <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> as salvage therapy in ACC. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>registered</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>German</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>Registry</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>offered</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>body</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>950</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>rest</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>2006</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2008</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Evaluation of tumour response was performed by imaging according to response evaluation criteria in solid tumours every 12 weeks. ### results Ten patients were treated with <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b>. None of them experienced any objective response or stable disease. Two patients had to stop therapy after few weeks due to hand-foot syndrome, and three patients died on progressive disease within 12 weeks. Other adverse events were mild (grade I-II). Median survival after treatment initiation was 124 days. ### conclusions <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> has no activity in patients with very advanced ACC. Hence, this regimen cannot be recommended as a salvage therapy.", "tokens": [{"text": "Patients", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "registered", "start": 9, "end": 19, "id": 1, "ws": true}, {"text": "with", "start": 20, "end": 24, "id": 2, "ws": true}, {"text": "the", "start": 25, "end": 28, "id": 3, "ws": true}, {"text": "German", "start": 29, "end": 35, "id": 4, "ws": true}, {"text": "ACC", "start": 36, "end": 39, "id": 5, "ws": true}, {"text": "Registry", "start": 40, "end": 48, "id": 6, "ws": true}, {"text": "with", "start": 49, "end": 53, "id": 7, "ws": true}, {"text": "refractory", "start": 54, "end": 64, "id": 8, "ws": true}, {"text": "ACC", "start": 65, "end": 68, "id": 9, "ws": true}, {"text": "progressing", "start": 69, "end": 80, "id": 10, "ws": true}, {"text": "after", "start": 81, "end": 86, "id": 11, "ws": true}, {"text": "cytotoxic", "start": 87, "end": 96, "id": 12, "ws": true}, {"text": "therapies", "start": 97, "end": 106, "id": 13, "ws": true}, {"text": "were", "start": 107, "end": 111, "id": 14, "ws": true}, {"text": "offered", "start": 112, "end": 119, "id": 15, "ws": true}, {"text": "treatment", "start": 120, "end": 129, "id": 16, "ws": true}, {"text": "with", "start": 130, "end": 134, "id": 17, "ws": true}, {"text": "bevacizumab", "start": 135, "end": 146, "id": 18, "ws": true}, {"text": "(", "start": 147, "end": 148, "id": 19, "ws": true}, {"text": "5", "start": 149, "end": 150, "id": 20, "ws": true}, {"text": "mg/kg", "start": 151, "end": 156, "id": 21, "ws": true}, {"text": "body", "start": 157, "end": 161, "id": 22, "ws": true}, {"text": "weight", "start": 162, "end": 168, "id": 23, "ws": true}, {"text": "i.v", "start": 169, "end": 172, "id": 24, "ws": true}, {"text": ".", "start": 173, "end": 174, "id": 25, "ws": true}, {"text": "every", "start": 175, "end": 180, "id": 26, "ws": true}, {"text": "21", "start": 181, "end": 183, "id": 27, "ws": true}, {"text": "days", "start": 184, "end": 188, "id": 28, "ws": true}, {"text": ")", "start": 189, "end": 190, "id": 29, "ws": true}, {"text": "and", "start": 191, "end": 194, "id": 30, "ws": true}, {"text": "oral", "start": 195, "end": 199, "id": 31, "ws": true}, {"text": "capecitabine", "start": 200, "end": 212, "id": 32, "ws": true}, {"text": "(", "start": 213, "end": 214, "id": 33, "ws": true}, {"text": "950", "start": 215, "end": 218, "id": 34, "ws": true}, {"text": "mg/m(2", "start": 219, "end": 225, "id": 35, "ws": true}, {"text": ")", "start": 226, "end": 227, "id": 36, "ws": true}, {"text": "twice", "start": 228, "end": 233, "id": 37, "ws": true}, {"text": "daily", "start": 234, "end": 239, "id": 38, "ws": true}, {"text": "for", "start": 240, "end": 243, "id": 39, "ws": true}, {"text": "14", "start": 244, "end": 246, "id": 40, "ws": true}, {"text": "days", "start": 247, "end": 251, "id": 41, "ws": true}, {"text": "followed", "start": 252, "end": 260, "id": 42, "ws": true}, {"text": "by", "start": 261, "end": 263, "id": 43, "ws": true}, {"text": "7", "start": 264, "end": 265, "id": 44, "ws": true}, {"text": "days", "start": 266, "end": 270, "id": 45, "ws": true}, {"text": "of", "start": 271, "end": 273, "id": 46, "ws": true}, {"text": "rest", "start": 274, "end": 278, "id": 47, "ws": true}, {"text": ")", "start": 279, "end": 280, "id": 48, "ws": true}, {"text": "in", "start": 281, "end": 283, "id": 49, "ws": true}, {"text": "2006", "start": 284, "end": 288, "id": 50, "ws": true}, {"text": "-", "start": 289, "end": 290, "id": 51, "ws": true}, {"text": "2008", "start": 291, "end": 295, "id": 52, "ws": true}, {"text": ".", "start": 296, "end": 297, "id": 53, "ws": false}], "spans": [{"start": 135, "end": 146, "token_start": 18, "token_end": 18, "label": "DRUG"}, {"start": 200, "end": 212, "token_start": 32, "token_end": 32, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/19903796/", "_input_hash": 1011764762, "_task_hash": -827463686, "_session_id": "drug_drug_pilot_shared2b-hagit", "_view_id": "blocks", "relations": [{"head": 18, "child": 32, "head_span": {"start": 135, "end": 146, "token_start": 18, "token_end": 18, "label": "DRUG"}, "child_span": {"start": 200, "end": 212, "token_start": 32, "token_end": 32, "label": "DRUG"}, "color": "#c2f2f6", "label": "NEG1"}], "radio": ["NEG11"], "answer": "accept"}
{"text": "Patients who had pathologically been proven to have measurable lesions were treated with paclitaxel ( 200 mg/m(2 ) for 3 h ) and carboplatin [ area under the concentration-time curve ( AUC = 6 ) ] on day 1 and in 21 day cycles .", "paragraph": "<h3><u>Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.</u></h3>The combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> has been used to treat patients with many types of tumor, including gastric cancer. We evaluated the efficacy and safety of this combination in advanced gastric cancer patients previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>pathologically</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>proven</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>measurable</i></b> <b style='color:DodgerBlue;'><i>lesions</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results A partial response was achieved in 10 of 45 patients [22%, 95% confidence interval (CI), 10-34]. Of the 32 patients previously treated with cisplatin, four (13%) achieved partial response, whereas, of the 13 patients previously treated with heptaplatin, six (46%) achieved partial response. In all patients, the median time to progression was 14 weeks (95% CI, 10-18), and the median overall survival was 32 weeks (95% CI, 26-38). The most common grade 3/4 adverse events were neutropenia (40% of patients) and neuropathy (2.2%). Two patients developed neutropenic fever. However, there were no treatment-related deaths. ### conclusions Combination chemotherapy with <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> is feasible in patients with advanced gastric cancer who were previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum.", "tokens": [{"text": "Patients", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "who", "start": 9, "end": 12, "id": 1, "ws": true}, {"text": "had", "start": 13, "end": 16, "id": 2, "ws": true}, {"text": "pathologically", "start": 17, "end": 31, "id": 3, "ws": true}, {"text": "been", "start": 32, "end": 36, "id": 4, "ws": true}, {"text": "proven", "start": 37, "end": 43, "id": 5, "ws": true}, {"text": "to", "start": 44, "end": 46, "id": 6, "ws": true}, {"text": "have", "start": 47, "end": 51, "id": 7, "ws": true}, {"text": "measurable", "start": 52, "end": 62, "id": 8, "ws": true}, {"text": "lesions", "start": 63, "end": 70, "id": 9, "ws": true}, {"text": "were", "start": 71, "end": 75, "id": 10, "ws": true}, {"text": "treated", "start": 76, "end": 83, "id": 11, "ws": true}, {"text": "with", "start": 84, "end": 88, "id": 12, "ws": true}, {"text": "paclitaxel", "start": 89, "end": 99, "id": 13, "ws": true}, {"text": "(", "start": 100, "end": 101, "id": 14, "ws": true}, {"text": "200", "start": 102, "end": 105, "id": 15, "ws": true}, {"text": "mg/m(2", "start": 106, "end": 112, "id": 16, "ws": true}, {"text": ")", "start": 113, "end": 114, "id": 17, "ws": true}, {"text": "for", "start": 115, "end": 118, "id": 18, "ws": true}, {"text": "3", "start": 119, "end": 120, "id": 19, "ws": true}, {"text": "h", "start": 121, "end": 122, "id": 20, "ws": true}, {"text": ")", "start": 123, "end": 124, "id": 21, "ws": true}, {"text": "and", "start": 125, "end": 128, "id": 22, "ws": true}, {"text": "carboplatin", "start": 129, "end": 140, "id": 23, "ws": true}, {"text": "[", "start": 141, "end": 142, "id": 24, "ws": true}, {"text": "area", "start": 143, "end": 147, "id": 25, "ws": true}, {"text": "under", "start": 148, "end": 153, "id": 26, "ws": true}, {"text": "the", "start": 154, "end": 157, "id": 27, "ws": true}, {"text": "concentration-time", "start": 158, "end": 176, "id": 28, "ws": true}, {"text": "curve", "start": 177, "end": 182, "id": 29, "ws": true}, {"text": "(", "start": 183, "end": 184, "id": 30, "ws": true}, {"text": "AUC", "start": 185, "end": 188, "id": 31, "ws": true}, {"text": "=", "start": 189, "end": 190, "id": 32, "ws": true}, {"text": "6", "start": 191, "end": 192, "id": 33, "ws": true}, {"text": ")", "start": 193, "end": 194, "id": 34, "ws": true}, {"text": "]", "start": 195, "end": 196, "id": 35, "ws": true}, {"text": "on", "start": 197, "end": 199, "id": 36, "ws": true}, {"text": "day", "start": 200, "end": 203, "id": 37, "ws": true}, {"text": "1", "start": 204, "end": 205, "id": 38, "ws": true}, {"text": "and", "start": 206, "end": 209, "id": 39, "ws": true}, {"text": "in", "start": 210, "end": 212, "id": 40, "ws": true}, {"text": "21", "start": 213, "end": 215, "id": 41, "ws": true}, {"text": "day", "start": 216, "end": 219, "id": 42, "ws": true}, {"text": "cycles", "start": 220, "end": 226, "id": 43, "ws": true}, {"text": ".", "start": 227, "end": 228, "id": 44, "ws": false}], "spans": [{"start": 89, "end": 99, "token_start": 13, "token_end": 13, "label": "DRUG"}, {"start": 129, "end": 140, "token_start": 23, "token_end": 23, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/15886269/", "_input_hash": 980401099, "_task_hash": -2112546825, "_session_id": "drug_drug_pilot_shared2b-hagit", "_view_id": "blocks", "relations": [{"head": 13, "child": 23, "head_span": {"start": 89, "end": 99, "token_start": 13, "token_end": 13, "label": "DRUG"}, "child_span": {"start": 129, "end": 140, "token_start": 23, "token_end": 23, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Eligible patients received ramucirumab ( 10mg/kg ) + dacarbazine ( 1000 mg/m(2 ) ) ( Arm A ) or ramucirumab only ( 10mg/kg ) ( Arm B ) every 3 weeks .", "paragraph": "<h3><u>A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.</u></h3>To evaluate the efficacy and safety of <b style='color:Tomato;'><i>ramucirumab</i></b> (IMC-1121B; LY3009806), a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2, alone and in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> in chemotherapy-na\u00efve patients with metastatic melanoma (MM). ### methods <b style='color:DodgerBlue;'><i>Eligible</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end-point was progression-free survival (PFS); secondary end-points included overall survival (OS), overall response and safety. ### findings Of 106 randomised patients, 102 received study treatment (Arm A, N=52; Arm B, N=50). Baseline characteristics were similar in both arms. Median PFS was 2.6 months (Arm A) and 1.7 months (Arm B); median 6-month PFS rates were 30.7% and 17.9% and 12-month PFS rates were 23.7% and 15.6%, respectively. In Arm A, 9 (17.3%) patients had partial response (PR) and 19 (36.5%), stable disease (SD); PR and SD in Arm B were 2 (4.0%) and 21 (42.0%), respectively. Median OS was 8.7 months in Arm A and 11.1 months in Arm B. Patients in both arms tolerated the treatment with limited Grade 3/4 toxicities. ### interpretation <b style='color:Tomato;'><i>ramucirumab</i></b> alone or in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> was associated with an acceptable safety profile in patients with MM. Although the study was not powered for comparison between treatment arms, PFS appeared greater with combination therapy. Sustained disease control was observed on both study arm.", "tokens": [{"text": "Eligible", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "patients", "start": 9, "end": 17, "id": 1, "ws": true}, {"text": "received", "start": 18, "end": 26, "id": 2, "ws": true}, {"text": "ramucirumab", "start": 27, "end": 38, "id": 3, "ws": true}, {"text": "(", "start": 39, "end": 40, "id": 4, "ws": true}, {"text": "10mg/kg", "start": 41, "end": 48, "id": 5, "ws": true}, {"text": ")", "start": 49, "end": 50, "id": 6, "ws": true}, {"text": "+", "start": 51, "end": 52, "id": 7, "ws": true}, {"text": "dacarbazine", "start": 53, "end": 64, "id": 8, "ws": true}, {"text": "(", "start": 65, "end": 66, "id": 9, "ws": true}, {"text": "1000", "start": 67, "end": 71, "id": 10, "ws": true}, {"text": "mg/m(2", "start": 72, "end": 78, "id": 11, "ws": true}, {"text": ")", "start": 79, "end": 80, "id": 12, "ws": true}, {"text": ")", "start": 81, "end": 82, "id": 13, "ws": true}, {"text": "(", "start": 83, "end": 84, "id": 14, "ws": true}, {"text": "Arm", "start": 85, "end": 88, "id": 15, "ws": true}, {"text": "A", "start": 89, "end": 90, "id": 16, "ws": true}, {"text": ")", "start": 91, "end": 92, "id": 17, "ws": true}, {"text": "or", "start": 93, "end": 95, "id": 18, "ws": true}, {"text": "ramucirumab", "start": 96, "end": 107, "id": 19, "ws": true}, {"text": "only", "start": 108, "end": 112, "id": 20, "ws": true}, {"text": "(", "start": 113, "end": 114, "id": 21, "ws": true}, {"text": "10mg/kg", "start": 115, "end": 122, "id": 22, "ws": true}, {"text": ")", "start": 123, "end": 124, "id": 23, "ws": true}, {"text": "(", "start": 125, "end": 126, "id": 24, "ws": true}, {"text": "Arm", "start": 127, "end": 130, "id": 25, "ws": true}, {"text": "B", "start": 131, "end": 132, "id": 26, "ws": true}, {"text": ")", "start": 133, "end": 134, "id": 27, "ws": true}, {"text": "every", "start": 135, "end": 140, "id": 28, "ws": true}, {"text": "3", "start": 141, "end": 142, "id": 29, "ws": true}, {"text": "weeks", "start": 143, "end": 148, "id": 30, "ws": true}, {"text": ".", "start": 149, "end": 150, "id": 31, "ws": false}], "spans": [{"start": 27, "end": 38, "token_start": 3, "token_end": 3, "label": "DRUG"}, {"start": 53, "end": 64, "token_start": 8, "token_end": 8, "label": "DRUG"}, {"start": 96, "end": 107, "token_start": 19, "token_end": 19, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/24930625/", "_input_hash": 633570856, "_task_hash": -1516010704, "_session_id": "drug_drug_pilot_shared2b-hagit", "_view_id": "blocks", "relations": [{"head": 3, "child": 8, "head_span": {"start": 27, "end": 38, "token_start": 3, "token_end": 3, "label": "DRUG"}, "child_span": {"start": 53, "end": 64, "token_start": 8, "token_end": 8, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "The aim of this study was to investigate the mutagenic and antigenotoxic effects of different doses of the flavonoid , apigenin , alone and in combination with the antitumor drugs , cyclophosphamide and doxorubicin , in vitro and in vivo .", "paragraph": "<h3><u>The effect of apigenin on cyclophosphamide and doxorubicin genotoxicity in vitro and in vivo.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mutagenic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>antigenotoxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>flavonoid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>apigenin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Using bacterial reverse mutation inhibition in vitro, with and without metabolic activation, the effect of apigenin (10-400 \u03bcg/plate) was studied on genotoxicity induced by <b style='color:Tomato;'><i>cyclophosphamide</i></b> (800 \u03bcg/plate) and by <b style='color:Tomato;'><i>doxorubicin</i></b> (0.2 \u03bcg/plate). Subsequent to a dose-finding study in vivo, CD1 mice were treated with either <b style='color:Tomato;'><i>cyclophosphamide</i></b> (40 mg/kg, i.p.) or <b style='color:Tomato;'><i>doxorubicin</i></b> (5 mg/kg, i.p.) with or without co-administration of apigenin (1-100 mg/kg, p.o.). Micronuclei were determined microscopically in blood smears and glutathione peroxidase (GPX), superoxide dismutase (SOD) and total antioxidative status (TAS) in whole blood, erythrocytes and plasma, respectively. Apigenin decreased <b style='color:Tomato;'><i>doxorubicin</i></b>-induced, but not <b style='color:Tomato;'><i>cyclophosphamide</i></b>-induced mutagenicity in vitro. In vivo, apigenin caused a statistically significant decrease in micronucleus frequency in response to <b style='color:Tomato;'><i>cyclophosphamide</i></b>, possibly due to active flavonoid metabolite formation or inhibition of <b style='color:Tomato;'><i>cyclophosphamide</i></b> metabolic activation. In animals treated with apigenin and <b style='color:Tomato;'><i>doxorubicin</i></b>, a significant decrease in micronucleus frequency was not observed, probably due to interindividual variability. No changes in GPX, SOD or TAS were observed in response to either cytotoxic agents or the flavonoid, possibly due to limited metabolic transformation of the drugs at the doses used. The results of the present study provide further evidence for the chemo-preventative properties of apigenin.", "tokens": [{"text": "The", "start": 0, "end": 3, "id": 0, "ws": true}, {"text": "aim", "start": 4, "end": 7, "id": 1, "ws": true}, {"text": "of", "start": 8, "end": 10, "id": 2, "ws": true}, {"text": "this", "start": 11, "end": 15, "id": 3, "ws": true}, {"text": "study", "start": 16, "end": 21, "id": 4, "ws": true}, {"text": "was", "start": 22, "end": 25, "id": 5, "ws": true}, {"text": "to", "start": 26, "end": 28, "id": 6, "ws": true}, {"text": "investigate", "start": 29, "end": 40, "id": 7, "ws": true}, {"text": "the", "start": 41, "end": 44, "id": 8, "ws": true}, {"text": "mutagenic", "start": 45, "end": 54, "id": 9, "ws": true}, {"text": "and", "start": 55, "end": 58, "id": 10, "ws": true}, {"text": "antigenotoxic", "start": 59, "end": 72, "id": 11, "ws": true}, {"text": "effects", "start": 73, "end": 80, "id": 12, "ws": true}, {"text": "of", "start": 81, "end": 83, "id": 13, "ws": true}, {"text": "different", "start": 84, "end": 93, "id": 14, "ws": true}, {"text": "doses", "start": 94, "end": 99, "id": 15, "ws": true}, {"text": "of", "start": 100, "end": 102, "id": 16, "ws": true}, {"text": "the", "start": 103, "end": 106, "id": 17, "ws": true}, {"text": "flavonoid", "start": 107, "end": 116, "id": 18, "ws": true}, {"text": ",", "start": 117, "end": 118, "id": 19, "ws": true}, {"text": "apigenin", "start": 119, "end": 127, "id": 20, "ws": true}, {"text": ",", "start": 128, "end": 129, "id": 21, "ws": true}, {"text": "alone", "start": 130, "end": 135, "id": 22, "ws": true}, {"text": "and", "start": 136, "end": 139, "id": 23, "ws": true}, {"text": "in", "start": 140, "end": 142, "id": 24, "ws": true}, {"text": "combination", "start": 143, "end": 154, "id": 25, "ws": true}, {"text": "with", "start": 155, "end": 159, "id": 26, "ws": true}, {"text": "the", "start": 160, "end": 163, "id": 27, "ws": true}, {"text": "antitumor", "start": 164, "end": 173, "id": 28, "ws": true}, {"text": "drugs", "start": 174, "end": 179, "id": 29, "ws": true}, {"text": ",", "start": 180, "end": 181, "id": 30, "ws": true}, {"text": "cyclophosphamide", "start": 182, "end": 198, "id": 31, "ws": true}, {"text": "and", "start": 199, "end": 202, "id": 32, "ws": true}, {"text": "doxorubicin", "start": 203, "end": 214, "id": 33, "ws": true}, {"text": ",", "start": 215, "end": 216, "id": 34, "ws": true}, {"text": "in", "start": 217, "end": 219, "id": 35, "ws": true}, {"text": "vitro", "start": 220, "end": 225, "id": 36, "ws": true}, {"text": "and", "start": 226, "end": 229, "id": 37, "ws": true}, {"text": "in", "start": 230, "end": 232, "id": 38, "ws": true}, {"text": "vivo", "start": 233, "end": 237, "id": 39, "ws": true}, {"text": ".", "start": 238, "end": 239, "id": 40, "ws": false}], "spans": [{"start": 182, "end": 198, "token_start": 31, "token_end": 31, "label": "DRUG"}, {"start": 203, "end": 214, "token_start": 33, "token_end": 33, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/21469013/", "_input_hash": 1631768353, "_task_hash": -923842770, "_session_id": "drug_drug_pilot_shared2b-hagit", "_view_id": "blocks", "relations": [{"head": 20, "child": 31, "head_span": {"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": null}, "child_span": {"start": 182, "end": 198, "token_start": 31, "token_end": 31, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}, {"head": 20, "child": 33, "head_span": {"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": null}, "child_span": {"start": 203, "end": 214, "token_start": 33, "token_end": 33, "label": "DRUG"}, "color": "#96e8ce", "label": "COMB1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of docetaxel , platinum , and fluorouracil ( TPF ) for treating metastatic SCCE .", "paragraph": "<h3><u>Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.</u></h3> <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>urgently</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>esophagus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TPF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This phase I/II trial (n = 12/39) was conducted in our institute from April 2005 to June 2008. Progression-free survival (PFS) and overall survival were analyzed by the Kaplan-Meier method. ### results The recommended dose of <b style='color:Tomato;'><i>docetaxel</i></b> was determined to be 50 mg/m in phase I. In phase II with a mean follow-up period of 13.3 months, the objective response rate was 66.6%, a median survival period of 13 months and PFS of 7 months was achieved, and the 1-year survival and PFS rates were 52.9% and 19.6%, respectively. Grade 3/4 toxicities of leukopenia, neutropenia, and anorexia were observed in 53.8%, 43.6%, and 25.6%, respectively. ### conclusions A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens. Randomized phase III trials of the TPF regimen are warranted and urgently required.", "tokens": [{"text": "More", "start": 0, "end": 4, "id": 0, "ws": true}, {"text": "effective", "start": 5, "end": 14, "id": 1, "ws": true}, {"text": "regimens", "start": 15, "end": 23, "id": 2, "ws": true}, {"text": "are", "start": 24, "end": 27, "id": 3, "ws": true}, {"text": "urgently", "start": 28, "end": 36, "id": 4, "ws": true}, {"text": "needed", "start": 37, "end": 43, "id": 5, "ws": true}, {"text": "for", "start": 44, "end": 47, "id": 6, "ws": true}, {"text": "squamous", "start": 48, "end": 56, "id": 7, "ws": true}, {"text": "cell", "start": 57, "end": 61, "id": 8, "ws": true}, {"text": "carcinoma", "start": 62, "end": 71, "id": 9, "ws": true}, {"text": "of", "start": 72, "end": 74, "id": 10, "ws": true}, {"text": "esophagus", "start": 75, "end": 84, "id": 11, "ws": true}, {"text": "(", "start": 85, "end": 86, "id": 12, "ws": true}, {"text": "SCCE", "start": 87, "end": 91, "id": 13, "ws": true}, {"text": ")", "start": 92, "end": 93, "id": 14, "ws": true}, {"text": ",", "start": 94, "end": 95, "id": 15, "ws": true}, {"text": "therefore", "start": 96, "end": 105, "id": 16, "ws": true}, {"text": ",", "start": 106, "end": 107, "id": 17, "ws": true}, {"text": "we", "start": 108, "end": 110, "id": 18, "ws": true}, {"text": "conducted", "start": 111, "end": 120, "id": 19, "ws": true}, {"text": "a", "start": 121, "end": 122, "id": 20, "ws": true}, {"text": "phase", "start": 123, "end": 128, "id": 21, "ws": true}, {"text": "I/II", "start": 129, "end": 133, "id": 22, "ws": true}, {"text": "trial", "start": 134, "end": 139, "id": 23, "ws": true}, {"text": "of", "start": 140, "end": 142, "id": 24, "ws": true}, {"text": "a", "start": 143, "end": 144, "id": 25, "ws": true}, {"text": "combination", "start": 145, "end": 156, "id": 26, "ws": true}, {"text": "of", "start": 157, "end": 159, "id": 27, "ws": true}, {"text": "docetaxel", "start": 160, "end": 169, "id": 28, "ws": true}, {"text": ",", "start": 170, "end": 171, "id": 29, "ws": true}, {"text": "platinum", "start": 172, "end": 180, "id": 30, "ws": true}, {"text": ",", "start": 181, "end": 182, "id": 31, "ws": true}, {"text": "and", "start": 183, "end": 186, "id": 32, "ws": true}, {"text": "fluorouracil", "start": 187, "end": 199, "id": 33, "ws": true}, {"text": "(", "start": 200, "end": 201, "id": 34, "ws": true}, {"text": "TPF", "start": 202, "end": 205, "id": 35, "ws": true}, {"text": ")", "start": 206, "end": 207, "id": 36, "ws": true}, {"text": "for", "start": 208, "end": 211, "id": 37, "ws": true}, {"text": "treating", "start": 212, "end": 220, "id": 38, "ws": true}, {"text": "metastatic", "start": 221, "end": 231, "id": 39, "ws": true}, {"text": "SCCE", "start": 232, "end": 236, "id": 40, "ws": true}, {"text": ".", "start": 237, "end": 238, "id": 41, "ws": false}], "spans": [{"start": 160, "end": 169, "token_start": 28, "token_end": 28, "label": "DRUG"}, {"start": 187, "end": 199, "token_start": 33, "token_end": 33, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/19898259/", "_input_hash": -830932666, "_task_hash": 1318102472, "_session_id": "drug_drug_pilot_shared2b-hagit", "_view_id": "blocks", "relations": [{"head": 28, "child": 30, "head_span": {"start": 160, "end": 169, "token_start": 28, "token_end": 28, "label": "DRUG"}, "child_span": {"start": 172, "end": 180, "token_start": 30, "token_end": 30, "label": null}, "color": "#c5bdf4", "label": "POS1"}, {"head": 33, "child": 30, "head_span": {"start": 187, "end": 199, "token_start": 33, "token_end": 33, "label": "DRUG"}, "child_span": {"start": 172, "end": 180, "token_start": 30, "token_end": 30, "label": null}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "We determined the effects of diclofenac sodium , octreotide , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice .", "paragraph": "<h3><u>Diclofenac Sodium Treatment Ameliorates Extrapancreatic Organ Injuries in a Murine Model of Acute Pancreatitis Induced by Caerulein.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>determined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>diclofenac</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>extrapancreatic</i></b> <b style='color:DodgerBlue;'><i>organ</i></b> <b style='color:DodgerBlue;'><i>injuries</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>caerulein-induced</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>pancreatitis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A total of 58 BALB-C male mice (25\u2009g) were divided into seven groups and used to create a caerulein-induced acute pancreatitis model. <b style='color:Tomato;'><i>diclofenac</i></b> sodium, <b style='color:Tomato;'><i>octreotide</i></b>, and their combination were given for treatment of caerulin-induced acute pancreatitis in mice. At the end of the experiment, the lung, liver, kidney, and stomach were removed for histopathologic assessment. ### results Histopathologic investigation revealed a statistically significant difference between the groups in mean congestion, edema, tubular injury, perirenal fat tissue inflammation, and tubular stasis scores in kidney tissue ( ### conclusion <b style='color:Tomato;'><i>diclofenac</i></b> sodium alone ameliorates lung edema due to caerulin-induced acute pancreatitis.", "tokens": [{"text": "We", "start": 0, "end": 2, "id": 0, "ws": true}, {"text": "determined", "start": 3, "end": 13, "id": 1, "ws": true}, {"text": "the", "start": 14, "end": 17, "id": 2, "ws": true}, {"text": "effects", "start": 18, "end": 25, "id": 3, "ws": true}, {"text": "of", "start": 26, "end": 28, "id": 4, "ws": true}, {"text": "diclofenac", "start": 29, "end": 39, "id": 5, "ws": true}, {"text": "sodium", "start": 40, "end": 46, "id": 6, "ws": true}, {"text": ",", "start": 47, "end": 48, "id": 7, "ws": true}, {"text": "octreotide", "start": 49, "end": 59, "id": 8, "ws": true}, {"text": ",", "start": 60, "end": 61, "id": 9, "ws": true}, {"text": "and", "start": 62, "end": 65, "id": 10, "ws": true}, {"text": "their", "start": 66, "end": 71, "id": 11, "ws": true}, {"text": "combination", "start": 72, "end": 83, "id": 12, "ws": true}, {"text": "on", "start": 84, "end": 86, "id": 13, "ws": true}, {"text": "extrapancreatic", "start": 87, "end": 102, "id": 14, "ws": true}, {"text": "organ", "start": 103, "end": 108, "id": 15, "ws": true}, {"text": "injuries", "start": 109, "end": 117, "id": 16, "ws": true}, {"text": "in", "start": 118, "end": 120, "id": 17, "ws": true}, {"text": "caerulein-induced", "start": 121, "end": 138, "id": 18, "ws": true}, {"text": "acute", "start": 139, "end": 144, "id": 19, "ws": true}, {"text": "pancreatitis", "start": 145, "end": 157, "id": 20, "ws": true}, {"text": "in", "start": 158, "end": 160, "id": 21, "ws": true}, {"text": "mice", "start": 161, "end": 165, "id": 22, "ws": true}, {"text": ".", "start": 166, "end": 167, "id": 23, "ws": false}], "spans": [{"start": 29, "end": 39, "token_start": 5, "token_end": 5, "label": "DRUG"}, {"start": 49, "end": 59, "token_start": 8, "token_end": 8, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/30515205/", "_input_hash": 526527182, "_task_hash": 526499652, "_session_id": "drug_drug_pilot_shared2b-hagit", "_view_id": "blocks", "relations": [{"head": 5, "child": 8, "head_span": {"start": 29, "end": 39, "token_start": 5, "token_end": 5, "label": "DRUG"}, "child_span": {"start": 49, "end": 59, "token_start": 8, "token_end": 8, "label": "DRUG"}, "color": "#c2f2f6", "label": "NEG1"}], "radio": ["NEG11"], "answer": "accept"}
{"text": "Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib ( MLN9708 ) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant .", "paragraph": "<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>Ib</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Oral</i></b> <b style='color:DodgerBlue;'><i>Proteasome</i></b> <b style='color:DodgerBlue;'><i>Inhibitor</i></b> <b style='color:MediumOrchid;'><i>Ixazomib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MLN9708</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Advanced</i></b> <b style='color:DodgerBlue;'><i>ER+</i></b> <b style='color:DodgerBlue;'><i>Breast</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>Progressing</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### background <b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### methods This is a single-center phase Ib study with a 3+3 design of <b style='color:Tomato;'><i>fulvestrant</i></b> and the proteasome inhibitor <b style='color:Tomato;'><i>ixazomib</i></b> (MLN9708) in patients with advanced ER+ breast cancer that was progressing on <b style='color:Tomato;'><i>fulvestrant</i></b>. A dose-escalation design allowed establishment of the <b style='color:Tomato;'><i>ixazomib</i></b> maximum tolerated dose (MTD). Secondary objectives included progression-free survival, pharmacokinetics, and tumor molecular analyses. ### results Among nine evaluable subjects, treatment was well-tolerated without dose-limiting toxicities The MTD of <b style='color:Tomato;'><i>ixazomib</i></b> was 4 mg in combination with <b style='color:Tomato;'><i>fulvestrant</i></b>. Plasma concentrations of the active form of <b style='color:Tomato;'><i>ixazomib</i></b> (MLN2238) in the 4-mg dose cohort had a median (range) Cmax of 155 (122-171) ng/mL; Tmax of 1 (1-1.5) h; terminal elimination half-life of 66.6 (57.3-102.6) hr after initial dose; AUC of 5,025 (4,160-5,345) ng*h/mL. One partial response was observed, and median progression-free survival was 51\u2009days (range 47-137). ### conclusion This drug combination has a favorable safety profile and anti-tumor activity in patients with <b style='color:Tomato;'><i>fulvestrant</i></b>-resistant advanced ER+ breast cancer that justifies future testing.", "tokens": [{"text": "Phase", "start": 0, "end": 5, "id": 0, "ws": true}, {"text": "Ib", "start": 6, "end": 8, "id": 1, "ws": true}, {"text": "Study", "start": 9, "end": 14, "id": 2, "ws": true}, {"text": "of", "start": 15, "end": 17, "id": 3, "ws": true}, {"text": "the", "start": 18, "end": 21, "id": 4, "ws": true}, {"text": "Oral", "start": 22, "end": 26, "id": 5, "ws": true}, {"text": "Proteasome", "start": 27, "end": 37, "id": 6, "ws": true}, {"text": "Inhibitor", "start": 38, "end": 47, "id": 7, "ws": true}, {"text": "Ixazomib", "start": 48, "end": 56, "id": 8, "ws": true}, {"text": "(", "start": 57, "end": 58, "id": 9, "ws": true}, {"text": "MLN9708", "start": 59, "end": 66, "id": 10, "ws": true}, {"text": ")", "start": 67, "end": 68, "id": 11, "ws": true}, {"text": "and", "start": 69, "end": 72, "id": 12, "ws": true}, {"text": "Fulvestrant", "start": 73, "end": 84, "id": 13, "ws": true}, {"text": "in", "start": 85, "end": 87, "id": 14, "ws": true}, {"text": "Advanced", "start": 88, "end": 96, "id": 15, "ws": true}, {"text": "ER+", "start": 97, "end": 100, "id": 16, "ws": true}, {"text": "Breast", "start": 101, "end": 107, "id": 17, "ws": true}, {"text": "Cancer", "start": 108, "end": 114, "id": 18, "ws": true}, {"text": "Progressing", "start": 115, "end": 126, "id": 19, "ws": true}, {"text": "on", "start": 127, "end": 129, "id": 20, "ws": true}, {"text": "Fulvestrant", "start": 130, "end": 141, "id": 21, "ws": true}, {"text": ".", "start": 142, "end": 143, "id": 22, "ws": false}], "spans": [{"start": 48, "end": 56, "token_start": 8, "token_end": 8, "label": "DRUG"}, {"start": 73, "end": 84, "token_start": 13, "token_end": 13, "label": "DRUG"}, {"start": 130, "end": 141, "token_start": 21, "token_end": 21, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/33641211/", "_input_hash": -1014334224, "_task_hash": 1740062343, "_session_id": "drug_drug_pilot_shared2b-dana_n", "_view_id": "blocks", "relations": [{"head": 8, "child": 13, "head_span": {"start": 48, "end": 56, "token_start": 8, "token_end": 8, "label": "DRUG"}, "child_span": {"start": 73, "end": 84, "token_start": 13, "token_end": 13, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Pharmacokinetic studies showed that chronic lymphocytic leukemia involving more than 80 % of the bone marrow at study start was associated with lower trough concentrations of alemtuzumab and rituximab , and that higher trough serum concentrations of alemtuzumab were associated with complete bone marrow clearance .", "paragraph": "<h3><u>A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.</u></h3>This study assessed the safety and preliminary efficacy of escalated dose subcutaneous <b style='color:Tomato;'><i>alemtuzumab</i></b> in combination with <b style='color:Tomato;'><i>rituximab</i></b> in chronic lymphocytic leukemia. Twenty-eight patients with relapsed refractory chronic lymphocytic leukemia were treated on four dosing cohorts of weekly <b style='color:Tomato;'><i>rituximab</i></b> at 375 mg/m(2) and <b style='color:Tomato;'><i>alemtuzumab</i></b> doses that started at 30 mg three times per week and escalated to weekly dosing over four weeks, culminating with 90 mg weekly. One dose limiting toxicity of a <b style='color:Tomato;'><i>rituximab</i></b> infusion reaction was seen in cohort 2, but the regimen was otherwise well tolerated without evidence of differential toxicity by cohort. The overall response rate by National Cancer Institute-Working Group criteria was 61%, and the rate of complete bone marrow response was 43%, most of whom were negative for minimal residual disease. The addition of CT scan evaluation per International Workshop on Chronic Lymphocytic Leukemia 2008 criteria reduced the overall response rate to 14%. Median overall survival was 35 months, with 12 patients able to proceed to stem cell transplantation. <b style='color:DodgerBlue;'><i>Pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>lymphocytic</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>involving</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>start</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>clearance</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We conclude that escalated subcutaneous doses of <b style='color:Tomato;'><i>alemtuzumab</i></b> given weekly are well tolerated and result in excellent bone marrow clearance of chronic lymphocytic leukemia, helping patients to proceed to stem cell transplantation. This study is registered at ClinicalTrials.gov (Identifier:00330252).", "tokens": [{"text": "Pharmacokinetic", "start": 0, "end": 15, "id": 0, "ws": true}, {"text": "studies", "start": 16, "end": 23, "id": 1, "ws": true}, {"text": "showed", "start": 24, "end": 30, "id": 2, "ws": true}, {"text": "that", "start": 31, "end": 35, "id": 3, "ws": true}, {"text": "chronic", "start": 36, "end": 43, "id": 4, "ws": true}, {"text": "lymphocytic", "start": 44, "end": 55, "id": 5, "ws": true}, {"text": "leukemia", "start": 56, "end": 64, "id": 6, "ws": true}, {"text": "involving", "start": 65, "end": 74, "id": 7, "ws": true}, {"text": "more", "start": 75, "end": 79, "id": 8, "ws": true}, {"text": "than", "start": 80, "end": 84, "id": 9, "ws": true}, {"text": "80", "start": 85, "end": 87, "id": 10, "ws": true}, {"text": "%", "start": 88, "end": 89, "id": 11, "ws": true}, {"text": "of", "start": 90, "end": 92, "id": 12, "ws": true}, {"text": "the", "start": 93, "end": 96, "id": 13, "ws": true}, {"text": "bone", "start": 97, "end": 101, "id": 14, "ws": true}, {"text": "marrow", "start": 102, "end": 108, "id": 15, "ws": true}, {"text": "at", "start": 109, "end": 111, "id": 16, "ws": true}, {"text": "study", "start": 112, "end": 117, "id": 17, "ws": true}, {"text": "start", "start": 118, "end": 123, "id": 18, "ws": true}, {"text": "was", "start": 124, "end": 127, "id": 19, "ws": true}, {"text": "associated", "start": 128, "end": 138, "id": 20, "ws": true}, {"text": "with", "start": 139, "end": 143, "id": 21, "ws": true}, {"text": "lower", "start": 144, "end": 149, "id": 22, "ws": true}, {"text": "trough", "start": 150, "end": 156, "id": 23, "ws": true}, {"text": "concentrations", "start": 157, "end": 171, "id": 24, "ws": true}, {"text": "of", "start": 172, "end": 174, "id": 25, "ws": true}, {"text": "alemtuzumab", "start": 175, "end": 186, "id": 26, "ws": true}, {"text": "and", "start": 187, "end": 190, "id": 27, "ws": true}, {"text": "rituximab", "start": 191, "end": 200, "id": 28, "ws": true}, {"text": ",", "start": 201, "end": 202, "id": 29, "ws": true}, {"text": "and", "start": 203, "end": 206, "id": 30, "ws": true}, {"text": "that", "start": 207, "end": 211, "id": 31, "ws": true}, {"text": "higher", "start": 212, "end": 218, "id": 32, "ws": true}, {"text": "trough", "start": 219, "end": 225, "id": 33, "ws": true}, {"text": "serum", "start": 226, "end": 231, "id": 34, "ws": true}, {"text": "concentrations", "start": 232, "end": 246, "id": 35, "ws": true}, {"text": "of", "start": 247, "end": 249, "id": 36, "ws": true}, {"text": "alemtuzumab", "start": 250, "end": 261, "id": 37, "ws": true}, {"text": "were", "start": 262, "end": 266, "id": 38, "ws": true}, {"text": "associated", "start": 267, "end": 277, "id": 39, "ws": true}, {"text": "with", "start": 278, "end": 282, "id": 40, "ws": true}, {"text": "complete", "start": 283, "end": 291, "id": 41, "ws": true}, {"text": "bone", "start": 292, "end": 296, "id": 42, "ws": true}, {"text": "marrow", "start": 297, "end": 303, "id": 43, "ws": true}, {"text": "clearance", "start": 304, "end": 313, "id": 44, "ws": true}, {"text": ".", "start": 314, "end": 315, "id": 45, "ws": false}], "spans": [{"start": 175, "end": 186, "token_start": 26, "token_end": 26, "label": "DRUG"}, {"start": 191, "end": 200, "token_start": 28, "token_end": 28, "label": "DRUG"}, {"start": 250, "end": 261, "token_start": 37, "token_end": 37, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/23645694/", "_input_hash": -1128840740, "_task_hash": -278706627, "_session_id": "drug_drug_pilot_shared2b-dana_n", "_view_id": "blocks", "relations": [{"head": 26, "child": 28, "head_span": {"start": 175, "end": 186, "token_start": 26, "token_end": 26, "label": "DRUG"}, "child_span": {"start": 191, "end": 200, "token_start": 28, "token_end": 28, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with bevacizumab ( 5 mg/kg body weight i.v . every 21 days ) and oral capecitabine ( 950 mg/m(2 ) twice daily for 14 days followed by 7 days of rest ) in 2006 - 2008 .", "paragraph": "<h3><u>Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.</u></h3>No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended <b style='color:Tomato;'><i>mitotane</i></b> as monotherapy or combined with <b style='color:Tomato;'><i>etoposide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b> and cisplatin or with <b style='color:Tomato;'><i>streptozotocin</i></b> as first-line systemic therapy. However, there is no evidence for any therapy beneficial in patients failing these therapies. Therefore, we evaluated the effects of the anti-VEGF antibody <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> as salvage therapy in ACC. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>registered</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>German</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>Registry</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>offered</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>body</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>950</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>rest</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>2006</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2008</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Evaluation of tumour response was performed by imaging according to response evaluation criteria in solid tumours every 12 weeks. ### results Ten patients were treated with <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b>. None of them experienced any objective response or stable disease. Two patients had to stop therapy after few weeks due to hand-foot syndrome, and three patients died on progressive disease within 12 weeks. Other adverse events were mild (grade I-II). Median survival after treatment initiation was 124 days. ### conclusions <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> has no activity in patients with very advanced ACC. Hence, this regimen cannot be recommended as a salvage therapy.", "tokens": [{"text": "Patients", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "registered", "start": 9, "end": 19, "id": 1, "ws": true}, {"text": "with", "start": 20, "end": 24, "id": 2, "ws": true}, {"text": "the", "start": 25, "end": 28, "id": 3, "ws": true}, {"text": "German", "start": 29, "end": 35, "id": 4, "ws": true}, {"text": "ACC", "start": 36, "end": 39, "id": 5, "ws": true}, {"text": "Registry", "start": 40, "end": 48, "id": 6, "ws": true}, {"text": "with", "start": 49, "end": 53, "id": 7, "ws": true}, {"text": "refractory", "start": 54, "end": 64, "id": 8, "ws": true}, {"text": "ACC", "start": 65, "end": 68, "id": 9, "ws": true}, {"text": "progressing", "start": 69, "end": 80, "id": 10, "ws": true}, {"text": "after", "start": 81, "end": 86, "id": 11, "ws": true}, {"text": "cytotoxic", "start": 87, "end": 96, "id": 12, "ws": true}, {"text": "therapies", "start": 97, "end": 106, "id": 13, "ws": true}, {"text": "were", "start": 107, "end": 111, "id": 14, "ws": true}, {"text": "offered", "start": 112, "end": 119, "id": 15, "ws": true}, {"text": "treatment", "start": 120, "end": 129, "id": 16, "ws": true}, {"text": "with", "start": 130, "end": 134, "id": 17, "ws": true}, {"text": "bevacizumab", "start": 135, "end": 146, "id": 18, "ws": true}, {"text": "(", "start": 147, "end": 148, "id": 19, "ws": true}, {"text": "5", "start": 149, "end": 150, "id": 20, "ws": true}, {"text": "mg/kg", "start": 151, "end": 156, "id": 21, "ws": true}, {"text": "body", "start": 157, "end": 161, "id": 22, "ws": true}, {"text": "weight", "start": 162, "end": 168, "id": 23, "ws": true}, {"text": "i.v", "start": 169, "end": 172, "id": 24, "ws": true}, {"text": ".", "start": 173, "end": 174, "id": 25, "ws": true}, {"text": "every", "start": 175, "end": 180, "id": 26, "ws": true}, {"text": "21", "start": 181, "end": 183, "id": 27, "ws": true}, {"text": "days", "start": 184, "end": 188, "id": 28, "ws": true}, {"text": ")", "start": 189, "end": 190, "id": 29, "ws": true}, {"text": "and", "start": 191, "end": 194, "id": 30, "ws": true}, {"text": "oral", "start": 195, "end": 199, "id": 31, "ws": true}, {"text": "capecitabine", "start": 200, "end": 212, "id": 32, "ws": true}, {"text": "(", "start": 213, "end": 214, "id": 33, "ws": true}, {"text": "950", "start": 215, "end": 218, "id": 34, "ws": true}, {"text": "mg/m(2", "start": 219, "end": 225, "id": 35, "ws": true}, {"text": ")", "start": 226, "end": 227, "id": 36, "ws": true}, {"text": "twice", "start": 228, "end": 233, "id": 37, "ws": true}, {"text": "daily", "start": 234, "end": 239, "id": 38, "ws": true}, {"text": "for", "start": 240, "end": 243, "id": 39, "ws": true}, {"text": "14", "start": 244, "end": 246, "id": 40, "ws": true}, {"text": "days", "start": 247, "end": 251, "id": 41, "ws": true}, {"text": "followed", "start": 252, "end": 260, "id": 42, "ws": true}, {"text": "by", "start": 261, "end": 263, "id": 43, "ws": true}, {"text": "7", "start": 264, "end": 265, "id": 44, "ws": true}, {"text": "days", "start": 266, "end": 270, "id": 45, "ws": true}, {"text": "of", "start": 271, "end": 273, "id": 46, "ws": true}, {"text": "rest", "start": 274, "end": 278, "id": 47, "ws": true}, {"text": ")", "start": 279, "end": 280, "id": 48, "ws": true}, {"text": "in", "start": 281, "end": 283, "id": 49, "ws": true}, {"text": "2006", "start": 284, "end": 288, "id": 50, "ws": true}, {"text": "-", "start": 289, "end": 290, "id": 51, "ws": true}, {"text": "2008", "start": 291, "end": 295, "id": 52, "ws": true}, {"text": ".", "start": 296, "end": 297, "id": 53, "ws": false}], "spans": [{"start": 135, "end": 146, "token_start": 18, "token_end": 18, "label": "DRUG"}, {"start": 200, "end": 212, "token_start": 32, "token_end": 32, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/19903796/", "_input_hash": 1011764762, "_task_hash": -827463686, "_session_id": "drug_drug_pilot_shared2b-dana_n", "_view_id": "blocks", "relations": [{"head": 18, "child": 32, "head_span": {"start": 135, "end": 146, "token_start": 18, "token_end": 18, "label": "DRUG"}, "child_span": {"start": 200, "end": 212, "token_start": 32, "token_end": 32, "label": "DRUG"}, "color": "#96e8ce", "label": "COMB1"}], "radio": [], "answer": "accept"}
{"text": "Patients who had pathologically been proven to have measurable lesions were treated with paclitaxel ( 200 mg/m(2 ) for 3 h ) and carboplatin [ area under the concentration-time curve ( AUC = 6 ) ] on day 1 and in 21 day cycles .", "paragraph": "<h3><u>Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.</u></h3>The combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> has been used to treat patients with many types of tumor, including gastric cancer. We evaluated the efficacy and safety of this combination in advanced gastric cancer patients previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>pathologically</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>proven</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>measurable</i></b> <b style='color:DodgerBlue;'><i>lesions</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results A partial response was achieved in 10 of 45 patients [22%, 95% confidence interval (CI), 10-34]. Of the 32 patients previously treated with cisplatin, four (13%) achieved partial response, whereas, of the 13 patients previously treated with heptaplatin, six (46%) achieved partial response. In all patients, the median time to progression was 14 weeks (95% CI, 10-18), and the median overall survival was 32 weeks (95% CI, 26-38). The most common grade 3/4 adverse events were neutropenia (40% of patients) and neuropathy (2.2%). Two patients developed neutropenic fever. However, there were no treatment-related deaths. ### conclusions Combination chemotherapy with <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> is feasible in patients with advanced gastric cancer who were previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum.", "tokens": [{"text": "Patients", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "who", "start": 9, "end": 12, "id": 1, "ws": true}, {"text": "had", "start": 13, "end": 16, "id": 2, "ws": true}, {"text": "pathologically", "start": 17, "end": 31, "id": 3, "ws": true}, {"text": "been", "start": 32, "end": 36, "id": 4, "ws": true}, {"text": "proven", "start": 37, "end": 43, "id": 5, "ws": true}, {"text": "to", "start": 44, "end": 46, "id": 6, "ws": true}, {"text": "have", "start": 47, "end": 51, "id": 7, "ws": true}, {"text": "measurable", "start": 52, "end": 62, "id": 8, "ws": true}, {"text": "lesions", "start": 63, "end": 70, "id": 9, "ws": true}, {"text": "were", "start": 71, "end": 75, "id": 10, "ws": true}, {"text": "treated", "start": 76, "end": 83, "id": 11, "ws": true}, {"text": "with", "start": 84, "end": 88, "id": 12, "ws": true}, {"text": "paclitaxel", "start": 89, "end": 99, "id": 13, "ws": true}, {"text": "(", "start": 100, "end": 101, "id": 14, "ws": true}, {"text": "200", "start": 102, "end": 105, "id": 15, "ws": true}, {"text": "mg/m(2", "start": 106, "end": 112, "id": 16, "ws": true}, {"text": ")", "start": 113, "end": 114, "id": 17, "ws": true}, {"text": "for", "start": 115, "end": 118, "id": 18, "ws": true}, {"text": "3", "start": 119, "end": 120, "id": 19, "ws": true}, {"text": "h", "start": 121, "end": 122, "id": 20, "ws": true}, {"text": ")", "start": 123, "end": 124, "id": 21, "ws": true}, {"text": "and", "start": 125, "end": 128, "id": 22, "ws": true}, {"text": "carboplatin", "start": 129, "end": 140, "id": 23, "ws": true}, {"text": "[", "start": 141, "end": 142, "id": 24, "ws": true}, {"text": "area", "start": 143, "end": 147, "id": 25, "ws": true}, {"text": "under", "start": 148, "end": 153, "id": 26, "ws": true}, {"text": "the", "start": 154, "end": 157, "id": 27, "ws": true}, {"text": "concentration-time", "start": 158, "end": 176, "id": 28, "ws": true}, {"text": "curve", "start": 177, "end": 182, "id": 29, "ws": true}, {"text": "(", "start": 183, "end": 184, "id": 30, "ws": true}, {"text": "AUC", "start": 185, "end": 188, "id": 31, "ws": true}, {"text": "=", "start": 189, "end": 190, "id": 32, "ws": true}, {"text": "6", "start": 191, "end": 192, "id": 33, "ws": true}, {"text": ")", "start": 193, "end": 194, "id": 34, "ws": true}, {"text": "]", "start": 195, "end": 196, "id": 35, "ws": true}, {"text": "on", "start": 197, "end": 199, "id": 36, "ws": true}, {"text": "day", "start": 200, "end": 203, "id": 37, "ws": true}, {"text": "1", "start": 204, "end": 205, "id": 38, "ws": true}, {"text": "and", "start": 206, "end": 209, "id": 39, "ws": true}, {"text": "in", "start": 210, "end": 212, "id": 40, "ws": true}, {"text": "21", "start": 213, "end": 215, "id": 41, "ws": true}, {"text": "day", "start": 216, "end": 219, "id": 42, "ws": true}, {"text": "cycles", "start": 220, "end": 226, "id": 43, "ws": true}, {"text": ".", "start": 227, "end": 228, "id": 44, "ws": false}], "spans": [{"start": 89, "end": 99, "token_start": 13, "token_end": 13, "label": "DRUG"}, {"start": 129, "end": 140, "token_start": 23, "token_end": 23, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/15886269/", "_input_hash": 980401099, "_task_hash": -2112546825, "_session_id": "drug_drug_pilot_shared2b-dana_n", "_view_id": "blocks", "relations": [{"head": 23, "child": 13, "head_span": {"start": 129, "end": 140, "token_start": 23, "token_end": 23, "label": "DRUG"}, "child_span": {"start": 89, "end": 99, "token_start": 13, "token_end": 13, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Eligible patients received ramucirumab ( 10mg/kg ) + dacarbazine ( 1000 mg/m(2 ) ) ( Arm A ) or ramucirumab only ( 10mg/kg ) ( Arm B ) every 3 weeks .", "paragraph": "<h3><u>A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.</u></h3>To evaluate the efficacy and safety of <b style='color:Tomato;'><i>ramucirumab</i></b> (IMC-1121B; LY3009806), a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2, alone and in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> in chemotherapy-na\u00efve patients with metastatic melanoma (MM). ### methods <b style='color:DodgerBlue;'><i>Eligible</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end-point was progression-free survival (PFS); secondary end-points included overall survival (OS), overall response and safety. ### findings Of 106 randomised patients, 102 received study treatment (Arm A, N=52; Arm B, N=50). Baseline characteristics were similar in both arms. Median PFS was 2.6 months (Arm A) and 1.7 months (Arm B); median 6-month PFS rates were 30.7% and 17.9% and 12-month PFS rates were 23.7% and 15.6%, respectively. In Arm A, 9 (17.3%) patients had partial response (PR) and 19 (36.5%), stable disease (SD); PR and SD in Arm B were 2 (4.0%) and 21 (42.0%), respectively. Median OS was 8.7 months in Arm A and 11.1 months in Arm B. Patients in both arms tolerated the treatment with limited Grade 3/4 toxicities. ### interpretation <b style='color:Tomato;'><i>ramucirumab</i></b> alone or in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> was associated with an acceptable safety profile in patients with MM. Although the study was not powered for comparison between treatment arms, PFS appeared greater with combination therapy. Sustained disease control was observed on both study arm.", "tokens": [{"text": "Eligible", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "patients", "start": 9, "end": 17, "id": 1, "ws": true}, {"text": "received", "start": 18, "end": 26, "id": 2, "ws": true}, {"text": "ramucirumab", "start": 27, "end": 38, "id": 3, "ws": true}, {"text": "(", "start": 39, "end": 40, "id": 4, "ws": true}, {"text": "10mg/kg", "start": 41, "end": 48, "id": 5, "ws": true}, {"text": ")", "start": 49, "end": 50, "id": 6, "ws": true}, {"text": "+", "start": 51, "end": 52, "id": 7, "ws": true}, {"text": "dacarbazine", "start": 53, "end": 64, "id": 8, "ws": true}, {"text": "(", "start": 65, "end": 66, "id": 9, "ws": true}, {"text": "1000", "start": 67, "end": 71, "id": 10, "ws": true}, {"text": "mg/m(2", "start": 72, "end": 78, "id": 11, "ws": true}, {"text": ")", "start": 79, "end": 80, "id": 12, "ws": true}, {"text": ")", "start": 81, "end": 82, "id": 13, "ws": true}, {"text": "(", "start": 83, "end": 84, "id": 14, "ws": true}, {"text": "Arm", "start": 85, "end": 88, "id": 15, "ws": true}, {"text": "A", "start": 89, "end": 90, "id": 16, "ws": true}, {"text": ")", "start": 91, "end": 92, "id": 17, "ws": true}, {"text": "or", "start": 93, "end": 95, "id": 18, "ws": true}, {"text": "ramucirumab", "start": 96, "end": 107, "id": 19, "ws": true}, {"text": "only", "start": 108, "end": 112, "id": 20, "ws": true}, {"text": "(", "start": 113, "end": 114, "id": 21, "ws": true}, {"text": "10mg/kg", "start": 115, "end": 122, "id": 22, "ws": true}, {"text": ")", "start": 123, "end": 124, "id": 23, "ws": true}, {"text": "(", "start": 125, "end": 126, "id": 24, "ws": true}, {"text": "Arm", "start": 127, "end": 130, "id": 25, "ws": true}, {"text": "B", "start": 131, "end": 132, "id": 26, "ws": true}, {"text": ")", "start": 133, "end": 134, "id": 27, "ws": true}, {"text": "every", "start": 135, "end": 140, "id": 28, "ws": true}, {"text": "3", "start": 141, "end": 142, "id": 29, "ws": true}, {"text": "weeks", "start": 143, "end": 148, "id": 30, "ws": true}, {"text": ".", "start": 149, "end": 150, "id": 31, "ws": false}], "spans": [{"start": 27, "end": 38, "token_start": 3, "token_end": 3, "label": "DRUG"}, {"start": 53, "end": 64, "token_start": 8, "token_end": 8, "label": "DRUG"}, {"start": 96, "end": 107, "token_start": 19, "token_end": 19, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/24930625/", "_input_hash": 633570856, "_task_hash": -1516010704, "_session_id": "drug_drug_pilot_shared2b-dana_n", "_view_id": "blocks", "relations": [{"head": 3, "child": 8, "head_span": {"start": 27, "end": 38, "token_start": 3, "token_end": 3, "label": "DRUG"}, "child_span": {"start": 53, "end": 64, "token_start": 8, "token_end": 8, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "The aim of this study was to investigate the mutagenic and antigenotoxic effects of different doses of the flavonoid , apigenin , alone and in combination with the antitumor drugs , cyclophosphamide and doxorubicin , in vitro and in vivo .", "paragraph": "<h3><u>The effect of apigenin on cyclophosphamide and doxorubicin genotoxicity in vitro and in vivo.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mutagenic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>antigenotoxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>flavonoid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>apigenin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Using bacterial reverse mutation inhibition in vitro, with and without metabolic activation, the effect of apigenin (10-400 \u03bcg/plate) was studied on genotoxicity induced by <b style='color:Tomato;'><i>cyclophosphamide</i></b> (800 \u03bcg/plate) and by <b style='color:Tomato;'><i>doxorubicin</i></b> (0.2 \u03bcg/plate). Subsequent to a dose-finding study in vivo, CD1 mice were treated with either <b style='color:Tomato;'><i>cyclophosphamide</i></b> (40 mg/kg, i.p.) or <b style='color:Tomato;'><i>doxorubicin</i></b> (5 mg/kg, i.p.) with or without co-administration of apigenin (1-100 mg/kg, p.o.). Micronuclei were determined microscopically in blood smears and glutathione peroxidase (GPX), superoxide dismutase (SOD) and total antioxidative status (TAS) in whole blood, erythrocytes and plasma, respectively. Apigenin decreased <b style='color:Tomato;'><i>doxorubicin</i></b>-induced, but not <b style='color:Tomato;'><i>cyclophosphamide</i></b>-induced mutagenicity in vitro. In vivo, apigenin caused a statistically significant decrease in micronucleus frequency in response to <b style='color:Tomato;'><i>cyclophosphamide</i></b>, possibly due to active flavonoid metabolite formation or inhibition of <b style='color:Tomato;'><i>cyclophosphamide</i></b> metabolic activation. In animals treated with apigenin and <b style='color:Tomato;'><i>doxorubicin</i></b>, a significant decrease in micronucleus frequency was not observed, probably due to interindividual variability. No changes in GPX, SOD or TAS were observed in response to either cytotoxic agents or the flavonoid, possibly due to limited metabolic transformation of the drugs at the doses used. The results of the present study provide further evidence for the chemo-preventative properties of apigenin.", "tokens": [{"text": "The", "start": 0, "end": 3, "id": 0, "ws": true}, {"text": "aim", "start": 4, "end": 7, "id": 1, "ws": true}, {"text": "of", "start": 8, "end": 10, "id": 2, "ws": true}, {"text": "this", "start": 11, "end": 15, "id": 3, "ws": true}, {"text": "study", "start": 16, "end": 21, "id": 4, "ws": true}, {"text": "was", "start": 22, "end": 25, "id": 5, "ws": true}, {"text": "to", "start": 26, "end": 28, "id": 6, "ws": true}, {"text": "investigate", "start": 29, "end": 40, "id": 7, "ws": true}, {"text": "the", "start": 41, "end": 44, "id": 8, "ws": true}, {"text": "mutagenic", "start": 45, "end": 54, "id": 9, "ws": true}, {"text": "and", "start": 55, "end": 58, "id": 10, "ws": true}, {"text": "antigenotoxic", "start": 59, "end": 72, "id": 11, "ws": true}, {"text": "effects", "start": 73, "end": 80, "id": 12, "ws": true}, {"text": "of", "start": 81, "end": 83, "id": 13, "ws": true}, {"text": "different", "start": 84, "end": 93, "id": 14, "ws": true}, {"text": "doses", "start": 94, "end": 99, "id": 15, "ws": true}, {"text": "of", "start": 100, "end": 102, "id": 16, "ws": true}, {"text": "the", "start": 103, "end": 106, "id": 17, "ws": true}, {"text": "flavonoid", "start": 107, "end": 116, "id": 18, "ws": true}, {"text": ",", "start": 117, "end": 118, "id": 19, "ws": true}, {"text": "apigenin", "start": 119, "end": 127, "id": 20, "ws": true}, {"text": ",", "start": 128, "end": 129, "id": 21, "ws": true}, {"text": "alone", "start": 130, "end": 135, "id": 22, "ws": true}, {"text": "and", "start": 136, "end": 139, "id": 23, "ws": true}, {"text": "in", "start": 140, "end": 142, "id": 24, "ws": true}, {"text": "combination", "start": 143, "end": 154, "id": 25, "ws": true}, {"text": "with", "start": 155, "end": 159, "id": 26, "ws": true}, {"text": "the", "start": 160, "end": 163, "id": 27, "ws": true}, {"text": "antitumor", "start": 164, "end": 173, "id": 28, "ws": true}, {"text": "drugs", "start": 174, "end": 179, "id": 29, "ws": true}, {"text": ",", "start": 180, "end": 181, "id": 30, "ws": true}, {"text": "cyclophosphamide", "start": 182, "end": 198, "id": 31, "ws": true}, {"text": "and", "start": 199, "end": 202, "id": 32, "ws": true}, {"text": "doxorubicin", "start": 203, "end": 214, "id": 33, "ws": true}, {"text": ",", "start": 215, "end": 216, "id": 34, "ws": true}, {"text": "in", "start": 217, "end": 219, "id": 35, "ws": true}, {"text": "vitro", "start": 220, "end": 225, "id": 36, "ws": true}, {"text": "and", "start": 226, "end": 229, "id": 37, "ws": true}, {"text": "in", "start": 230, "end": 232, "id": 38, "ws": true}, {"text": "vivo", "start": 233, "end": 237, "id": 39, "ws": true}, {"text": ".", "start": 238, "end": 239, "id": 40, "ws": false}], "spans": [{"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": "DRUG"}, {"start": 182, "end": 198, "token_start": 31, "token_end": 31, "label": "DRUG"}, {"start": 203, "end": 214, "token_start": 33, "token_end": 33, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/21469013/", "_input_hash": 1631768353, "_task_hash": -923842770, "_session_id": "drug_drug_pilot_shared2b-dana_n", "_view_id": "blocks", "relations": [{"head": 20, "child": 31, "head_span": {"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": "DRUG"}, "child_span": {"start": 182, "end": 198, "token_start": 31, "token_end": 31, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}, {"head": 20, "child": 33, "head_span": {"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": "DRUG"}, "child_span": {"start": 203, "end": 214, "token_start": 33, "token_end": 33, "label": "DRUG"}, "color": "#ffd882", "label": "POS2"}], "radio": ["POS11", "POS21"], "answer": "accept"}
{"text": "More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of docetaxel , platinum , and fluorouracil ( TPF ) for treating metastatic SCCE .", "paragraph": "<h3><u>Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.</u></h3> <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>urgently</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>esophagus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TPF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This phase I/II trial (n = 12/39) was conducted in our institute from April 2005 to June 2008. Progression-free survival (PFS) and overall survival were analyzed by the Kaplan-Meier method. ### results The recommended dose of <b style='color:Tomato;'><i>docetaxel</i></b> was determined to be 50 mg/m in phase I. In phase II with a mean follow-up period of 13.3 months, the objective response rate was 66.6%, a median survival period of 13 months and PFS of 7 months was achieved, and the 1-year survival and PFS rates were 52.9% and 19.6%, respectively. Grade 3/4 toxicities of leukopenia, neutropenia, and anorexia were observed in 53.8%, 43.6%, and 25.6%, respectively. ### conclusions A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens. Randomized phase III trials of the TPF regimen are warranted and urgently required.", "tokens": [{"text": "More", "start": 0, "end": 4, "id": 0, "ws": true}, {"text": "effective", "start": 5, "end": 14, "id": 1, "ws": true}, {"text": "regimens", "start": 15, "end": 23, "id": 2, "ws": true}, {"text": "are", "start": 24, "end": 27, "id": 3, "ws": true}, {"text": "urgently", "start": 28, "end": 36, "id": 4, "ws": true}, {"text": "needed", "start": 37, "end": 43, "id": 5, "ws": true}, {"text": "for", "start": 44, "end": 47, "id": 6, "ws": true}, {"text": "squamous", "start": 48, "end": 56, "id": 7, "ws": true}, {"text": "cell", "start": 57, "end": 61, "id": 8, "ws": true}, {"text": "carcinoma", "start": 62, "end": 71, "id": 9, "ws": true}, {"text": "of", "start": 72, "end": 74, "id": 10, "ws": true}, {"text": "esophagus", "start": 75, "end": 84, "id": 11, "ws": true}, {"text": "(", "start": 85, "end": 86, "id": 12, "ws": true}, {"text": "SCCE", "start": 87, "end": 91, "id": 13, "ws": true}, {"text": ")", "start": 92, "end": 93, "id": 14, "ws": true}, {"text": ",", "start": 94, "end": 95, "id": 15, "ws": true}, {"text": "therefore", "start": 96, "end": 105, "id": 16, "ws": true}, {"text": ",", "start": 106, "end": 107, "id": 17, "ws": true}, {"text": "we", "start": 108, "end": 110, "id": 18, "ws": true}, {"text": "conducted", "start": 111, "end": 120, "id": 19, "ws": true}, {"text": "a", "start": 121, "end": 122, "id": 20, "ws": true}, {"text": "phase", "start": 123, "end": 128, "id": 21, "ws": true}, {"text": "I/II", "start": 129, "end": 133, "id": 22, "ws": true}, {"text": "trial", "start": 134, "end": 139, "id": 23, "ws": true}, {"text": "of", "start": 140, "end": 142, "id": 24, "ws": true}, {"text": "a", "start": 143, "end": 144, "id": 25, "ws": true}, {"text": "combination", "start": 145, "end": 156, "id": 26, "ws": true}, {"text": "of", "start": 157, "end": 159, "id": 27, "ws": true}, {"text": "docetaxel", "start": 160, "end": 169, "id": 28, "ws": true}, {"text": ",", "start": 170, "end": 171, "id": 29, "ws": true}, {"text": "platinum", "start": 172, "end": 180, "id": 30, "ws": true}, {"text": ",", "start": 181, "end": 182, "id": 31, "ws": true}, {"text": "and", "start": 183, "end": 186, "id": 32, "ws": true}, {"text": "fluorouracil", "start": 187, "end": 199, "id": 33, "ws": true}, {"text": "(", "start": 200, "end": 201, "id": 34, "ws": true}, {"text": "TPF", "start": 202, "end": 205, "id": 35, "ws": true}, {"text": ")", "start": 206, "end": 207, "id": 36, "ws": true}, {"text": "for", "start": 208, "end": 211, "id": 37, "ws": true}, {"text": "treating", "start": 212, "end": 220, "id": 38, "ws": true}, {"text": "metastatic", "start": 221, "end": 231, "id": 39, "ws": true}, {"text": "SCCE", "start": 232, "end": 236, "id": 40, "ws": true}, {"text": ".", "start": 237, "end": 238, "id": 41, "ws": false}], "spans": [{"start": 160, "end": 169, "token_start": 28, "token_end": 28, "label": "DRUG"}, {"start": 172, "end": 180, "token_start": 30, "token_end": 30, "label": "DRUG"}, {"start": 187, "end": 199, "token_start": 33, "token_end": 33, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/19898259/", "_input_hash": -830932666, "_task_hash": 1318102472, "_session_id": "drug_drug_pilot_shared2b-dana_n", "_view_id": "blocks", "relations": [{"head": 30, "child": 28, "head_span": {"start": 172, "end": 180, "token_start": 30, "token_end": 30, "label": "DRUG"}, "child_span": {"start": 160, "end": 169, "token_start": 28, "token_end": 28, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}, {"head": 30, "child": 33, "head_span": {"start": 172, "end": 180, "token_start": 30, "token_end": 30, "label": "DRUG"}, "child_span": {"start": 187, "end": 199, "token_start": 33, "token_end": 33, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "We determined the effects of diclofenac sodium , octreotide , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice .", "paragraph": "<h3><u>Diclofenac Sodium Treatment Ameliorates Extrapancreatic Organ Injuries in a Murine Model of Acute Pancreatitis Induced by Caerulein.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>determined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>diclofenac</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>extrapancreatic</i></b> <b style='color:DodgerBlue;'><i>organ</i></b> <b style='color:DodgerBlue;'><i>injuries</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>caerulein-induced</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>pancreatitis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A total of 58 BALB-C male mice (25\u2009g) were divided into seven groups and used to create a caerulein-induced acute pancreatitis model. <b style='color:Tomato;'><i>diclofenac</i></b> sodium, <b style='color:Tomato;'><i>octreotide</i></b>, and their combination were given for treatment of caerulin-induced acute pancreatitis in mice. At the end of the experiment, the lung, liver, kidney, and stomach were removed for histopathologic assessment. ### results Histopathologic investigation revealed a statistically significant difference between the groups in mean congestion, edema, tubular injury, perirenal fat tissue inflammation, and tubular stasis scores in kidney tissue ( ### conclusion <b style='color:Tomato;'><i>diclofenac</i></b> sodium alone ameliorates lung edema due to caerulin-induced acute pancreatitis.", "tokens": [{"text": "We", "start": 0, "end": 2, "id": 0, "ws": true}, {"text": "determined", "start": 3, "end": 13, "id": 1, "ws": true}, {"text": "the", "start": 14, "end": 17, "id": 2, "ws": true}, {"text": "effects", "start": 18, "end": 25, "id": 3, "ws": true}, {"text": "of", "start": 26, "end": 28, "id": 4, "ws": true}, {"text": "diclofenac", "start": 29, "end": 39, "id": 5, "ws": true}, {"text": "sodium", "start": 40, "end": 46, "id": 6, "ws": true}, {"text": ",", "start": 47, "end": 48, "id": 7, "ws": true}, {"text": "octreotide", "start": 49, "end": 59, "id": 8, "ws": true}, {"text": ",", "start": 60, "end": 61, "id": 9, "ws": true}, {"text": "and", "start": 62, "end": 65, "id": 10, "ws": true}, {"text": "their", "start": 66, "end": 71, "id": 11, "ws": true}, {"text": "combination", "start": 72, "end": 83, "id": 12, "ws": true}, {"text": "on", "start": 84, "end": 86, "id": 13, "ws": true}, {"text": "extrapancreatic", "start": 87, "end": 102, "id": 14, "ws": true}, {"text": "organ", "start": 103, "end": 108, "id": 15, "ws": true}, {"text": "injuries", "start": 109, "end": 117, "id": 16, "ws": true}, {"text": "in", "start": 118, "end": 120, "id": 17, "ws": true}, {"text": "caerulein-induced", "start": 121, "end": 138, "id": 18, "ws": true}, {"text": "acute", "start": 139, "end": 144, "id": 19, "ws": true}, {"text": "pancreatitis", "start": 145, "end": 157, "id": 20, "ws": true}, {"text": "in", "start": 158, "end": 160, "id": 21, "ws": true}, {"text": "mice", "start": 161, "end": 165, "id": 22, "ws": true}, {"text": ".", "start": 166, "end": 167, "id": 23, "ws": false}], "spans": [{"start": 29, "end": 39, "token_start": 5, "token_end": 5, "label": "DRUG"}, {"start": 49, "end": 59, "token_start": 8, "token_end": 8, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/30515205/", "_input_hash": 526527182, "_task_hash": 526499652, "_session_id": "drug_drug_pilot_shared2b-dana_n", "_view_id": "blocks", "relations": [{"head": 5, "child": 8, "head_span": {"start": 29, "end": 39, "token_start": 5, "token_end": 5, "label": "DRUG"}, "child_span": {"start": 49, "end": 59, "token_start": 8, "token_end": 8, "label": "DRUG"}, "color": "#96e8ce", "label": "COMB1"}], "radio": [], "answer": "accept"}
{"text": "Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib ( MLN9708 ) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant .", "paragraph": "<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>Ib</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Oral</i></b> <b style='color:DodgerBlue;'><i>Proteasome</i></b> <b style='color:DodgerBlue;'><i>Inhibitor</i></b> <b style='color:MediumOrchid;'><i>Ixazomib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MLN9708</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Advanced</i></b> <b style='color:DodgerBlue;'><i>ER+</i></b> <b style='color:DodgerBlue;'><i>Breast</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>Progressing</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### background <b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### methods This is a single-center phase Ib study with a 3+3 design of <b style='color:Tomato;'><i>fulvestrant</i></b> and the proteasome inhibitor <b style='color:Tomato;'><i>ixazomib</i></b> (MLN9708) in patients with advanced ER+ breast cancer that was progressing on <b style='color:Tomato;'><i>fulvestrant</i></b>. A dose-escalation design allowed establishment of the <b style='color:Tomato;'><i>ixazomib</i></b> maximum tolerated dose (MTD). Secondary objectives included progression-free survival, pharmacokinetics, and tumor molecular analyses. ### results Among nine evaluable subjects, treatment was well-tolerated without dose-limiting toxicities The MTD of <b style='color:Tomato;'><i>ixazomib</i></b> was 4 mg in combination with <b style='color:Tomato;'><i>fulvestrant</i></b>. Plasma concentrations of the active form of <b style='color:Tomato;'><i>ixazomib</i></b> (MLN2238) in the 4-mg dose cohort had a median (range) Cmax of 155 (122-171) ng/mL; Tmax of 1 (1-1.5) h; terminal elimination half-life of 66.6 (57.3-102.6) hr after initial dose; AUC of 5,025 (4,160-5,345) ng*h/mL. One partial response was observed, and median progression-free survival was 51\u2009days (range 47-137). ### conclusion This drug combination has a favorable safety profile and anti-tumor activity in patients with <b style='color:Tomato;'><i>fulvestrant</i></b>-resistant advanced ER+ breast cancer that justifies future testing.", "tokens": [{"text": "Phase", "start": 0, "end": 5, "id": 0, "ws": true}, {"text": "Ib", "start": 6, "end": 8, "id": 1, "ws": true}, {"text": "Study", "start": 9, "end": 14, "id": 2, "ws": true}, {"text": "of", "start": 15, "end": 17, "id": 3, "ws": true}, {"text": "the", "start": 18, "end": 21, "id": 4, "ws": true}, {"text": "Oral", "start": 22, "end": 26, "id": 5, "ws": true}, {"text": "Proteasome", "start": 27, "end": 37, "id": 6, "ws": true}, {"text": "Inhibitor", "start": 38, "end": 47, "id": 7, "ws": true}, {"text": "Ixazomib", "start": 48, "end": 56, "id": 8, "ws": true}, {"text": "(", "start": 57, "end": 58, "id": 9, "ws": true}, {"text": "MLN9708", "start": 59, "end": 66, "id": 10, "ws": true}, {"text": ")", "start": 67, "end": 68, "id": 11, "ws": true}, {"text": "and", "start": 69, "end": 72, "id": 12, "ws": true}, {"text": "Fulvestrant", "start": 73, "end": 84, "id": 13, "ws": true}, {"text": "in", "start": 85, "end": 87, "id": 14, "ws": true}, {"text": "Advanced", "start": 88, "end": 96, "id": 15, "ws": true}, {"text": "ER+", "start": 97, "end": 100, "id": 16, "ws": true}, {"text": "Breast", "start": 101, "end": 107, "id": 17, "ws": true}, {"text": "Cancer", "start": 108, "end": 114, "id": 18, "ws": true}, {"text": "Progressing", "start": 115, "end": 126, "id": 19, "ws": true}, {"text": "on", "start": 127, "end": 129, "id": 20, "ws": true}, {"text": "Fulvestrant", "start": 130, "end": 141, "id": 21, "ws": true}, {"text": ".", "start": 142, "end": 143, "id": 22, "ws": false}], "spans": [{"start": 48, "end": 56, "token_start": 8, "token_end": 8, "label": "DRUG"}, {"start": 73, "end": 84, "token_start": 13, "token_end": 13, "label": "DRUG"}, {"start": 130, "end": 141, "token_start": 21, "token_end": 21, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/33641211/", "_input_hash": -1014334224, "_task_hash": 1740062343, "_session_id": "drug_drug_pilot_shared2b-dana_a", "_view_id": "blocks", "relations": [{"head": 8, "child": 13, "head_span": {"start": 48, "end": 56, "token_start": 8, "token_end": 8, "label": "DRUG"}, "child_span": {"start": 73, "end": 84, "token_start": 13, "token_end": 13, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Pharmacokinetic studies showed that chronic lymphocytic leukemia involving more than 80 % of the bone marrow at study start was associated with lower trough concentrations of alemtuzumab and rituximab , and that higher trough serum concentrations of alemtuzumab were associated with complete bone marrow clearance .", "paragraph": "<h3><u>A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.</u></h3>This study assessed the safety and preliminary efficacy of escalated dose subcutaneous <b style='color:Tomato;'><i>alemtuzumab</i></b> in combination with <b style='color:Tomato;'><i>rituximab</i></b> in chronic lymphocytic leukemia. Twenty-eight patients with relapsed refractory chronic lymphocytic leukemia were treated on four dosing cohorts of weekly <b style='color:Tomato;'><i>rituximab</i></b> at 375 mg/m(2) and <b style='color:Tomato;'><i>alemtuzumab</i></b> doses that started at 30 mg three times per week and escalated to weekly dosing over four weeks, culminating with 90 mg weekly. One dose limiting toxicity of a <b style='color:Tomato;'><i>rituximab</i></b> infusion reaction was seen in cohort 2, but the regimen was otherwise well tolerated without evidence of differential toxicity by cohort. The overall response rate by National Cancer Institute-Working Group criteria was 61%, and the rate of complete bone marrow response was 43%, most of whom were negative for minimal residual disease. The addition of CT scan evaluation per International Workshop on Chronic Lymphocytic Leukemia 2008 criteria reduced the overall response rate to 14%. Median overall survival was 35 months, with 12 patients able to proceed to stem cell transplantation. <b style='color:DodgerBlue;'><i>Pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>lymphocytic</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>involving</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>start</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>clearance</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We conclude that escalated subcutaneous doses of <b style='color:Tomato;'><i>alemtuzumab</i></b> given weekly are well tolerated and result in excellent bone marrow clearance of chronic lymphocytic leukemia, helping patients to proceed to stem cell transplantation. This study is registered at ClinicalTrials.gov (Identifier:00330252).", "tokens": [{"text": "Pharmacokinetic", "start": 0, "end": 15, "id": 0, "ws": true}, {"text": "studies", "start": 16, "end": 23, "id": 1, "ws": true}, {"text": "showed", "start": 24, "end": 30, "id": 2, "ws": true}, {"text": "that", "start": 31, "end": 35, "id": 3, "ws": true}, {"text": "chronic", "start": 36, "end": 43, "id": 4, "ws": true}, {"text": "lymphocytic", "start": 44, "end": 55, "id": 5, "ws": true}, {"text": "leukemia", "start": 56, "end": 64, "id": 6, "ws": true}, {"text": "involving", "start": 65, "end": 74, "id": 7, "ws": true}, {"text": "more", "start": 75, "end": 79, "id": 8, "ws": true}, {"text": "than", "start": 80, "end": 84, "id": 9, "ws": true}, {"text": "80", "start": 85, "end": 87, "id": 10, "ws": true}, {"text": "%", "start": 88, "end": 89, "id": 11, "ws": true}, {"text": "of", "start": 90, "end": 92, "id": 12, "ws": true}, {"text": "the", "start": 93, "end": 96, "id": 13, "ws": true}, {"text": "bone", "start": 97, "end": 101, "id": 14, "ws": true}, {"text": "marrow", "start": 102, "end": 108, "id": 15, "ws": true}, {"text": "at", "start": 109, "end": 111, "id": 16, "ws": true}, {"text": "study", "start": 112, "end": 117, "id": 17, "ws": true}, {"text": "start", "start": 118, "end": 123, "id": 18, "ws": true}, {"text": "was", "start": 124, "end": 127, "id": 19, "ws": true}, {"text": "associated", "start": 128, "end": 138, "id": 20, "ws": true}, {"text": "with", "start": 139, "end": 143, "id": 21, "ws": true}, {"text": "lower", "start": 144, "end": 149, "id": 22, "ws": true}, {"text": "trough", "start": 150, "end": 156, "id": 23, "ws": true}, {"text": "concentrations", "start": 157, "end": 171, "id": 24, "ws": true}, {"text": "of", "start": 172, "end": 174, "id": 25, "ws": true}, {"text": "alemtuzumab", "start": 175, "end": 186, "id": 26, "ws": true}, {"text": "and", "start": 187, "end": 190, "id": 27, "ws": true}, {"text": "rituximab", "start": 191, "end": 200, "id": 28, "ws": true}, {"text": ",", "start": 201, "end": 202, "id": 29, "ws": true}, {"text": "and", "start": 203, "end": 206, "id": 30, "ws": true}, {"text": "that", "start": 207, "end": 211, "id": 31, "ws": true}, {"text": "higher", "start": 212, "end": 218, "id": 32, "ws": true}, {"text": "trough", "start": 219, "end": 225, "id": 33, "ws": true}, {"text": "serum", "start": 226, "end": 231, "id": 34, "ws": true}, {"text": "concentrations", "start": 232, "end": 246, "id": 35, "ws": true}, {"text": "of", "start": 247, "end": 249, "id": 36, "ws": true}, {"text": "alemtuzumab", "start": 250, "end": 261, "id": 37, "ws": true}, {"text": "were", "start": 262, "end": 266, "id": 38, "ws": true}, {"text": "associated", "start": 267, "end": 277, "id": 39, "ws": true}, {"text": "with", "start": 278, "end": 282, "id": 40, "ws": true}, {"text": "complete", "start": 283, "end": 291, "id": 41, "ws": true}, {"text": "bone", "start": 292, "end": 296, "id": 42, "ws": true}, {"text": "marrow", "start": 297, "end": 303, "id": 43, "ws": true}, {"text": "clearance", "start": 304, "end": 313, "id": 44, "ws": true}, {"text": ".", "start": 314, "end": 315, "id": 45, "ws": false}], "spans": [{"start": 175, "end": 186, "token_start": 26, "token_end": 26, "label": "DRUG"}, {"start": 191, "end": 200, "token_start": 28, "token_end": 28, "label": "DRUG"}, {"start": 250, "end": 261, "token_start": 37, "token_end": 37, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/23645694/", "_input_hash": -1128840740, "_task_hash": -278706627, "_session_id": "drug_drug_pilot_shared2b-dana_a", "_view_id": "blocks", "relations": [{"head": 26, "child": 28, "head_span": {"start": 175, "end": 186, "token_start": 26, "token_end": 26, "label": "DRUG"}, "child_span": {"start": 191, "end": 200, "token_start": 28, "token_end": 28, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with bevacizumab ( 5 mg/kg body weight i.v . every 21 days ) and oral capecitabine ( 950 mg/m(2 ) twice daily for 14 days followed by 7 days of rest ) in 2006 - 2008 .", "paragraph": "<h3><u>Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.</u></h3>No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended <b style='color:Tomato;'><i>mitotane</i></b> as monotherapy or combined with <b style='color:Tomato;'><i>etoposide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b> and cisplatin or with <b style='color:Tomato;'><i>streptozotocin</i></b> as first-line systemic therapy. However, there is no evidence for any therapy beneficial in patients failing these therapies. Therefore, we evaluated the effects of the anti-VEGF antibody <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> as salvage therapy in ACC. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>registered</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>German</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>Registry</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>offered</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>body</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>950</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>rest</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>2006</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2008</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Evaluation of tumour response was performed by imaging according to response evaluation criteria in solid tumours every 12 weeks. ### results Ten patients were treated with <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b>. None of them experienced any objective response or stable disease. Two patients had to stop therapy after few weeks due to hand-foot syndrome, and three patients died on progressive disease within 12 weeks. Other adverse events were mild (grade I-II). Median survival after treatment initiation was 124 days. ### conclusions <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> has no activity in patients with very advanced ACC. Hence, this regimen cannot be recommended as a salvage therapy.", "tokens": [{"text": "Patients", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "registered", "start": 9, "end": 19, "id": 1, "ws": true}, {"text": "with", "start": 20, "end": 24, "id": 2, "ws": true}, {"text": "the", "start": 25, "end": 28, "id": 3, "ws": true}, {"text": "German", "start": 29, "end": 35, "id": 4, "ws": true}, {"text": "ACC", "start": 36, "end": 39, "id": 5, "ws": true}, {"text": "Registry", "start": 40, "end": 48, "id": 6, "ws": true}, {"text": "with", "start": 49, "end": 53, "id": 7, "ws": true}, {"text": "refractory", "start": 54, "end": 64, "id": 8, "ws": true}, {"text": "ACC", "start": 65, "end": 68, "id": 9, "ws": true}, {"text": "progressing", "start": 69, "end": 80, "id": 10, "ws": true}, {"text": "after", "start": 81, "end": 86, "id": 11, "ws": true}, {"text": "cytotoxic", "start": 87, "end": 96, "id": 12, "ws": true}, {"text": "therapies", "start": 97, "end": 106, "id": 13, "ws": true}, {"text": "were", "start": 107, "end": 111, "id": 14, "ws": true}, {"text": "offered", "start": 112, "end": 119, "id": 15, "ws": true}, {"text": "treatment", "start": 120, "end": 129, "id": 16, "ws": true}, {"text": "with", "start": 130, "end": 134, "id": 17, "ws": true}, {"text": "bevacizumab", "start": 135, "end": 146, "id": 18, "ws": true}, {"text": "(", "start": 147, "end": 148, "id": 19, "ws": true}, {"text": "5", "start": 149, "end": 150, "id": 20, "ws": true}, {"text": "mg/kg", "start": 151, "end": 156, "id": 21, "ws": true}, {"text": "body", "start": 157, "end": 161, "id": 22, "ws": true}, {"text": "weight", "start": 162, "end": 168, "id": 23, "ws": true}, {"text": "i.v", "start": 169, "end": 172, "id": 24, "ws": true}, {"text": ".", "start": 173, "end": 174, "id": 25, "ws": true}, {"text": "every", "start": 175, "end": 180, "id": 26, "ws": true}, {"text": "21", "start": 181, "end": 183, "id": 27, "ws": true}, {"text": "days", "start": 184, "end": 188, "id": 28, "ws": true}, {"text": ")", "start": 189, "end": 190, "id": 29, "ws": true}, {"text": "and", "start": 191, "end": 194, "id": 30, "ws": true}, {"text": "oral", "start": 195, "end": 199, "id": 31, "ws": true}, {"text": "capecitabine", "start": 200, "end": 212, "id": 32, "ws": true}, {"text": "(", "start": 213, "end": 214, "id": 33, "ws": true}, {"text": "950", "start": 215, "end": 218, "id": 34, "ws": true}, {"text": "mg/m(2", "start": 219, "end": 225, "id": 35, "ws": true}, {"text": ")", "start": 226, "end": 227, "id": 36, "ws": true}, {"text": "twice", "start": 228, "end": 233, "id": 37, "ws": true}, {"text": "daily", "start": 234, "end": 239, "id": 38, "ws": true}, {"text": "for", "start": 240, "end": 243, "id": 39, "ws": true}, {"text": "14", "start": 244, "end": 246, "id": 40, "ws": true}, {"text": "days", "start": 247, "end": 251, "id": 41, "ws": true}, {"text": "followed", "start": 252, "end": 260, "id": 42, "ws": true}, {"text": "by", "start": 261, "end": 263, "id": 43, "ws": true}, {"text": "7", "start": 264, "end": 265, "id": 44, "ws": true}, {"text": "days", "start": 266, "end": 270, "id": 45, "ws": true}, {"text": "of", "start": 271, "end": 273, "id": 46, "ws": true}, {"text": "rest", "start": 274, "end": 278, "id": 47, "ws": true}, {"text": ")", "start": 279, "end": 280, "id": 48, "ws": true}, {"text": "in", "start": 281, "end": 283, "id": 49, "ws": true}, {"text": "2006", "start": 284, "end": 288, "id": 50, "ws": true}, {"text": "-", "start": 289, "end": 290, "id": 51, "ws": true}, {"text": "2008", "start": 291, "end": 295, "id": 52, "ws": true}, {"text": ".", "start": 296, "end": 297, "id": 53, "ws": false}], "spans": [{"start": 135, "end": 146, "token_start": 18, "token_end": 18, "label": "DRUG"}, {"start": 200, "end": 212, "token_start": 32, "token_end": 32, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/19903796/", "_input_hash": 1011764762, "_task_hash": -827463686, "_session_id": "drug_drug_pilot_shared2b-dana_a", "_view_id": "blocks", "relations": [{"head": 18, "child": 32, "head_span": {"start": 135, "end": 146, "token_start": 18, "token_end": 18, "label": "DRUG"}, "child_span": {"start": 200, "end": 212, "token_start": 32, "token_end": 32, "label": "DRUG"}, "color": "#c2f2f6", "label": "NEG1"}], "radio": ["NEG11"], "answer": "accept"}
{"text": "Patients who had pathologically been proven to have measurable lesions were treated with paclitaxel ( 200 mg/m(2 ) for 3 h ) and carboplatin [ area under the concentration-time curve ( AUC = 6 ) ] on day 1 and in 21 day cycles .", "paragraph": "<h3><u>Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.</u></h3>The combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> has been used to treat patients with many types of tumor, including gastric cancer. We evaluated the efficacy and safety of this combination in advanced gastric cancer patients previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>pathologically</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>proven</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>measurable</i></b> <b style='color:DodgerBlue;'><i>lesions</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results A partial response was achieved in 10 of 45 patients [22%, 95% confidence interval (CI), 10-34]. Of the 32 patients previously treated with cisplatin, four (13%) achieved partial response, whereas, of the 13 patients previously treated with heptaplatin, six (46%) achieved partial response. In all patients, the median time to progression was 14 weeks (95% CI, 10-18), and the median overall survival was 32 weeks (95% CI, 26-38). The most common grade 3/4 adverse events were neutropenia (40% of patients) and neuropathy (2.2%). Two patients developed neutropenic fever. However, there were no treatment-related deaths. ### conclusions Combination chemotherapy with <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> is feasible in patients with advanced gastric cancer who were previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum.", "tokens": [{"text": "Patients", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "who", "start": 9, "end": 12, "id": 1, "ws": true}, {"text": "had", "start": 13, "end": 16, "id": 2, "ws": true}, {"text": "pathologically", "start": 17, "end": 31, "id": 3, "ws": true}, {"text": "been", "start": 32, "end": 36, "id": 4, "ws": true}, {"text": "proven", "start": 37, "end": 43, "id": 5, "ws": true}, {"text": "to", "start": 44, "end": 46, "id": 6, "ws": true}, {"text": "have", "start": 47, "end": 51, "id": 7, "ws": true}, {"text": "measurable", "start": 52, "end": 62, "id": 8, "ws": true}, {"text": "lesions", "start": 63, "end": 70, "id": 9, "ws": true}, {"text": "were", "start": 71, "end": 75, "id": 10, "ws": true}, {"text": "treated", "start": 76, "end": 83, "id": 11, "ws": true}, {"text": "with", "start": 84, "end": 88, "id": 12, "ws": true}, {"text": "paclitaxel", "start": 89, "end": 99, "id": 13, "ws": true}, {"text": "(", "start": 100, "end": 101, "id": 14, "ws": true}, {"text": "200", "start": 102, "end": 105, "id": 15, "ws": true}, {"text": "mg/m(2", "start": 106, "end": 112, "id": 16, "ws": true}, {"text": ")", "start": 113, "end": 114, "id": 17, "ws": true}, {"text": "for", "start": 115, "end": 118, "id": 18, "ws": true}, {"text": "3", "start": 119, "end": 120, "id": 19, "ws": true}, {"text": "h", "start": 121, "end": 122, "id": 20, "ws": true}, {"text": ")", "start": 123, "end": 124, "id": 21, "ws": true}, {"text": "and", "start": 125, "end": 128, "id": 22, "ws": true}, {"text": "carboplatin", "start": 129, "end": 140, "id": 23, "ws": true}, {"text": "[", "start": 141, "end": 142, "id": 24, "ws": true}, {"text": "area", "start": 143, "end": 147, "id": 25, "ws": true}, {"text": "under", "start": 148, "end": 153, "id": 26, "ws": true}, {"text": "the", "start": 154, "end": 157, "id": 27, "ws": true}, {"text": "concentration-time", "start": 158, "end": 176, "id": 28, "ws": true}, {"text": "curve", "start": 177, "end": 182, "id": 29, "ws": true}, {"text": "(", "start": 183, "end": 184, "id": 30, "ws": true}, {"text": "AUC", "start": 185, "end": 188, "id": 31, "ws": true}, {"text": "=", "start": 189, "end": 190, "id": 32, "ws": true}, {"text": "6", "start": 191, "end": 192, "id": 33, "ws": true}, {"text": ")", "start": 193, "end": 194, "id": 34, "ws": true}, {"text": "]", "start": 195, "end": 196, "id": 35, "ws": true}, {"text": "on", "start": 197, "end": 199, "id": 36, "ws": true}, {"text": "day", "start": 200, "end": 203, "id": 37, "ws": true}, {"text": "1", "start": 204, "end": 205, "id": 38, "ws": true}, {"text": "and", "start": 206, "end": 209, "id": 39, "ws": true}, {"text": "in", "start": 210, "end": 212, "id": 40, "ws": true}, {"text": "21", "start": 213, "end": 215, "id": 41, "ws": true}, {"text": "day", "start": 216, "end": 219, "id": 42, "ws": true}, {"text": "cycles", "start": 220, "end": 226, "id": 43, "ws": true}, {"text": ".", "start": 227, "end": 228, "id": 44, "ws": false}], "spans": [{"start": 89, "end": 99, "token_start": 13, "token_end": 13, "label": "DRUG"}, {"start": 129, "end": 140, "token_start": 23, "token_end": 23, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/15886269/", "_input_hash": 980401099, "_task_hash": -2112546825, "_session_id": "drug_drug_pilot_shared2b-dana_a", "_view_id": "blocks", "relations": [{"head": 23, "child": 13, "head_span": {"start": 129, "end": 140, "token_start": 23, "token_end": 23, "label": "DRUG"}, "child_span": {"start": 89, "end": 99, "token_start": 13, "token_end": 13, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib ( MLN9708 ) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant .", "paragraph": "<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>Ib</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Oral</i></b> <b style='color:DodgerBlue;'><i>Proteasome</i></b> <b style='color:DodgerBlue;'><i>Inhibitor</i></b> <b style='color:MediumOrchid;'><i>Ixazomib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MLN9708</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Advanced</i></b> <b style='color:DodgerBlue;'><i>ER+</i></b> <b style='color:DodgerBlue;'><i>Breast</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>Progressing</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### background <b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### methods This is a single-center phase Ib study with a 3+3 design of <b style='color:Tomato;'><i>fulvestrant</i></b> and the proteasome inhibitor <b style='color:Tomato;'><i>ixazomib</i></b> (MLN9708) in patients with advanced ER+ breast cancer that was progressing on <b style='color:Tomato;'><i>fulvestrant</i></b>. A dose-escalation design allowed establishment of the <b style='color:Tomato;'><i>ixazomib</i></b> maximum tolerated dose (MTD). Secondary objectives included progression-free survival, pharmacokinetics, and tumor molecular analyses. ### results Among nine evaluable subjects, treatment was well-tolerated without dose-limiting toxicities The MTD of <b style='color:Tomato;'><i>ixazomib</i></b> was 4 mg in combination with <b style='color:Tomato;'><i>fulvestrant</i></b>. Plasma concentrations of the active form of <b style='color:Tomato;'><i>ixazomib</i></b> (MLN2238) in the 4-mg dose cohort had a median (range) Cmax of 155 (122-171) ng/mL; Tmax of 1 (1-1.5) h; terminal elimination half-life of 66.6 (57.3-102.6) hr after initial dose; AUC of 5,025 (4,160-5,345) ng*h/mL. One partial response was observed, and median progression-free survival was 51\u2009days (range 47-137). ### conclusion This drug combination has a favorable safety profile and anti-tumor activity in patients with <b style='color:Tomato;'><i>fulvestrant</i></b>-resistant advanced ER+ breast cancer that justifies future testing.", "tokens": [{"text": "Phase", "start": 0, "end": 5, "id": 0, "ws": true}, {"text": "Ib", "start": 6, "end": 8, "id": 1, "ws": true}, {"text": "Study", "start": 9, "end": 14, "id": 2, "ws": true}, {"text": "of", "start": 15, "end": 17, "id": 3, "ws": true}, {"text": "the", "start": 18, "end": 21, "id": 4, "ws": true}, {"text": "Oral", "start": 22, "end": 26, "id": 5, "ws": true}, {"text": "Proteasome", "start": 27, "end": 37, "id": 6, "ws": true}, {"text": "Inhibitor", "start": 38, "end": 47, "id": 7, "ws": true}, {"text": "Ixazomib", "start": 48, "end": 56, "id": 8, "ws": true}, {"text": "(", "start": 57, "end": 58, "id": 9, "ws": true}, {"text": "MLN9708", "start": 59, "end": 66, "id": 10, "ws": true}, {"text": ")", "start": 67, "end": 68, "id": 11, "ws": true}, {"text": "and", "start": 69, "end": 72, "id": 12, "ws": true}, {"text": "Fulvestrant", "start": 73, "end": 84, "id": 13, "ws": true}, {"text": "in", "start": 85, "end": 87, "id": 14, "ws": true}, {"text": "Advanced", "start": 88, "end": 96, "id": 15, "ws": true}, {"text": "ER+", "start": 97, "end": 100, "id": 16, "ws": true}, {"text": "Breast", "start": 101, "end": 107, "id": 17, "ws": true}, {"text": "Cancer", "start": 108, "end": 114, "id": 18, "ws": true}, {"text": "Progressing", "start": 115, "end": 126, "id": 19, "ws": true}, {"text": "on", "start": 127, "end": 129, "id": 20, "ws": true}, {"text": "Fulvestrant", "start": 130, "end": 141, "id": 21, "ws": true}, {"text": ".", "start": 142, "end": 143, "id": 22, "ws": false}], "spans": [{"start": 48, "end": 56, "token_start": 8, "token_end": 8, "label": "DRUG"}, {"start": 73, "end": 84, "token_start": 13, "token_end": 13, "label": "DRUG"}, {"start": 130, "end": 141, "token_start": 21, "token_end": 21, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/33641211/", "_input_hash": -1014334224, "_task_hash": 1740062343, "_session_id": "drug_drug_pilot_shared2b-maytal", "_view_id": "blocks", "relations": [{"head": 8, "child": 13, "head_span": {"start": 48, "end": 56, "token_start": 8, "token_end": 8, "label": "DRUG"}, "child_span": {"start": 73, "end": 84, "token_start": 13, "token_end": 13, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Eligible patients received ramucirumab ( 10mg/kg ) + dacarbazine ( 1000 mg/m(2 ) ) ( Arm A ) or ramucirumab only ( 10mg/kg ) ( Arm B ) every 3 weeks .", "paragraph": "<h3><u>A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.</u></h3>To evaluate the efficacy and safety of <b style='color:Tomato;'><i>ramucirumab</i></b> (IMC-1121B; LY3009806), a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2, alone and in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> in chemotherapy-na\u00efve patients with metastatic melanoma (MM). ### methods <b style='color:DodgerBlue;'><i>Eligible</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end-point was progression-free survival (PFS); secondary end-points included overall survival (OS), overall response and safety. ### findings Of 106 randomised patients, 102 received study treatment (Arm A, N=52; Arm B, N=50). Baseline characteristics were similar in both arms. Median PFS was 2.6 months (Arm A) and 1.7 months (Arm B); median 6-month PFS rates were 30.7% and 17.9% and 12-month PFS rates were 23.7% and 15.6%, respectively. In Arm A, 9 (17.3%) patients had partial response (PR) and 19 (36.5%), stable disease (SD); PR and SD in Arm B were 2 (4.0%) and 21 (42.0%), respectively. Median OS was 8.7 months in Arm A and 11.1 months in Arm B. Patients in both arms tolerated the treatment with limited Grade 3/4 toxicities. ### interpretation <b style='color:Tomato;'><i>ramucirumab</i></b> alone or in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> was associated with an acceptable safety profile in patients with MM. Although the study was not powered for comparison between treatment arms, PFS appeared greater with combination therapy. Sustained disease control was observed on both study arm.", "tokens": [{"text": "Eligible", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "patients", "start": 9, "end": 17, "id": 1, "ws": true}, {"text": "received", "start": 18, "end": 26, "id": 2, "ws": true}, {"text": "ramucirumab", "start": 27, "end": 38, "id": 3, "ws": true}, {"text": "(", "start": 39, "end": 40, "id": 4, "ws": true}, {"text": "10mg/kg", "start": 41, "end": 48, "id": 5, "ws": true}, {"text": ")", "start": 49, "end": 50, "id": 6, "ws": true}, {"text": "+", "start": 51, "end": 52, "id": 7, "ws": true}, {"text": "dacarbazine", "start": 53, "end": 64, "id": 8, "ws": true}, {"text": "(", "start": 65, "end": 66, "id": 9, "ws": true}, {"text": "1000", "start": 67, "end": 71, "id": 10, "ws": true}, {"text": "mg/m(2", "start": 72, "end": 78, "id": 11, "ws": true}, {"text": ")", "start": 79, "end": 80, "id": 12, "ws": true}, {"text": ")", "start": 81, "end": 82, "id": 13, "ws": true}, {"text": "(", "start": 83, "end": 84, "id": 14, "ws": true}, {"text": "Arm", "start": 85, "end": 88, "id": 15, "ws": true}, {"text": "A", "start": 89, "end": 90, "id": 16, "ws": true}, {"text": ")", "start": 91, "end": 92, "id": 17, "ws": true}, {"text": "or", "start": 93, "end": 95, "id": 18, "ws": true}, {"text": "ramucirumab", "start": 96, "end": 107, "id": 19, "ws": true}, {"text": "only", "start": 108, "end": 112, "id": 20, "ws": true}, {"text": "(", "start": 113, "end": 114, "id": 21, "ws": true}, {"text": "10mg/kg", "start": 115, "end": 122, "id": 22, "ws": true}, {"text": ")", "start": 123, "end": 124, "id": 23, "ws": true}, {"text": "(", "start": 125, "end": 126, "id": 24, "ws": true}, {"text": "Arm", "start": 127, "end": 130, "id": 25, "ws": true}, {"text": "B", "start": 131, "end": 132, "id": 26, "ws": true}, {"text": ")", "start": 133, "end": 134, "id": 27, "ws": true}, {"text": "every", "start": 135, "end": 140, "id": 28, "ws": true}, {"text": "3", "start": 141, "end": 142, "id": 29, "ws": true}, {"text": "weeks", "start": 143, "end": 148, "id": 30, "ws": true}, {"text": ".", "start": 149, "end": 150, "id": 31, "ws": false}], "spans": [{"start": 27, "end": 38, "token_start": 3, "token_end": 3, "label": "DRUG"}, {"start": 53, "end": 64, "token_start": 8, "token_end": 8, "label": "DRUG"}, {"start": 96, "end": 107, "token_start": 19, "token_end": 19, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/24930625/", "_input_hash": 633570856, "_task_hash": -1516010704, "_session_id": "drug_drug_pilot_shared2b-dana_a", "_view_id": "blocks", "relations": [{"head": 3, "child": 8, "head_span": {"start": 27, "end": 38, "token_start": 3, "token_end": 3, "label": "DRUG"}, "child_span": {"start": 53, "end": 64, "token_start": 8, "token_end": 8, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Pharmacokinetic studies showed that chronic lymphocytic leukemia involving more than 80 % of the bone marrow at study start was associated with lower trough concentrations of alemtuzumab and rituximab , and that higher trough serum concentrations of alemtuzumab were associated with complete bone marrow clearance .", "paragraph": "<h3><u>A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.</u></h3>This study assessed the safety and preliminary efficacy of escalated dose subcutaneous <b style='color:Tomato;'><i>alemtuzumab</i></b> in combination with <b style='color:Tomato;'><i>rituximab</i></b> in chronic lymphocytic leukemia. Twenty-eight patients with relapsed refractory chronic lymphocytic leukemia were treated on four dosing cohorts of weekly <b style='color:Tomato;'><i>rituximab</i></b> at 375 mg/m(2) and <b style='color:Tomato;'><i>alemtuzumab</i></b> doses that started at 30 mg three times per week and escalated to weekly dosing over four weeks, culminating with 90 mg weekly. One dose limiting toxicity of a <b style='color:Tomato;'><i>rituximab</i></b> infusion reaction was seen in cohort 2, but the regimen was otherwise well tolerated without evidence of differential toxicity by cohort. The overall response rate by National Cancer Institute-Working Group criteria was 61%, and the rate of complete bone marrow response was 43%, most of whom were negative for minimal residual disease. The addition of CT scan evaluation per International Workshop on Chronic Lymphocytic Leukemia 2008 criteria reduced the overall response rate to 14%. Median overall survival was 35 months, with 12 patients able to proceed to stem cell transplantation. <b style='color:DodgerBlue;'><i>Pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>lymphocytic</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>involving</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>start</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>clearance</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We conclude that escalated subcutaneous doses of <b style='color:Tomato;'><i>alemtuzumab</i></b> given weekly are well tolerated and result in excellent bone marrow clearance of chronic lymphocytic leukemia, helping patients to proceed to stem cell transplantation. This study is registered at ClinicalTrials.gov (Identifier:00330252).", "tokens": [{"text": "Pharmacokinetic", "start": 0, "end": 15, "id": 0, "ws": true}, {"text": "studies", "start": 16, "end": 23, "id": 1, "ws": true}, {"text": "showed", "start": 24, "end": 30, "id": 2, "ws": true}, {"text": "that", "start": 31, "end": 35, "id": 3, "ws": true}, {"text": "chronic", "start": 36, "end": 43, "id": 4, "ws": true}, {"text": "lymphocytic", "start": 44, "end": 55, "id": 5, "ws": true}, {"text": "leukemia", "start": 56, "end": 64, "id": 6, "ws": true}, {"text": "involving", "start": 65, "end": 74, "id": 7, "ws": true}, {"text": "more", "start": 75, "end": 79, "id": 8, "ws": true}, {"text": "than", "start": 80, "end": 84, "id": 9, "ws": true}, {"text": "80", "start": 85, "end": 87, "id": 10, "ws": true}, {"text": "%", "start": 88, "end": 89, "id": 11, "ws": true}, {"text": "of", "start": 90, "end": 92, "id": 12, "ws": true}, {"text": "the", "start": 93, "end": 96, "id": 13, "ws": true}, {"text": "bone", "start": 97, "end": 101, "id": 14, "ws": true}, {"text": "marrow", "start": 102, "end": 108, "id": 15, "ws": true}, {"text": "at", "start": 109, "end": 111, "id": 16, "ws": true}, {"text": "study", "start": 112, "end": 117, "id": 17, "ws": true}, {"text": "start", "start": 118, "end": 123, "id": 18, "ws": true}, {"text": "was", "start": 124, "end": 127, "id": 19, "ws": true}, {"text": "associated", "start": 128, "end": 138, "id": 20, "ws": true}, {"text": "with", "start": 139, "end": 143, "id": 21, "ws": true}, {"text": "lower", "start": 144, "end": 149, "id": 22, "ws": true}, {"text": "trough", "start": 150, "end": 156, "id": 23, "ws": true}, {"text": "concentrations", "start": 157, "end": 171, "id": 24, "ws": true}, {"text": "of", "start": 172, "end": 174, "id": 25, "ws": true}, {"text": "alemtuzumab", "start": 175, "end": 186, "id": 26, "ws": true}, {"text": "and", "start": 187, "end": 190, "id": 27, "ws": true}, {"text": "rituximab", "start": 191, "end": 200, "id": 28, "ws": true}, {"text": ",", "start": 201, "end": 202, "id": 29, "ws": true}, {"text": "and", "start": 203, "end": 206, "id": 30, "ws": true}, {"text": "that", "start": 207, "end": 211, "id": 31, "ws": true}, {"text": "higher", "start": 212, "end": 218, "id": 32, "ws": true}, {"text": "trough", "start": 219, "end": 225, "id": 33, "ws": true}, {"text": "serum", "start": 226, "end": 231, "id": 34, "ws": true}, {"text": "concentrations", "start": 232, "end": 246, "id": 35, "ws": true}, {"text": "of", "start": 247, "end": 249, "id": 36, "ws": true}, {"text": "alemtuzumab", "start": 250, "end": 261, "id": 37, "ws": true}, {"text": "were", "start": 262, "end": 266, "id": 38, "ws": true}, {"text": "associated", "start": 267, "end": 277, "id": 39, "ws": true}, {"text": "with", "start": 278, "end": 282, "id": 40, "ws": true}, {"text": "complete", "start": 283, "end": 291, "id": 41, "ws": true}, {"text": "bone", "start": 292, "end": 296, "id": 42, "ws": true}, {"text": "marrow", "start": 297, "end": 303, "id": 43, "ws": true}, {"text": "clearance", "start": 304, "end": 313, "id": 44, "ws": true}, {"text": ".", "start": 314, "end": 315, "id": 45, "ws": false}], "spans": [{"start": 175, "end": 186, "token_start": 26, "token_end": 26, "label": "DRUG"}, {"start": 191, "end": 200, "token_start": 28, "token_end": 28, "label": "DRUG"}, {"start": 250, "end": 261, "token_start": 37, "token_end": 37, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/23645694/", "_input_hash": -1128840740, "_task_hash": -278706627, "_session_id": "drug_drug_pilot_shared2b-maytal", "_view_id": "blocks", "relations": [{"head": 26, "child": 28, "head_span": {"start": 175, "end": 186, "token_start": 26, "token_end": 26, "label": "DRUG"}, "child_span": {"start": 191, "end": 200, "token_start": 28, "token_end": 28, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with bevacizumab ( 5 mg/kg body weight i.v . every 21 days ) and oral capecitabine ( 950 mg/m(2 ) twice daily for 14 days followed by 7 days of rest ) in 2006 - 2008 .", "paragraph": "<h3><u>Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.</u></h3>No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended <b style='color:Tomato;'><i>mitotane</i></b> as monotherapy or combined with <b style='color:Tomato;'><i>etoposide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b> and cisplatin or with <b style='color:Tomato;'><i>streptozotocin</i></b> as first-line systemic therapy. However, there is no evidence for any therapy beneficial in patients failing these therapies. Therefore, we evaluated the effects of the anti-VEGF antibody <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> as salvage therapy in ACC. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>registered</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>German</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>Registry</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>offered</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>body</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>950</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>rest</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>2006</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2008</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Evaluation of tumour response was performed by imaging according to response evaluation criteria in solid tumours every 12 weeks. ### results Ten patients were treated with <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b>. None of them experienced any objective response or stable disease. Two patients had to stop therapy after few weeks due to hand-foot syndrome, and three patients died on progressive disease within 12 weeks. Other adverse events were mild (grade I-II). Median survival after treatment initiation was 124 days. ### conclusions <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> has no activity in patients with very advanced ACC. Hence, this regimen cannot be recommended as a salvage therapy.", "tokens": [{"text": "Patients", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "registered", "start": 9, "end": 19, "id": 1, "ws": true}, {"text": "with", "start": 20, "end": 24, "id": 2, "ws": true}, {"text": "the", "start": 25, "end": 28, "id": 3, "ws": true}, {"text": "German", "start": 29, "end": 35, "id": 4, "ws": true}, {"text": "ACC", "start": 36, "end": 39, "id": 5, "ws": true}, {"text": "Registry", "start": 40, "end": 48, "id": 6, "ws": true}, {"text": "with", "start": 49, "end": 53, "id": 7, "ws": true}, {"text": "refractory", "start": 54, "end": 64, "id": 8, "ws": true}, {"text": "ACC", "start": 65, "end": 68, "id": 9, "ws": true}, {"text": "progressing", "start": 69, "end": 80, "id": 10, "ws": true}, {"text": "after", "start": 81, "end": 86, "id": 11, "ws": true}, {"text": "cytotoxic", "start": 87, "end": 96, "id": 12, "ws": true}, {"text": "therapies", "start": 97, "end": 106, "id": 13, "ws": true}, {"text": "were", "start": 107, "end": 111, "id": 14, "ws": true}, {"text": "offered", "start": 112, "end": 119, "id": 15, "ws": true}, {"text": "treatment", "start": 120, "end": 129, "id": 16, "ws": true}, {"text": "with", "start": 130, "end": 134, "id": 17, "ws": true}, {"text": "bevacizumab", "start": 135, "end": 146, "id": 18, "ws": true}, {"text": "(", "start": 147, "end": 148, "id": 19, "ws": true}, {"text": "5", "start": 149, "end": 150, "id": 20, "ws": true}, {"text": "mg/kg", "start": 151, "end": 156, "id": 21, "ws": true}, {"text": "body", "start": 157, "end": 161, "id": 22, "ws": true}, {"text": "weight", "start": 162, "end": 168, "id": 23, "ws": true}, {"text": "i.v", "start": 169, "end": 172, "id": 24, "ws": true}, {"text": ".", "start": 173, "end": 174, "id": 25, "ws": true}, {"text": "every", "start": 175, "end": 180, "id": 26, "ws": true}, {"text": "21", "start": 181, "end": 183, "id": 27, "ws": true}, {"text": "days", "start": 184, "end": 188, "id": 28, "ws": true}, {"text": ")", "start": 189, "end": 190, "id": 29, "ws": true}, {"text": "and", "start": 191, "end": 194, "id": 30, "ws": true}, {"text": "oral", "start": 195, "end": 199, "id": 31, "ws": true}, {"text": "capecitabine", "start": 200, "end": 212, "id": 32, "ws": true}, {"text": "(", "start": 213, "end": 214, "id": 33, "ws": true}, {"text": "950", "start": 215, "end": 218, "id": 34, "ws": true}, {"text": "mg/m(2", "start": 219, "end": 225, "id": 35, "ws": true}, {"text": ")", "start": 226, "end": 227, "id": 36, "ws": true}, {"text": "twice", "start": 228, "end": 233, "id": 37, "ws": true}, {"text": "daily", "start": 234, "end": 239, "id": 38, "ws": true}, {"text": "for", "start": 240, "end": 243, "id": 39, "ws": true}, {"text": "14", "start": 244, "end": 246, "id": 40, "ws": true}, {"text": "days", "start": 247, "end": 251, "id": 41, "ws": true}, {"text": "followed", "start": 252, "end": 260, "id": 42, "ws": true}, {"text": "by", "start": 261, "end": 263, "id": 43, "ws": true}, {"text": "7", "start": 264, "end": 265, "id": 44, "ws": true}, {"text": "days", "start": 266, "end": 270, "id": 45, "ws": true}, {"text": "of", "start": 271, "end": 273, "id": 46, "ws": true}, {"text": "rest", "start": 274, "end": 278, "id": 47, "ws": true}, {"text": ")", "start": 279, "end": 280, "id": 48, "ws": true}, {"text": "in", "start": 281, "end": 283, "id": 49, "ws": true}, {"text": "2006", "start": 284, "end": 288, "id": 50, "ws": true}, {"text": "-", "start": 289, "end": 290, "id": 51, "ws": true}, {"text": "2008", "start": 291, "end": 295, "id": 52, "ws": true}, {"text": ".", "start": 296, "end": 297, "id": 53, "ws": false}], "spans": [{"start": 135, "end": 146, "token_start": 18, "token_end": 18, "label": "DRUG"}, {"start": 200, "end": 212, "token_start": 32, "token_end": 32, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/19903796/", "_input_hash": 1011764762, "_task_hash": -827463686, "_session_id": "drug_drug_pilot_shared2b-maytal", "_view_id": "blocks", "relations": [{"head": 18, "child": 32, "head_span": {"start": 135, "end": 146, "token_start": 18, "token_end": 18, "label": "DRUG"}, "child_span": {"start": 200, "end": 212, "token_start": 32, "token_end": 32, "label": "DRUG"}, "color": "#96e8ce", "label": "COMB1"}], "radio": [], "answer": "accept"}
{"text": "Patients who had pathologically been proven to have measurable lesions were treated with paclitaxel ( 200 mg/m(2 ) for 3 h ) and carboplatin [ area under the concentration-time curve ( AUC = 6 ) ] on day 1 and in 21 day cycles .", "paragraph": "<h3><u>Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.</u></h3>The combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> has been used to treat patients with many types of tumor, including gastric cancer. We evaluated the efficacy and safety of this combination in advanced gastric cancer patients previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>pathologically</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>proven</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>measurable</i></b> <b style='color:DodgerBlue;'><i>lesions</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results A partial response was achieved in 10 of 45 patients [22%, 95% confidence interval (CI), 10-34]. Of the 32 patients previously treated with cisplatin, four (13%) achieved partial response, whereas, of the 13 patients previously treated with heptaplatin, six (46%) achieved partial response. In all patients, the median time to progression was 14 weeks (95% CI, 10-18), and the median overall survival was 32 weeks (95% CI, 26-38). The most common grade 3/4 adverse events were neutropenia (40% of patients) and neuropathy (2.2%). Two patients developed neutropenic fever. However, there were no treatment-related deaths. ### conclusions Combination chemotherapy with <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> is feasible in patients with advanced gastric cancer who were previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum.", "tokens": [{"text": "Patients", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "who", "start": 9, "end": 12, "id": 1, "ws": true}, {"text": "had", "start": 13, "end": 16, "id": 2, "ws": true}, {"text": "pathologically", "start": 17, "end": 31, "id": 3, "ws": true}, {"text": "been", "start": 32, "end": 36, "id": 4, "ws": true}, {"text": "proven", "start": 37, "end": 43, "id": 5, "ws": true}, {"text": "to", "start": 44, "end": 46, "id": 6, "ws": true}, {"text": "have", "start": 47, "end": 51, "id": 7, "ws": true}, {"text": "measurable", "start": 52, "end": 62, "id": 8, "ws": true}, {"text": "lesions", "start": 63, "end": 70, "id": 9, "ws": true}, {"text": "were", "start": 71, "end": 75, "id": 10, "ws": true}, {"text": "treated", "start": 76, "end": 83, "id": 11, "ws": true}, {"text": "with", "start": 84, "end": 88, "id": 12, "ws": true}, {"text": "paclitaxel", "start": 89, "end": 99, "id": 13, "ws": true}, {"text": "(", "start": 100, "end": 101, "id": 14, "ws": true}, {"text": "200", "start": 102, "end": 105, "id": 15, "ws": true}, {"text": "mg/m(2", "start": 106, "end": 112, "id": 16, "ws": true}, {"text": ")", "start": 113, "end": 114, "id": 17, "ws": true}, {"text": "for", "start": 115, "end": 118, "id": 18, "ws": true}, {"text": "3", "start": 119, "end": 120, "id": 19, "ws": true}, {"text": "h", "start": 121, "end": 122, "id": 20, "ws": true}, {"text": ")", "start": 123, "end": 124, "id": 21, "ws": true}, {"text": "and", "start": 125, "end": 128, "id": 22, "ws": true}, {"text": "carboplatin", "start": 129, "end": 140, "id": 23, "ws": true}, {"text": "[", "start": 141, "end": 142, "id": 24, "ws": true}, {"text": "area", "start": 143, "end": 147, "id": 25, "ws": true}, {"text": "under", "start": 148, "end": 153, "id": 26, "ws": true}, {"text": "the", "start": 154, "end": 157, "id": 27, "ws": true}, {"text": "concentration-time", "start": 158, "end": 176, "id": 28, "ws": true}, {"text": "curve", "start": 177, "end": 182, "id": 29, "ws": true}, {"text": "(", "start": 183, "end": 184, "id": 30, "ws": true}, {"text": "AUC", "start": 185, "end": 188, "id": 31, "ws": true}, {"text": "=", "start": 189, "end": 190, "id": 32, "ws": true}, {"text": "6", "start": 191, "end": 192, "id": 33, "ws": true}, {"text": ")", "start": 193, "end": 194, "id": 34, "ws": true}, {"text": "]", "start": 195, "end": 196, "id": 35, "ws": true}, {"text": "on", "start": 197, "end": 199, "id": 36, "ws": true}, {"text": "day", "start": 200, "end": 203, "id": 37, "ws": true}, {"text": "1", "start": 204, "end": 205, "id": 38, "ws": true}, {"text": "and", "start": 206, "end": 209, "id": 39, "ws": true}, {"text": "in", "start": 210, "end": 212, "id": 40, "ws": true}, {"text": "21", "start": 213, "end": 215, "id": 41, "ws": true}, {"text": "day", "start": 216, "end": 219, "id": 42, "ws": true}, {"text": "cycles", "start": 220, "end": 226, "id": 43, "ws": true}, {"text": ".", "start": 227, "end": 228, "id": 44, "ws": false}], "spans": [{"start": 89, "end": 99, "token_start": 13, "token_end": 13, "label": "DRUG"}, {"start": 129, "end": 140, "token_start": 23, "token_end": 23, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/15886269/", "_input_hash": 980401099, "_task_hash": -2112546825, "_session_id": "drug_drug_pilot_shared2b-maytal", "_view_id": "blocks", "relations": [{"head": 13, "child": 23, "head_span": {"start": 89, "end": 99, "token_start": 13, "token_end": 13, "label": "DRUG"}, "child_span": {"start": 129, "end": 140, "token_start": 23, "token_end": 23, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "The aim of this study was to investigate the mutagenic and antigenotoxic effects of different doses of the flavonoid , apigenin , alone and in combination with the antitumor drugs , cyclophosphamide and doxorubicin , in vitro and in vivo .", "paragraph": "<h3><u>The effect of apigenin on cyclophosphamide and doxorubicin genotoxicity in vitro and in vivo.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mutagenic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>antigenotoxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>flavonoid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>apigenin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Using bacterial reverse mutation inhibition in vitro, with and without metabolic activation, the effect of apigenin (10-400 \u03bcg/plate) was studied on genotoxicity induced by <b style='color:Tomato;'><i>cyclophosphamide</i></b> (800 \u03bcg/plate) and by <b style='color:Tomato;'><i>doxorubicin</i></b> (0.2 \u03bcg/plate). Subsequent to a dose-finding study in vivo, CD1 mice were treated with either <b style='color:Tomato;'><i>cyclophosphamide</i></b> (40 mg/kg, i.p.) or <b style='color:Tomato;'><i>doxorubicin</i></b> (5 mg/kg, i.p.) with or without co-administration of apigenin (1-100 mg/kg, p.o.). Micronuclei were determined microscopically in blood smears and glutathione peroxidase (GPX), superoxide dismutase (SOD) and total antioxidative status (TAS) in whole blood, erythrocytes and plasma, respectively. Apigenin decreased <b style='color:Tomato;'><i>doxorubicin</i></b>-induced, but not <b style='color:Tomato;'><i>cyclophosphamide</i></b>-induced mutagenicity in vitro. In vivo, apigenin caused a statistically significant decrease in micronucleus frequency in response to <b style='color:Tomato;'><i>cyclophosphamide</i></b>, possibly due to active flavonoid metabolite formation or inhibition of <b style='color:Tomato;'><i>cyclophosphamide</i></b> metabolic activation. In animals treated with apigenin and <b style='color:Tomato;'><i>doxorubicin</i></b>, a significant decrease in micronucleus frequency was not observed, probably due to interindividual variability. No changes in GPX, SOD or TAS were observed in response to either cytotoxic agents or the flavonoid, possibly due to limited metabolic transformation of the drugs at the doses used. The results of the present study provide further evidence for the chemo-preventative properties of apigenin.", "tokens": [{"text": "The", "start": 0, "end": 3, "id": 0, "ws": true}, {"text": "aim", "start": 4, "end": 7, "id": 1, "ws": true}, {"text": "of", "start": 8, "end": 10, "id": 2, "ws": true}, {"text": "this", "start": 11, "end": 15, "id": 3, "ws": true}, {"text": "study", "start": 16, "end": 21, "id": 4, "ws": true}, {"text": "was", "start": 22, "end": 25, "id": 5, "ws": true}, {"text": "to", "start": 26, "end": 28, "id": 6, "ws": true}, {"text": "investigate", "start": 29, "end": 40, "id": 7, "ws": true}, {"text": "the", "start": 41, "end": 44, "id": 8, "ws": true}, {"text": "mutagenic", "start": 45, "end": 54, "id": 9, "ws": true}, {"text": "and", "start": 55, "end": 58, "id": 10, "ws": true}, {"text": "antigenotoxic", "start": 59, "end": 72, "id": 11, "ws": true}, {"text": "effects", "start": 73, "end": 80, "id": 12, "ws": true}, {"text": "of", "start": 81, "end": 83, "id": 13, "ws": true}, {"text": "different", "start": 84, "end": 93, "id": 14, "ws": true}, {"text": "doses", "start": 94, "end": 99, "id": 15, "ws": true}, {"text": "of", "start": 100, "end": 102, "id": 16, "ws": true}, {"text": "the", "start": 103, "end": 106, "id": 17, "ws": true}, {"text": "flavonoid", "start": 107, "end": 116, "id": 18, "ws": true}, {"text": ",", "start": 117, "end": 118, "id": 19, "ws": true}, {"text": "apigenin", "start": 119, "end": 127, "id": 20, "ws": true}, {"text": ",", "start": 128, "end": 129, "id": 21, "ws": true}, {"text": "alone", "start": 130, "end": 135, "id": 22, "ws": true}, {"text": "and", "start": 136, "end": 139, "id": 23, "ws": true}, {"text": "in", "start": 140, "end": 142, "id": 24, "ws": true}, {"text": "combination", "start": 143, "end": 154, "id": 25, "ws": true}, {"text": "with", "start": 155, "end": 159, "id": 26, "ws": true}, {"text": "the", "start": 160, "end": 163, "id": 27, "ws": true}, {"text": "antitumor", "start": 164, "end": 173, "id": 28, "ws": true}, {"text": "drugs", "start": 174, "end": 179, "id": 29, "ws": true}, {"text": ",", "start": 180, "end": 181, "id": 30, "ws": true}, {"text": "cyclophosphamide", "start": 182, "end": 198, "id": 31, "ws": true}, {"text": "and", "start": 199, "end": 202, "id": 32, "ws": true}, {"text": "doxorubicin", "start": 203, "end": 214, "id": 33, "ws": true}, {"text": ",", "start": 215, "end": 216, "id": 34, "ws": true}, {"text": "in", "start": 217, "end": 219, "id": 35, "ws": true}, {"text": "vitro", "start": 220, "end": 225, "id": 36, "ws": true}, {"text": "and", "start": 226, "end": 229, "id": 37, "ws": true}, {"text": "in", "start": 230, "end": 232, "id": 38, "ws": true}, {"text": "vivo", "start": 233, "end": 237, "id": 39, "ws": true}, {"text": ".", "start": 238, "end": 239, "id": 40, "ws": false}], "spans": [{"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": "DRUG"}, {"start": 182, "end": 198, "token_start": 31, "token_end": 31, "label": "DRUG"}, {"start": 203, "end": 214, "token_start": 33, "token_end": 33, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/21469013/", "_input_hash": 1631768353, "_task_hash": -923842770, "_session_id": "drug_drug_pilot_shared2b-dana_a", "_view_id": "blocks", "relations": [{"head": 20, "child": 31, "head_span": {"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": "DRUG"}, "child_span": {"start": 182, "end": 198, "token_start": 31, "token_end": 31, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}, {"head": 20, "child": 33, "head_span": {"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": "DRUG"}, "child_span": {"start": 203, "end": 214, "token_start": 33, "token_end": 33, "label": "DRUG"}, "color": "#ffd882", "label": "POS2"}], "radio": ["POS11", "POS21"], "answer": "accept"}
{"text": "More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of docetaxel , platinum , and fluorouracil ( TPF ) for treating metastatic SCCE .", "paragraph": "<h3><u>Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.</u></h3> <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>urgently</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>esophagus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TPF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This phase I/II trial (n = 12/39) was conducted in our institute from April 2005 to June 2008. Progression-free survival (PFS) and overall survival were analyzed by the Kaplan-Meier method. ### results The recommended dose of <b style='color:Tomato;'><i>docetaxel</i></b> was determined to be 50 mg/m in phase I. In phase II with a mean follow-up period of 13.3 months, the objective response rate was 66.6%, a median survival period of 13 months and PFS of 7 months was achieved, and the 1-year survival and PFS rates were 52.9% and 19.6%, respectively. Grade 3/4 toxicities of leukopenia, neutropenia, and anorexia were observed in 53.8%, 43.6%, and 25.6%, respectively. ### conclusions A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens. Randomized phase III trials of the TPF regimen are warranted and urgently required.", "tokens": [{"text": "More", "start": 0, "end": 4, "id": 0, "ws": true}, {"text": "effective", "start": 5, "end": 14, "id": 1, "ws": true}, {"text": "regimens", "start": 15, "end": 23, "id": 2, "ws": true}, {"text": "are", "start": 24, "end": 27, "id": 3, "ws": true}, {"text": "urgently", "start": 28, "end": 36, "id": 4, "ws": true}, {"text": "needed", "start": 37, "end": 43, "id": 5, "ws": true}, {"text": "for", "start": 44, "end": 47, "id": 6, "ws": true}, {"text": "squamous", "start": 48, "end": 56, "id": 7, "ws": true}, {"text": "cell", "start": 57, "end": 61, "id": 8, "ws": true}, {"text": "carcinoma", "start": 62, "end": 71, "id": 9, "ws": true}, {"text": "of", "start": 72, "end": 74, "id": 10, "ws": true}, {"text": "esophagus", "start": 75, "end": 84, "id": 11, "ws": true}, {"text": "(", "start": 85, "end": 86, "id": 12, "ws": true}, {"text": "SCCE", "start": 87, "end": 91, "id": 13, "ws": true}, {"text": ")", "start": 92, "end": 93, "id": 14, "ws": true}, {"text": ",", "start": 94, "end": 95, "id": 15, "ws": true}, {"text": "therefore", "start": 96, "end": 105, "id": 16, "ws": true}, {"text": ",", "start": 106, "end": 107, "id": 17, "ws": true}, {"text": "we", "start": 108, "end": 110, "id": 18, "ws": true}, {"text": "conducted", "start": 111, "end": 120, "id": 19, "ws": true}, {"text": "a", "start": 121, "end": 122, "id": 20, "ws": true}, {"text": "phase", "start": 123, "end": 128, "id": 21, "ws": true}, {"text": "I/II", "start": 129, "end": 133, "id": 22, "ws": true}, {"text": "trial", "start": 134, "end": 139, "id": 23, "ws": true}, {"text": "of", "start": 140, "end": 142, "id": 24, "ws": true}, {"text": "a", "start": 143, "end": 144, "id": 25, "ws": true}, {"text": "combination", "start": 145, "end": 156, "id": 26, "ws": true}, {"text": "of", "start": 157, "end": 159, "id": 27, "ws": true}, {"text": "docetaxel", "start": 160, "end": 169, "id": 28, "ws": true}, {"text": ",", "start": 170, "end": 171, "id": 29, "ws": true}, {"text": "platinum", "start": 172, "end": 180, "id": 30, "ws": true}, {"text": ",", "start": 181, "end": 182, "id": 31, "ws": true}, {"text": "and", "start": 183, "end": 186, "id": 32, "ws": true}, {"text": "fluorouracil", "start": 187, "end": 199, "id": 33, "ws": true}, {"text": "(", "start": 200, "end": 201, "id": 34, "ws": true}, {"text": "TPF", "start": 202, "end": 205, "id": 35, "ws": true}, {"text": ")", "start": 206, "end": 207, "id": 36, "ws": true}, {"text": "for", "start": 208, "end": 211, "id": 37, "ws": true}, {"text": "treating", "start": 212, "end": 220, "id": 38, "ws": true}, {"text": "metastatic", "start": 221, "end": 231, "id": 39, "ws": true}, {"text": "SCCE", "start": 232, "end": 236, "id": 40, "ws": true}, {"text": ".", "start": 237, "end": 238, "id": 41, "ws": false}], "spans": [{"start": 160, "end": 169, "token_start": 28, "token_end": 28, "label": "DRUG"}, {"start": 172, "end": 180, "token_start": 30, "token_end": 30, "label": "DRUG"}, {"start": 187, "end": 199, "token_start": 33, "token_end": 33, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/19898259/", "_input_hash": -830932666, "_task_hash": 1318102472, "_session_id": "drug_drug_pilot_shared2b-dana_a", "_view_id": "blocks", "relations": [{"head": 28, "child": 33, "head_span": {"start": 160, "end": 169, "token_start": 28, "token_end": 28, "label": "DRUG"}, "child_span": {"start": 187, "end": 199, "token_start": 33, "token_end": 33, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}, {"head": 30, "child": 28, "head_span": {"start": 172, "end": 180, "token_start": 30, "token_end": 30, "label": "DRUG"}, "child_span": {"start": 160, "end": 169, "token_start": 28, "token_end": 28, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "We determined the effects of diclofenac sodium , octreotide , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice .", "paragraph": "<h3><u>Diclofenac Sodium Treatment Ameliorates Extrapancreatic Organ Injuries in a Murine Model of Acute Pancreatitis Induced by Caerulein.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>determined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>diclofenac</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>extrapancreatic</i></b> <b style='color:DodgerBlue;'><i>organ</i></b> <b style='color:DodgerBlue;'><i>injuries</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>caerulein-induced</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>pancreatitis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A total of 58 BALB-C male mice (25\u2009g) were divided into seven groups and used to create a caerulein-induced acute pancreatitis model. <b style='color:Tomato;'><i>diclofenac</i></b> sodium, <b style='color:Tomato;'><i>octreotide</i></b>, and their combination were given for treatment of caerulin-induced acute pancreatitis in mice. At the end of the experiment, the lung, liver, kidney, and stomach were removed for histopathologic assessment. ### results Histopathologic investigation revealed a statistically significant difference between the groups in mean congestion, edema, tubular injury, perirenal fat tissue inflammation, and tubular stasis scores in kidney tissue ( ### conclusion <b style='color:Tomato;'><i>diclofenac</i></b> sodium alone ameliorates lung edema due to caerulin-induced acute pancreatitis.", "tokens": [{"text": "We", "start": 0, "end": 2, "id": 0, "ws": true}, {"text": "determined", "start": 3, "end": 13, "id": 1, "ws": true}, {"text": "the", "start": 14, "end": 17, "id": 2, "ws": true}, {"text": "effects", "start": 18, "end": 25, "id": 3, "ws": true}, {"text": "of", "start": 26, "end": 28, "id": 4, "ws": true}, {"text": "diclofenac", "start": 29, "end": 39, "id": 5, "ws": true}, {"text": "sodium", "start": 40, "end": 46, "id": 6, "ws": true}, {"text": ",", "start": 47, "end": 48, "id": 7, "ws": true}, {"text": "octreotide", "start": 49, "end": 59, "id": 8, "ws": true}, {"text": ",", "start": 60, "end": 61, "id": 9, "ws": true}, {"text": "and", "start": 62, "end": 65, "id": 10, "ws": true}, {"text": "their", "start": 66, "end": 71, "id": 11, "ws": true}, {"text": "combination", "start": 72, "end": 83, "id": 12, "ws": true}, {"text": "on", "start": 84, "end": 86, "id": 13, "ws": true}, {"text": "extrapancreatic", "start": 87, "end": 102, "id": 14, "ws": true}, {"text": "organ", "start": 103, "end": 108, "id": 15, "ws": true}, {"text": "injuries", "start": 109, "end": 117, "id": 16, "ws": true}, {"text": "in", "start": 118, "end": 120, "id": 17, "ws": true}, {"text": "caerulein-induced", "start": 121, "end": 138, "id": 18, "ws": true}, {"text": "acute", "start": 139, "end": 144, "id": 19, "ws": true}, {"text": "pancreatitis", "start": 145, "end": 157, "id": 20, "ws": true}, {"text": "in", "start": 158, "end": 160, "id": 21, "ws": true}, {"text": "mice", "start": 161, "end": 165, "id": 22, "ws": true}, {"text": ".", "start": 166, "end": 167, "id": 23, "ws": false}], "spans": [{"start": 29, "end": 39, "token_start": 5, "token_end": 5, "label": "DRUG"}, {"start": 49, "end": 59, "token_start": 8, "token_end": 8, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/30515205/", "_input_hash": 526527182, "_task_hash": 526499652, "_session_id": "drug_drug_pilot_shared2b-dana_a", "_view_id": "blocks", "relations": [{"head": 5, "child": 8, "head_span": {"start": 29, "end": 39, "token_start": 5, "token_end": 5, "label": "DRUG"}, "child_span": {"start": 49, "end": 59, "token_start": 8, "token_end": 8, "label": "DRUG"}, "color": "#c2f2f6", "label": "NEG1"}], "radio": ["NEG11"], "answer": "accept"}
{"text": "Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib ( MLN9708 ) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant .", "paragraph": "<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>Ib</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Oral</i></b> <b style='color:DodgerBlue;'><i>Proteasome</i></b> <b style='color:DodgerBlue;'><i>Inhibitor</i></b> <b style='color:MediumOrchid;'><i>Ixazomib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MLN9708</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Advanced</i></b> <b style='color:DodgerBlue;'><i>ER+</i></b> <b style='color:DodgerBlue;'><i>Breast</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>Progressing</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### background <b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### methods This is a single-center phase Ib study with a 3+3 design of <b style='color:Tomato;'><i>fulvestrant</i></b> and the proteasome inhibitor <b style='color:Tomato;'><i>ixazomib</i></b> (MLN9708) in patients with advanced ER+ breast cancer that was progressing on <b style='color:Tomato;'><i>fulvestrant</i></b>. A dose-escalation design allowed establishment of the <b style='color:Tomato;'><i>ixazomib</i></b> maximum tolerated dose (MTD). Secondary objectives included progression-free survival, pharmacokinetics, and tumor molecular analyses. ### results Among nine evaluable subjects, treatment was well-tolerated without dose-limiting toxicities The MTD of <b style='color:Tomato;'><i>ixazomib</i></b> was 4 mg in combination with <b style='color:Tomato;'><i>fulvestrant</i></b>. Plasma concentrations of the active form of <b style='color:Tomato;'><i>ixazomib</i></b> (MLN2238) in the 4-mg dose cohort had a median (range) Cmax of 155 (122-171) ng/mL; Tmax of 1 (1-1.5) h; terminal elimination half-life of 66.6 (57.3-102.6) hr after initial dose; AUC of 5,025 (4,160-5,345) ng*h/mL. One partial response was observed, and median progression-free survival was 51\u2009days (range 47-137). ### conclusion This drug combination has a favorable safety profile and anti-tumor activity in patients with <b style='color:Tomato;'><i>fulvestrant</i></b>-resistant advanced ER+ breast cancer that justifies future testing.", "tokens": [{"text": "Phase", "start": 0, "end": 5, "id": 0, "ws": true}, {"text": "Ib", "start": 6, "end": 8, "id": 1, "ws": true}, {"text": "Study", "start": 9, "end": 14, "id": 2, "ws": true}, {"text": "of", "start": 15, "end": 17, "id": 3, "ws": true}, {"text": "the", "start": 18, "end": 21, "id": 4, "ws": true}, {"text": "Oral", "start": 22, "end": 26, "id": 5, "ws": true}, {"text": "Proteasome", "start": 27, "end": 37, "id": 6, "ws": true}, {"text": "Inhibitor", "start": 38, "end": 47, "id": 7, "ws": true}, {"text": "Ixazomib", "start": 48, "end": 56, "id": 8, "ws": true}, {"text": "(", "start": 57, "end": 58, "id": 9, "ws": true}, {"text": "MLN9708", "start": 59, "end": 66, "id": 10, "ws": true}, {"text": ")", "start": 67, "end": 68, "id": 11, "ws": true}, {"text": "and", "start": 69, "end": 72, "id": 12, "ws": true}, {"text": "Fulvestrant", "start": 73, "end": 84, "id": 13, "ws": true}, {"text": "in", "start": 85, "end": 87, "id": 14, "ws": true}, {"text": "Advanced", "start": 88, "end": 96, "id": 15, "ws": true}, {"text": "ER+", "start": 97, "end": 100, "id": 16, "ws": true}, {"text": "Breast", "start": 101, "end": 107, "id": 17, "ws": true}, {"text": "Cancer", "start": 108, "end": 114, "id": 18, "ws": true}, {"text": "Progressing", "start": 115, "end": 126, "id": 19, "ws": true}, {"text": "on", "start": 127, "end": 129, "id": 20, "ws": true}, {"text": "Fulvestrant", "start": 130, "end": 141, "id": 21, "ws": true}, {"text": ".", "start": 142, "end": 143, "id": 22, "ws": false}], "spans": [{"start": 48, "end": 56, "token_start": 8, "token_end": 8, "label": "DRUG"}, {"start": 73, "end": 84, "token_start": 13, "token_end": 13, "label": "DRUG"}, {"start": 130, "end": 141, "token_start": 21, "token_end": 21, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/33641211/", "_input_hash": -1014334224, "_task_hash": 1740062343, "_session_id": "drug_drug_pilot_shared2b-yuval", "_view_id": "blocks", "relations": [{"head": 8, "child": 13, "head_span": {"start": 48, "end": 56, "token_start": 8, "token_end": 8, "label": "DRUG"}, "child_span": {"start": 73, "end": 84, "token_start": 13, "token_end": 13, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Pharmacokinetic studies showed that chronic lymphocytic leukemia involving more than 80 % of the bone marrow at study start was associated with lower trough concentrations of alemtuzumab and rituximab , and that higher trough serum concentrations of alemtuzumab were associated with complete bone marrow clearance .", "paragraph": "<h3><u>A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.</u></h3>This study assessed the safety and preliminary efficacy of escalated dose subcutaneous <b style='color:Tomato;'><i>alemtuzumab</i></b> in combination with <b style='color:Tomato;'><i>rituximab</i></b> in chronic lymphocytic leukemia. Twenty-eight patients with relapsed refractory chronic lymphocytic leukemia were treated on four dosing cohorts of weekly <b style='color:Tomato;'><i>rituximab</i></b> at 375 mg/m(2) and <b style='color:Tomato;'><i>alemtuzumab</i></b> doses that started at 30 mg three times per week and escalated to weekly dosing over four weeks, culminating with 90 mg weekly. One dose limiting toxicity of a <b style='color:Tomato;'><i>rituximab</i></b> infusion reaction was seen in cohort 2, but the regimen was otherwise well tolerated without evidence of differential toxicity by cohort. The overall response rate by National Cancer Institute-Working Group criteria was 61%, and the rate of complete bone marrow response was 43%, most of whom were negative for minimal residual disease. The addition of CT scan evaluation per International Workshop on Chronic Lymphocytic Leukemia 2008 criteria reduced the overall response rate to 14%. Median overall survival was 35 months, with 12 patients able to proceed to stem cell transplantation. <b style='color:DodgerBlue;'><i>Pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>lymphocytic</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>involving</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>start</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>clearance</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We conclude that escalated subcutaneous doses of <b style='color:Tomato;'><i>alemtuzumab</i></b> given weekly are well tolerated and result in excellent bone marrow clearance of chronic lymphocytic leukemia, helping patients to proceed to stem cell transplantation. This study is registered at ClinicalTrials.gov (Identifier:00330252).", "tokens": [{"text": "Pharmacokinetic", "start": 0, "end": 15, "id": 0, "ws": true}, {"text": "studies", "start": 16, "end": 23, "id": 1, "ws": true}, {"text": "showed", "start": 24, "end": 30, "id": 2, "ws": true}, {"text": "that", "start": 31, "end": 35, "id": 3, "ws": true}, {"text": "chronic", "start": 36, "end": 43, "id": 4, "ws": true}, {"text": "lymphocytic", "start": 44, "end": 55, "id": 5, "ws": true}, {"text": "leukemia", "start": 56, "end": 64, "id": 6, "ws": true}, {"text": "involving", "start": 65, "end": 74, "id": 7, "ws": true}, {"text": "more", "start": 75, "end": 79, "id": 8, "ws": true}, {"text": "than", "start": 80, "end": 84, "id": 9, "ws": true}, {"text": "80", "start": 85, "end": 87, "id": 10, "ws": true}, {"text": "%", "start": 88, "end": 89, "id": 11, "ws": true}, {"text": "of", "start": 90, "end": 92, "id": 12, "ws": true}, {"text": "the", "start": 93, "end": 96, "id": 13, "ws": true}, {"text": "bone", "start": 97, "end": 101, "id": 14, "ws": true}, {"text": "marrow", "start": 102, "end": 108, "id": 15, "ws": true}, {"text": "at", "start": 109, "end": 111, "id": 16, "ws": true}, {"text": "study", "start": 112, "end": 117, "id": 17, "ws": true}, {"text": "start", "start": 118, "end": 123, "id": 18, "ws": true}, {"text": "was", "start": 124, "end": 127, "id": 19, "ws": true}, {"text": "associated", "start": 128, "end": 138, "id": 20, "ws": true}, {"text": "with", "start": 139, "end": 143, "id": 21, "ws": true}, {"text": "lower", "start": 144, "end": 149, "id": 22, "ws": true}, {"text": "trough", "start": 150, "end": 156, "id": 23, "ws": true}, {"text": "concentrations", "start": 157, "end": 171, "id": 24, "ws": true}, {"text": "of", "start": 172, "end": 174, "id": 25, "ws": true}, {"text": "alemtuzumab", "start": 175, "end": 186, "id": 26, "ws": true}, {"text": "and", "start": 187, "end": 190, "id": 27, "ws": true}, {"text": "rituximab", "start": 191, "end": 200, "id": 28, "ws": true}, {"text": ",", "start": 201, "end": 202, "id": 29, "ws": true}, {"text": "and", "start": 203, "end": 206, "id": 30, "ws": true}, {"text": "that", "start": 207, "end": 211, "id": 31, "ws": true}, {"text": "higher", "start": 212, "end": 218, "id": 32, "ws": true}, {"text": "trough", "start": 219, "end": 225, "id": 33, "ws": true}, {"text": "serum", "start": 226, "end": 231, "id": 34, "ws": true}, {"text": "concentrations", "start": 232, "end": 246, "id": 35, "ws": true}, {"text": "of", "start": 247, "end": 249, "id": 36, "ws": true}, {"text": "alemtuzumab", "start": 250, "end": 261, "id": 37, "ws": true}, {"text": "were", "start": 262, "end": 266, "id": 38, "ws": true}, {"text": "associated", "start": 267, "end": 277, "id": 39, "ws": true}, {"text": "with", "start": 278, "end": 282, "id": 40, "ws": true}, {"text": "complete", "start": 283, "end": 291, "id": 41, "ws": true}, {"text": "bone", "start": 292, "end": 296, "id": 42, "ws": true}, {"text": "marrow", "start": 297, "end": 303, "id": 43, "ws": true}, {"text": "clearance", "start": 304, "end": 313, "id": 44, "ws": true}, {"text": ".", "start": 314, "end": 315, "id": 45, "ws": false}], "spans": [{"start": 175, "end": 186, "token_start": 26, "token_end": 26, "label": "DRUG"}, {"start": 191, "end": 200, "token_start": 28, "token_end": 28, "label": "DRUG"}, {"start": 250, "end": 261, "token_start": 37, "token_end": 37, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/23645694/", "_input_hash": -1128840740, "_task_hash": -278706627, "_session_id": "drug_drug_pilot_shared2b-yuval", "_view_id": "blocks", "relations": [{"head": 26, "child": 28, "head_span": {"start": 175, "end": 186, "token_start": 26, "token_end": 26, "label": "DRUG"}, "child_span": {"start": 191, "end": 200, "token_start": 28, "token_end": 28, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with bevacizumab ( 5 mg/kg body weight i.v . every 21 days ) and oral capecitabine ( 950 mg/m(2 ) twice daily for 14 days followed by 7 days of rest ) in 2006 - 2008 .", "paragraph": "<h3><u>Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.</u></h3>No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended <b style='color:Tomato;'><i>mitotane</i></b> as monotherapy or combined with <b style='color:Tomato;'><i>etoposide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b> and cisplatin or with <b style='color:Tomato;'><i>streptozotocin</i></b> as first-line systemic therapy. However, there is no evidence for any therapy beneficial in patients failing these therapies. Therefore, we evaluated the effects of the anti-VEGF antibody <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> as salvage therapy in ACC. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>registered</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>German</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>Registry</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>offered</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>body</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>950</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>rest</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>2006</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2008</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Evaluation of tumour response was performed by imaging according to response evaluation criteria in solid tumours every 12 weeks. ### results Ten patients were treated with <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b>. None of them experienced any objective response or stable disease. Two patients had to stop therapy after few weeks due to hand-foot syndrome, and three patients died on progressive disease within 12 weeks. Other adverse events were mild (grade I-II). Median survival after treatment initiation was 124 days. ### conclusions <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> has no activity in patients with very advanced ACC. Hence, this regimen cannot be recommended as a salvage therapy.", "tokens": [{"text": "Patients", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "registered", "start": 9, "end": 19, "id": 1, "ws": true}, {"text": "with", "start": 20, "end": 24, "id": 2, "ws": true}, {"text": "the", "start": 25, "end": 28, "id": 3, "ws": true}, {"text": "German", "start": 29, "end": 35, "id": 4, "ws": true}, {"text": "ACC", "start": 36, "end": 39, "id": 5, "ws": true}, {"text": "Registry", "start": 40, "end": 48, "id": 6, "ws": true}, {"text": "with", "start": 49, "end": 53, "id": 7, "ws": true}, {"text": "refractory", "start": 54, "end": 64, "id": 8, "ws": true}, {"text": "ACC", "start": 65, "end": 68, "id": 9, "ws": true}, {"text": "progressing", "start": 69, "end": 80, "id": 10, "ws": true}, {"text": "after", "start": 81, "end": 86, "id": 11, "ws": true}, {"text": "cytotoxic", "start": 87, "end": 96, "id": 12, "ws": true}, {"text": "therapies", "start": 97, "end": 106, "id": 13, "ws": true}, {"text": "were", "start": 107, "end": 111, "id": 14, "ws": true}, {"text": "offered", "start": 112, "end": 119, "id": 15, "ws": true}, {"text": "treatment", "start": 120, "end": 129, "id": 16, "ws": true}, {"text": "with", "start": 130, "end": 134, "id": 17, "ws": true}, {"text": "bevacizumab", "start": 135, "end": 146, "id": 18, "ws": true}, {"text": "(", "start": 147, "end": 148, "id": 19, "ws": true}, {"text": "5", "start": 149, "end": 150, "id": 20, "ws": true}, {"text": "mg/kg", "start": 151, "end": 156, "id": 21, "ws": true}, {"text": "body", "start": 157, "end": 161, "id": 22, "ws": true}, {"text": "weight", "start": 162, "end": 168, "id": 23, "ws": true}, {"text": "i.v", "start": 169, "end": 172, "id": 24, "ws": true}, {"text": ".", "start": 173, "end": 174, "id": 25, "ws": true}, {"text": "every", "start": 175, "end": 180, "id": 26, "ws": true}, {"text": "21", "start": 181, "end": 183, "id": 27, "ws": true}, {"text": "days", "start": 184, "end": 188, "id": 28, "ws": true}, {"text": ")", "start": 189, "end": 190, "id": 29, "ws": true}, {"text": "and", "start": 191, "end": 194, "id": 30, "ws": true}, {"text": "oral", "start": 195, "end": 199, "id": 31, "ws": true}, {"text": "capecitabine", "start": 200, "end": 212, "id": 32, "ws": true}, {"text": "(", "start": 213, "end": 214, "id": 33, "ws": true}, {"text": "950", "start": 215, "end": 218, "id": 34, "ws": true}, {"text": "mg/m(2", "start": 219, "end": 225, "id": 35, "ws": true}, {"text": ")", "start": 226, "end": 227, "id": 36, "ws": true}, {"text": "twice", "start": 228, "end": 233, "id": 37, "ws": true}, {"text": "daily", "start": 234, "end": 239, "id": 38, "ws": true}, {"text": "for", "start": 240, "end": 243, "id": 39, "ws": true}, {"text": "14", "start": 244, "end": 246, "id": 40, "ws": true}, {"text": "days", "start": 247, "end": 251, "id": 41, "ws": true}, {"text": "followed", "start": 252, "end": 260, "id": 42, "ws": true}, {"text": "by", "start": 261, "end": 263, "id": 43, "ws": true}, {"text": "7", "start": 264, "end": 265, "id": 44, "ws": true}, {"text": "days", "start": 266, "end": 270, "id": 45, "ws": true}, {"text": "of", "start": 271, "end": 273, "id": 46, "ws": true}, {"text": "rest", "start": 274, "end": 278, "id": 47, "ws": true}, {"text": ")", "start": 279, "end": 280, "id": 48, "ws": true}, {"text": "in", "start": 281, "end": 283, "id": 49, "ws": true}, {"text": "2006", "start": 284, "end": 288, "id": 50, "ws": true}, {"text": "-", "start": 289, "end": 290, "id": 51, "ws": true}, {"text": "2008", "start": 291, "end": 295, "id": 52, "ws": true}, {"text": ".", "start": 296, "end": 297, "id": 53, "ws": false}], "spans": [{"start": 135, "end": 146, "token_start": 18, "token_end": 18, "label": "DRUG"}, {"start": 200, "end": 212, "token_start": 32, "token_end": 32, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/19903796/", "_input_hash": 1011764762, "_task_hash": -827463686, "_session_id": "drug_drug_pilot_shared2b-yuval", "_view_id": "blocks", "relations": [{"head": 18, "child": 32, "head_span": {"start": 135, "end": 146, "token_start": 18, "token_end": 18, "label": "DRUG"}, "child_span": {"start": 200, "end": 212, "token_start": 32, "token_end": 32, "label": "DRUG"}, "color": "#c2f2f6", "label": "NEG1"}], "radio": ["NEG11"], "answer": "accept"}
{"text": "Patients who had pathologically been proven to have measurable lesions were treated with paclitaxel ( 200 mg/m(2 ) for 3 h ) and carboplatin [ area under the concentration-time curve ( AUC = 6 ) ] on day 1 and in 21 day cycles .", "paragraph": "<h3><u>Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.</u></h3>The combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> has been used to treat patients with many types of tumor, including gastric cancer. We evaluated the efficacy and safety of this combination in advanced gastric cancer patients previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>pathologically</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>proven</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>measurable</i></b> <b style='color:DodgerBlue;'><i>lesions</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results A partial response was achieved in 10 of 45 patients [22%, 95% confidence interval (CI), 10-34]. Of the 32 patients previously treated with cisplatin, four (13%) achieved partial response, whereas, of the 13 patients previously treated with heptaplatin, six (46%) achieved partial response. In all patients, the median time to progression was 14 weeks (95% CI, 10-18), and the median overall survival was 32 weeks (95% CI, 26-38). The most common grade 3/4 adverse events were neutropenia (40% of patients) and neuropathy (2.2%). Two patients developed neutropenic fever. However, there were no treatment-related deaths. ### conclusions Combination chemotherapy with <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> is feasible in patients with advanced gastric cancer who were previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum.", "tokens": [{"text": "Patients", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "who", "start": 9, "end": 12, "id": 1, "ws": true}, {"text": "had", "start": 13, "end": 16, "id": 2, "ws": true}, {"text": "pathologically", "start": 17, "end": 31, "id": 3, "ws": true}, {"text": "been", "start": 32, "end": 36, "id": 4, "ws": true}, {"text": "proven", "start": 37, "end": 43, "id": 5, "ws": true}, {"text": "to", "start": 44, "end": 46, "id": 6, "ws": true}, {"text": "have", "start": 47, "end": 51, "id": 7, "ws": true}, {"text": "measurable", "start": 52, "end": 62, "id": 8, "ws": true}, {"text": "lesions", "start": 63, "end": 70, "id": 9, "ws": true}, {"text": "were", "start": 71, "end": 75, "id": 10, "ws": true}, {"text": "treated", "start": 76, "end": 83, "id": 11, "ws": true}, {"text": "with", "start": 84, "end": 88, "id": 12, "ws": true}, {"text": "paclitaxel", "start": 89, "end": 99, "id": 13, "ws": true}, {"text": "(", "start": 100, "end": 101, "id": 14, "ws": true}, {"text": "200", "start": 102, "end": 105, "id": 15, "ws": true}, {"text": "mg/m(2", "start": 106, "end": 112, "id": 16, "ws": true}, {"text": ")", "start": 113, "end": 114, "id": 17, "ws": true}, {"text": "for", "start": 115, "end": 118, "id": 18, "ws": true}, {"text": "3", "start": 119, "end": 120, "id": 19, "ws": true}, {"text": "h", "start": 121, "end": 122, "id": 20, "ws": true}, {"text": ")", "start": 123, "end": 124, "id": 21, "ws": true}, {"text": "and", "start": 125, "end": 128, "id": 22, "ws": true}, {"text": "carboplatin", "start": 129, "end": 140, "id": 23, "ws": true}, {"text": "[", "start": 141, "end": 142, "id": 24, "ws": true}, {"text": "area", "start": 143, "end": 147, "id": 25, "ws": true}, {"text": "under", "start": 148, "end": 153, "id": 26, "ws": true}, {"text": "the", "start": 154, "end": 157, "id": 27, "ws": true}, {"text": "concentration-time", "start": 158, "end": 176, "id": 28, "ws": true}, {"text": "curve", "start": 177, "end": 182, "id": 29, "ws": true}, {"text": "(", "start": 183, "end": 184, "id": 30, "ws": true}, {"text": "AUC", "start": 185, "end": 188, "id": 31, "ws": true}, {"text": "=", "start": 189, "end": 190, "id": 32, "ws": true}, {"text": "6", "start": 191, "end": 192, "id": 33, "ws": true}, {"text": ")", "start": 193, "end": 194, "id": 34, "ws": true}, {"text": "]", "start": 195, "end": 196, "id": 35, "ws": true}, {"text": "on", "start": 197, "end": 199, "id": 36, "ws": true}, {"text": "day", "start": 200, "end": 203, "id": 37, "ws": true}, {"text": "1", "start": 204, "end": 205, "id": 38, "ws": true}, {"text": "and", "start": 206, "end": 209, "id": 39, "ws": true}, {"text": "in", "start": 210, "end": 212, "id": 40, "ws": true}, {"text": "21", "start": 213, "end": 215, "id": 41, "ws": true}, {"text": "day", "start": 216, "end": 219, "id": 42, "ws": true}, {"text": "cycles", "start": 220, "end": 226, "id": 43, "ws": true}, {"text": ".", "start": 227, "end": 228, "id": 44, "ws": false}], "spans": [{"start": 89, "end": 99, "token_start": 13, "token_end": 13, "label": "DRUG"}, {"start": 129, "end": 140, "token_start": 23, "token_end": 23, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/15886269/", "_input_hash": 980401099, "_task_hash": -2112546825, "_session_id": "drug_drug_pilot_shared2b-yuval", "_view_id": "blocks", "relations": [{"head": 13, "child": 23, "head_span": {"start": 89, "end": 99, "token_start": 13, "token_end": 13, "label": "DRUG"}, "child_span": {"start": 129, "end": 140, "token_start": 23, "token_end": 23, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Eligible patients received ramucirumab ( 10mg/kg ) + dacarbazine ( 1000 mg/m(2 ) ) ( Arm A ) or ramucirumab only ( 10mg/kg ) ( Arm B ) every 3 weeks .", "paragraph": "<h3><u>A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.</u></h3>To evaluate the efficacy and safety of <b style='color:Tomato;'><i>ramucirumab</i></b> (IMC-1121B; LY3009806), a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2, alone and in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> in chemotherapy-na\u00efve patients with metastatic melanoma (MM). ### methods <b style='color:DodgerBlue;'><i>Eligible</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end-point was progression-free survival (PFS); secondary end-points included overall survival (OS), overall response and safety. ### findings Of 106 randomised patients, 102 received study treatment (Arm A, N=52; Arm B, N=50). Baseline characteristics were similar in both arms. Median PFS was 2.6 months (Arm A) and 1.7 months (Arm B); median 6-month PFS rates were 30.7% and 17.9% and 12-month PFS rates were 23.7% and 15.6%, respectively. In Arm A, 9 (17.3%) patients had partial response (PR) and 19 (36.5%), stable disease (SD); PR and SD in Arm B were 2 (4.0%) and 21 (42.0%), respectively. Median OS was 8.7 months in Arm A and 11.1 months in Arm B. Patients in both arms tolerated the treatment with limited Grade 3/4 toxicities. ### interpretation <b style='color:Tomato;'><i>ramucirumab</i></b> alone or in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> was associated with an acceptable safety profile in patients with MM. Although the study was not powered for comparison between treatment arms, PFS appeared greater with combination therapy. Sustained disease control was observed on both study arm.", "tokens": [{"text": "Eligible", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "patients", "start": 9, "end": 17, "id": 1, "ws": true}, {"text": "received", "start": 18, "end": 26, "id": 2, "ws": true}, {"text": "ramucirumab", "start": 27, "end": 38, "id": 3, "ws": true}, {"text": "(", "start": 39, "end": 40, "id": 4, "ws": true}, {"text": "10mg/kg", "start": 41, "end": 48, "id": 5, "ws": true}, {"text": ")", "start": 49, "end": 50, "id": 6, "ws": true}, {"text": "+", "start": 51, "end": 52, "id": 7, "ws": true}, {"text": "dacarbazine", "start": 53, "end": 64, "id": 8, "ws": true}, {"text": "(", "start": 65, "end": 66, "id": 9, "ws": true}, {"text": "1000", "start": 67, "end": 71, "id": 10, "ws": true}, {"text": "mg/m(2", "start": 72, "end": 78, "id": 11, "ws": true}, {"text": ")", "start": 79, "end": 80, "id": 12, "ws": true}, {"text": ")", "start": 81, "end": 82, "id": 13, "ws": true}, {"text": "(", "start": 83, "end": 84, "id": 14, "ws": true}, {"text": "Arm", "start": 85, "end": 88, "id": 15, "ws": true}, {"text": "A", "start": 89, "end": 90, "id": 16, "ws": true}, {"text": ")", "start": 91, "end": 92, "id": 17, "ws": true}, {"text": "or", "start": 93, "end": 95, "id": 18, "ws": true}, {"text": "ramucirumab", "start": 96, "end": 107, "id": 19, "ws": true}, {"text": "only", "start": 108, "end": 112, "id": 20, "ws": true}, {"text": "(", "start": 113, "end": 114, "id": 21, "ws": true}, {"text": "10mg/kg", "start": 115, "end": 122, "id": 22, "ws": true}, {"text": ")", "start": 123, "end": 124, "id": 23, "ws": true}, {"text": "(", "start": 125, "end": 126, "id": 24, "ws": true}, {"text": "Arm", "start": 127, "end": 130, "id": 25, "ws": true}, {"text": "B", "start": 131, "end": 132, "id": 26, "ws": true}, {"text": ")", "start": 133, "end": 134, "id": 27, "ws": true}, {"text": "every", "start": 135, "end": 140, "id": 28, "ws": true}, {"text": "3", "start": 141, "end": 142, "id": 29, "ws": true}, {"text": "weeks", "start": 143, "end": 148, "id": 30, "ws": true}, {"text": ".", "start": 149, "end": 150, "id": 31, "ws": false}], "spans": [{"start": 27, "end": 38, "token_start": 3, "token_end": 3, "label": "DRUG"}, {"start": 53, "end": 64, "token_start": 8, "token_end": 8, "label": "DRUG"}, {"start": 96, "end": 107, "token_start": 19, "token_end": 19, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/24930625/", "_input_hash": 633570856, "_task_hash": -1516010704, "_session_id": "drug_drug_pilot_shared2b-yuval", "_view_id": "blocks", "relations": [{"head": 8, "child": 19, "head_span": {"start": 53, "end": 64, "token_start": 8, "token_end": 8, "label": "DRUG"}, "child_span": {"start": 96, "end": 107, "token_start": 19, "token_end": 19, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "The aim of this study was to investigate the mutagenic and antigenotoxic effects of different doses of the flavonoid , apigenin , alone and in combination with the antitumor drugs , cyclophosphamide and doxorubicin , in vitro and in vivo .", "paragraph": "<h3><u>The effect of apigenin on cyclophosphamide and doxorubicin genotoxicity in vitro and in vivo.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mutagenic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>antigenotoxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>flavonoid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>apigenin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Using bacterial reverse mutation inhibition in vitro, with and without metabolic activation, the effect of apigenin (10-400 \u03bcg/plate) was studied on genotoxicity induced by <b style='color:Tomato;'><i>cyclophosphamide</i></b> (800 \u03bcg/plate) and by <b style='color:Tomato;'><i>doxorubicin</i></b> (0.2 \u03bcg/plate). Subsequent to a dose-finding study in vivo, CD1 mice were treated with either <b style='color:Tomato;'><i>cyclophosphamide</i></b> (40 mg/kg, i.p.) or <b style='color:Tomato;'><i>doxorubicin</i></b> (5 mg/kg, i.p.) with or without co-administration of apigenin (1-100 mg/kg, p.o.). Micronuclei were determined microscopically in blood smears and glutathione peroxidase (GPX), superoxide dismutase (SOD) and total antioxidative status (TAS) in whole blood, erythrocytes and plasma, respectively. Apigenin decreased <b style='color:Tomato;'><i>doxorubicin</i></b>-induced, but not <b style='color:Tomato;'><i>cyclophosphamide</i></b>-induced mutagenicity in vitro. In vivo, apigenin caused a statistically significant decrease in micronucleus frequency in response to <b style='color:Tomato;'><i>cyclophosphamide</i></b>, possibly due to active flavonoid metabolite formation or inhibition of <b style='color:Tomato;'><i>cyclophosphamide</i></b> metabolic activation. In animals treated with apigenin and <b style='color:Tomato;'><i>doxorubicin</i></b>, a significant decrease in micronucleus frequency was not observed, probably due to interindividual variability. No changes in GPX, SOD or TAS were observed in response to either cytotoxic agents or the flavonoid, possibly due to limited metabolic transformation of the drugs at the doses used. The results of the present study provide further evidence for the chemo-preventative properties of apigenin.", "tokens": [{"text": "The", "start": 0, "end": 3, "id": 0, "ws": true}, {"text": "aim", "start": 4, "end": 7, "id": 1, "ws": true}, {"text": "of", "start": 8, "end": 10, "id": 2, "ws": true}, {"text": "this", "start": 11, "end": 15, "id": 3, "ws": true}, {"text": "study", "start": 16, "end": 21, "id": 4, "ws": true}, {"text": "was", "start": 22, "end": 25, "id": 5, "ws": true}, {"text": "to", "start": 26, "end": 28, "id": 6, "ws": true}, {"text": "investigate", "start": 29, "end": 40, "id": 7, "ws": true}, {"text": "the", "start": 41, "end": 44, "id": 8, "ws": true}, {"text": "mutagenic", "start": 45, "end": 54, "id": 9, "ws": true}, {"text": "and", "start": 55, "end": 58, "id": 10, "ws": true}, {"text": "antigenotoxic", "start": 59, "end": 72, "id": 11, "ws": true}, {"text": "effects", "start": 73, "end": 80, "id": 12, "ws": true}, {"text": "of", "start": 81, "end": 83, "id": 13, "ws": true}, {"text": "different", "start": 84, "end": 93, "id": 14, "ws": true}, {"text": "doses", "start": 94, "end": 99, "id": 15, "ws": true}, {"text": "of", "start": 100, "end": 102, "id": 16, "ws": true}, {"text": "the", "start": 103, "end": 106, "id": 17, "ws": true}, {"text": "flavonoid", "start": 107, "end": 116, "id": 18, "ws": true}, {"text": ",", "start": 117, "end": 118, "id": 19, "ws": true}, {"text": "apigenin", "start": 119, "end": 127, "id": 20, "ws": true}, {"text": ",", "start": 128, "end": 129, "id": 21, "ws": true}, {"text": "alone", "start": 130, "end": 135, "id": 22, "ws": true}, {"text": "and", "start": 136, "end": 139, "id": 23, "ws": true}, {"text": "in", "start": 140, "end": 142, "id": 24, "ws": true}, {"text": "combination", "start": 143, "end": 154, "id": 25, "ws": true}, {"text": "with", "start": 155, "end": 159, "id": 26, "ws": true}, {"text": "the", "start": 160, "end": 163, "id": 27, "ws": true}, {"text": "antitumor", "start": 164, "end": 173, "id": 28, "ws": true}, {"text": "drugs", "start": 174, "end": 179, "id": 29, "ws": true}, {"text": ",", "start": 180, "end": 181, "id": 30, "ws": true}, {"text": "cyclophosphamide", "start": 182, "end": 198, "id": 31, "ws": true}, {"text": "and", "start": 199, "end": 202, "id": 32, "ws": true}, {"text": "doxorubicin", "start": 203, "end": 214, "id": 33, "ws": true}, {"text": ",", "start": 215, "end": 216, "id": 34, "ws": true}, {"text": "in", "start": 217, "end": 219, "id": 35, "ws": true}, {"text": "vitro", "start": 220, "end": 225, "id": 36, "ws": true}, {"text": "and", "start": 226, "end": 229, "id": 37, "ws": true}, {"text": "in", "start": 230, "end": 232, "id": 38, "ws": true}, {"text": "vivo", "start": 233, "end": 237, "id": 39, "ws": true}, {"text": ".", "start": 238, "end": 239, "id": 40, "ws": false}], "spans": [{"start": 182, "end": 198, "token_start": 31, "token_end": 31, "label": "DRUG"}, {"start": 203, "end": 214, "token_start": 33, "token_end": 33, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/21469013/", "_input_hash": 1631768353, "_task_hash": -923842770, "_session_id": "drug_drug_pilot_shared2b-yuval", "_view_id": "blocks", "relations": [{"head": 20, "child": 31, "head_span": {"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": null}, "child_span": {"start": 182, "end": 198, "token_start": 31, "token_end": 31, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}, {"head": 20, "child": 33, "head_span": {"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": null}, "child_span": {"start": 203, "end": 214, "token_start": 33, "token_end": 33, "label": "DRUG"}, "color": "#ffd882", "label": "POS2"}], "radio": ["POS11", "POS21"], "answer": "accept"}
{"text": "More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of docetaxel , platinum , and fluorouracil ( TPF ) for treating metastatic SCCE .", "paragraph": "<h3><u>Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.</u></h3> <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>urgently</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>esophagus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TPF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This phase I/II trial (n = 12/39) was conducted in our institute from April 2005 to June 2008. Progression-free survival (PFS) and overall survival were analyzed by the Kaplan-Meier method. ### results The recommended dose of <b style='color:Tomato;'><i>docetaxel</i></b> was determined to be 50 mg/m in phase I. In phase II with a mean follow-up period of 13.3 months, the objective response rate was 66.6%, a median survival period of 13 months and PFS of 7 months was achieved, and the 1-year survival and PFS rates were 52.9% and 19.6%, respectively. Grade 3/4 toxicities of leukopenia, neutropenia, and anorexia were observed in 53.8%, 43.6%, and 25.6%, respectively. ### conclusions A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens. Randomized phase III trials of the TPF regimen are warranted and urgently required.", "tokens": [{"text": "More", "start": 0, "end": 4, "id": 0, "ws": true}, {"text": "effective", "start": 5, "end": 14, "id": 1, "ws": true}, {"text": "regimens", "start": 15, "end": 23, "id": 2, "ws": true}, {"text": "are", "start": 24, "end": 27, "id": 3, "ws": true}, {"text": "urgently", "start": 28, "end": 36, "id": 4, "ws": true}, {"text": "needed", "start": 37, "end": 43, "id": 5, "ws": true}, {"text": "for", "start": 44, "end": 47, "id": 6, "ws": true}, {"text": "squamous", "start": 48, "end": 56, "id": 7, "ws": true}, {"text": "cell", "start": 57, "end": 61, "id": 8, "ws": true}, {"text": "carcinoma", "start": 62, "end": 71, "id": 9, "ws": true}, {"text": "of", "start": 72, "end": 74, "id": 10, "ws": true}, {"text": "esophagus", "start": 75, "end": 84, "id": 11, "ws": true}, {"text": "(", "start": 85, "end": 86, "id": 12, "ws": true}, {"text": "SCCE", "start": 87, "end": 91, "id": 13, "ws": true}, {"text": ")", "start": 92, "end": 93, "id": 14, "ws": true}, {"text": ",", "start": 94, "end": 95, "id": 15, "ws": true}, {"text": "therefore", "start": 96, "end": 105, "id": 16, "ws": true}, {"text": ",", "start": 106, "end": 107, "id": 17, "ws": true}, {"text": "we", "start": 108, "end": 110, "id": 18, "ws": true}, {"text": "conducted", "start": 111, "end": 120, "id": 19, "ws": true}, {"text": "a", "start": 121, "end": 122, "id": 20, "ws": true}, {"text": "phase", "start": 123, "end": 128, "id": 21, "ws": true}, {"text": "I/II", "start": 129, "end": 133, "id": 22, "ws": true}, {"text": "trial", "start": 134, "end": 139, "id": 23, "ws": true}, {"text": "of", "start": 140, "end": 142, "id": 24, "ws": true}, {"text": "a", "start": 143, "end": 144, "id": 25, "ws": true}, {"text": "combination", "start": 145, "end": 156, "id": 26, "ws": true}, {"text": "of", "start": 157, "end": 159, "id": 27, "ws": true}, {"text": "docetaxel", "start": 160, "end": 169, "id": 28, "ws": true}, {"text": ",", "start": 170, "end": 171, "id": 29, "ws": true}, {"text": "platinum", "start": 172, "end": 180, "id": 30, "ws": true}, {"text": ",", "start": 181, "end": 182, "id": 31, "ws": true}, {"text": "and", "start": 183, "end": 186, "id": 32, "ws": true}, {"text": "fluorouracil", "start": 187, "end": 199, "id": 33, "ws": true}, {"text": "(", "start": 200, "end": 201, "id": 34, "ws": true}, {"text": "TPF", "start": 202, "end": 205, "id": 35, "ws": true}, {"text": ")", "start": 206, "end": 207, "id": 36, "ws": true}, {"text": "for", "start": 208, "end": 211, "id": 37, "ws": true}, {"text": "treating", "start": 212, "end": 220, "id": 38, "ws": true}, {"text": "metastatic", "start": 221, "end": 231, "id": 39, "ws": true}, {"text": "SCCE", "start": 232, "end": 236, "id": 40, "ws": true}, {"text": ".", "start": 237, "end": 238, "id": 41, "ws": false}], "spans": [{"start": 160, "end": 169, "token_start": 28, "token_end": 28, "label": "DRUG"}, {"start": 187, "end": 199, "token_start": 33, "token_end": 33, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/19898259/", "_input_hash": -830932666, "_task_hash": 1318102472, "_session_id": "drug_drug_pilot_shared2b-yuval", "_view_id": "blocks", "relations": [{"head": 33, "child": 28, "head_span": {"start": 187, "end": 199, "token_start": 33, "token_end": 33, "label": "DRUG"}, "child_span": {"start": 160, "end": 169, "token_start": 28, "token_end": 28, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}, {"head": 30, "child": 28, "head_span": {"start": 172, "end": 180, "token_start": 30, "token_end": 30, "label": null}, "child_span": {"start": 160, "end": 169, "token_start": 28, "token_end": 28, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "We determined the effects of diclofenac sodium , octreotide , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice .", "paragraph": "<h3><u>Diclofenac Sodium Treatment Ameliorates Extrapancreatic Organ Injuries in a Murine Model of Acute Pancreatitis Induced by Caerulein.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>determined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>diclofenac</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>extrapancreatic</i></b> <b style='color:DodgerBlue;'><i>organ</i></b> <b style='color:DodgerBlue;'><i>injuries</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>caerulein-induced</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>pancreatitis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A total of 58 BALB-C male mice (25\u2009g) were divided into seven groups and used to create a caerulein-induced acute pancreatitis model. <b style='color:Tomato;'><i>diclofenac</i></b> sodium, <b style='color:Tomato;'><i>octreotide</i></b>, and their combination were given for treatment of caerulin-induced acute pancreatitis in mice. At the end of the experiment, the lung, liver, kidney, and stomach were removed for histopathologic assessment. ### results Histopathologic investigation revealed a statistically significant difference between the groups in mean congestion, edema, tubular injury, perirenal fat tissue inflammation, and tubular stasis scores in kidney tissue ( ### conclusion <b style='color:Tomato;'><i>diclofenac</i></b> sodium alone ameliorates lung edema due to caerulin-induced acute pancreatitis.", "tokens": [{"text": "We", "start": 0, "end": 2, "id": 0, "ws": true}, {"text": "determined", "start": 3, "end": 13, "id": 1, "ws": true}, {"text": "the", "start": 14, "end": 17, "id": 2, "ws": true}, {"text": "effects", "start": 18, "end": 25, "id": 3, "ws": true}, {"text": "of", "start": 26, "end": 28, "id": 4, "ws": true}, {"text": "diclofenac", "start": 29, "end": 39, "id": 5, "ws": true}, {"text": "sodium", "start": 40, "end": 46, "id": 6, "ws": true}, {"text": ",", "start": 47, "end": 48, "id": 7, "ws": true}, {"text": "octreotide", "start": 49, "end": 59, "id": 8, "ws": true}, {"text": ",", "start": 60, "end": 61, "id": 9, "ws": true}, {"text": "and", "start": 62, "end": 65, "id": 10, "ws": true}, {"text": "their", "start": 66, "end": 71, "id": 11, "ws": true}, {"text": "combination", "start": 72, "end": 83, "id": 12, "ws": true}, {"text": "on", "start": 84, "end": 86, "id": 13, "ws": true}, {"text": "extrapancreatic", "start": 87, "end": 102, "id": 14, "ws": true}, {"text": "organ", "start": 103, "end": 108, "id": 15, "ws": true}, {"text": "injuries", "start": 109, "end": 117, "id": 16, "ws": true}, {"text": "in", "start": 118, "end": 120, "id": 17, "ws": true}, {"text": "caerulein-induced", "start": 121, "end": 138, "id": 18, "ws": true}, {"text": "acute", "start": 139, "end": 144, "id": 19, "ws": true}, {"text": "pancreatitis", "start": 145, "end": 157, "id": 20, "ws": true}, {"text": "in", "start": 158, "end": 160, "id": 21, "ws": true}, {"text": "mice", "start": 161, "end": 165, "id": 22, "ws": true}, {"text": ".", "start": 166, "end": 167, "id": 23, "ws": false}], "spans": [{"start": 29, "end": 46, "token_start": 5, "token_end": 6, "label": "DRUG"}, {"start": 49, "end": 59, "token_start": 8, "token_end": 8, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/30515205/", "_input_hash": 526527182, "_task_hash": 526499652, "_session_id": "drug_drug_pilot_shared2b-yuval", "_view_id": "blocks", "relations": [{"head": 6, "child": 8, "head_span": {"start": 29, "end": 46, "token_start": 5, "token_end": 6, "label": "DRUG"}, "child_span": {"start": 49, "end": 59, "token_start": 8, "token_end": 8, "label": "DRUG"}, "color": "#96e8ce", "label": "COMB1"}], "radio": [], "answer": "accept"}
{"text": "Eligible patients received ramucirumab ( 10mg/kg ) + dacarbazine ( 1000 mg/m(2 ) ) ( Arm A ) or ramucirumab only ( 10mg/kg ) ( Arm B ) every 3 weeks .", "paragraph": "<h3><u>A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.</u></h3>To evaluate the efficacy and safety of <b style='color:Tomato;'><i>ramucirumab</i></b> (IMC-1121B; LY3009806), a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2, alone and in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> in chemotherapy-na\u00efve patients with metastatic melanoma (MM). ### methods <b style='color:DodgerBlue;'><i>Eligible</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end-point was progression-free survival (PFS); secondary end-points included overall survival (OS), overall response and safety. ### findings Of 106 randomised patients, 102 received study treatment (Arm A, N=52; Arm B, N=50). Baseline characteristics were similar in both arms. Median PFS was 2.6 months (Arm A) and 1.7 months (Arm B); median 6-month PFS rates were 30.7% and 17.9% and 12-month PFS rates were 23.7% and 15.6%, respectively. In Arm A, 9 (17.3%) patients had partial response (PR) and 19 (36.5%), stable disease (SD); PR and SD in Arm B were 2 (4.0%) and 21 (42.0%), respectively. Median OS was 8.7 months in Arm A and 11.1 months in Arm B. Patients in both arms tolerated the treatment with limited Grade 3/4 toxicities. ### interpretation <b style='color:Tomato;'><i>ramucirumab</i></b> alone or in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> was associated with an acceptable safety profile in patients with MM. Although the study was not powered for comparison between treatment arms, PFS appeared greater with combination therapy. Sustained disease control was observed on both study arm.", "tokens": [{"text": "Eligible", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "patients", "start": 9, "end": 17, "id": 1, "ws": true}, {"text": "received", "start": 18, "end": 26, "id": 2, "ws": true}, {"text": "ramucirumab", "start": 27, "end": 38, "id": 3, "ws": true}, {"text": "(", "start": 39, "end": 40, "id": 4, "ws": true}, {"text": "10mg/kg", "start": 41, "end": 48, "id": 5, "ws": true}, {"text": ")", "start": 49, "end": 50, "id": 6, "ws": true}, {"text": "+", "start": 51, "end": 52, "id": 7, "ws": true}, {"text": "dacarbazine", "start": 53, "end": 64, "id": 8, "ws": true}, {"text": "(", "start": 65, "end": 66, "id": 9, "ws": true}, {"text": "1000", "start": 67, "end": 71, "id": 10, "ws": true}, {"text": "mg/m(2", "start": 72, "end": 78, "id": 11, "ws": true}, {"text": ")", "start": 79, "end": 80, "id": 12, "ws": true}, {"text": ")", "start": 81, "end": 82, "id": 13, "ws": true}, {"text": "(", "start": 83, "end": 84, "id": 14, "ws": true}, {"text": "Arm", "start": 85, "end": 88, "id": 15, "ws": true}, {"text": "A", "start": 89, "end": 90, "id": 16, "ws": true}, {"text": ")", "start": 91, "end": 92, "id": 17, "ws": true}, {"text": "or", "start": 93, "end": 95, "id": 18, "ws": true}, {"text": "ramucirumab", "start": 96, "end": 107, "id": 19, "ws": true}, {"text": "only", "start": 108, "end": 112, "id": 20, "ws": true}, {"text": "(", "start": 113, "end": 114, "id": 21, "ws": true}, {"text": "10mg/kg", "start": 115, "end": 122, "id": 22, "ws": true}, {"text": ")", "start": 123, "end": 124, "id": 23, "ws": true}, {"text": "(", "start": 125, "end": 126, "id": 24, "ws": true}, {"text": "Arm", "start": 127, "end": 130, "id": 25, "ws": true}, {"text": "B", "start": 131, "end": 132, "id": 26, "ws": true}, {"text": ")", "start": 133, "end": 134, "id": 27, "ws": true}, {"text": "every", "start": 135, "end": 140, "id": 28, "ws": true}, {"text": "3", "start": 141, "end": 142, "id": 29, "ws": true}, {"text": "weeks", "start": 143, "end": 148, "id": 30, "ws": true}, {"text": ".", "start": 149, "end": 150, "id": 31, "ws": false}], "spans": [{"start": 27, "end": 38, "token_start": 3, "token_end": 3, "label": "DRUG"}, {"start": 53, "end": 64, "token_start": 8, "token_end": 8, "label": "DRUG"}, {"start": 96, "end": 107, "token_start": 19, "token_end": 19, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/24930625/", "_input_hash": 633570856, "_task_hash": -1516010704, "_session_id": "drug_drug_pilot_shared2b-maytal", "_view_id": "blocks", "relations": [{"head": 3, "child": 8, "head_span": {"start": 27, "end": 38, "token_start": 3, "token_end": 3, "label": "DRUG"}, "child_span": {"start": 53, "end": 64, "token_start": 8, "token_end": 8, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "The aim of this study was to investigate the mutagenic and antigenotoxic effects of different doses of the flavonoid , apigenin , alone and in combination with the antitumor drugs , cyclophosphamide and doxorubicin , in vitro and in vivo .", "paragraph": "<h3><u>The effect of apigenin on cyclophosphamide and doxorubicin genotoxicity in vitro and in vivo.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mutagenic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>antigenotoxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>flavonoid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>apigenin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Using bacterial reverse mutation inhibition in vitro, with and without metabolic activation, the effect of apigenin (10-400 \u03bcg/plate) was studied on genotoxicity induced by <b style='color:Tomato;'><i>cyclophosphamide</i></b> (800 \u03bcg/plate) and by <b style='color:Tomato;'><i>doxorubicin</i></b> (0.2 \u03bcg/plate). Subsequent to a dose-finding study in vivo, CD1 mice were treated with either <b style='color:Tomato;'><i>cyclophosphamide</i></b> (40 mg/kg, i.p.) or <b style='color:Tomato;'><i>doxorubicin</i></b> (5 mg/kg, i.p.) with or without co-administration of apigenin (1-100 mg/kg, p.o.). Micronuclei were determined microscopically in blood smears and glutathione peroxidase (GPX), superoxide dismutase (SOD) and total antioxidative status (TAS) in whole blood, erythrocytes and plasma, respectively. Apigenin decreased <b style='color:Tomato;'><i>doxorubicin</i></b>-induced, but not <b style='color:Tomato;'><i>cyclophosphamide</i></b>-induced mutagenicity in vitro. In vivo, apigenin caused a statistically significant decrease in micronucleus frequency in response to <b style='color:Tomato;'><i>cyclophosphamide</i></b>, possibly due to active flavonoid metabolite formation or inhibition of <b style='color:Tomato;'><i>cyclophosphamide</i></b> metabolic activation. In animals treated with apigenin and <b style='color:Tomato;'><i>doxorubicin</i></b>, a significant decrease in micronucleus frequency was not observed, probably due to interindividual variability. No changes in GPX, SOD or TAS were observed in response to either cytotoxic agents or the flavonoid, possibly due to limited metabolic transformation of the drugs at the doses used. The results of the present study provide further evidence for the chemo-preventative properties of apigenin.", "tokens": [{"text": "The", "start": 0, "end": 3, "id": 0, "ws": true}, {"text": "aim", "start": 4, "end": 7, "id": 1, "ws": true}, {"text": "of", "start": 8, "end": 10, "id": 2, "ws": true}, {"text": "this", "start": 11, "end": 15, "id": 3, "ws": true}, {"text": "study", "start": 16, "end": 21, "id": 4, "ws": true}, {"text": "was", "start": 22, "end": 25, "id": 5, "ws": true}, {"text": "to", "start": 26, "end": 28, "id": 6, "ws": true}, {"text": "investigate", "start": 29, "end": 40, "id": 7, "ws": true}, {"text": "the", "start": 41, "end": 44, "id": 8, "ws": true}, {"text": "mutagenic", "start": 45, "end": 54, "id": 9, "ws": true}, {"text": "and", "start": 55, "end": 58, "id": 10, "ws": true}, {"text": "antigenotoxic", "start": 59, "end": 72, "id": 11, "ws": true}, {"text": "effects", "start": 73, "end": 80, "id": 12, "ws": true}, {"text": "of", "start": 81, "end": 83, "id": 13, "ws": true}, {"text": "different", "start": 84, "end": 93, "id": 14, "ws": true}, {"text": "doses", "start": 94, "end": 99, "id": 15, "ws": true}, {"text": "of", "start": 100, "end": 102, "id": 16, "ws": true}, {"text": "the", "start": 103, "end": 106, "id": 17, "ws": true}, {"text": "flavonoid", "start": 107, "end": 116, "id": 18, "ws": true}, {"text": ",", "start": 117, "end": 118, "id": 19, "ws": true}, {"text": "apigenin", "start": 119, "end": 127, "id": 20, "ws": true}, {"text": ",", "start": 128, "end": 129, "id": 21, "ws": true}, {"text": "alone", "start": 130, "end": 135, "id": 22, "ws": true}, {"text": "and", "start": 136, "end": 139, "id": 23, "ws": true}, {"text": "in", "start": 140, "end": 142, "id": 24, "ws": true}, {"text": "combination", "start": 143, "end": 154, "id": 25, "ws": true}, {"text": "with", "start": 155, "end": 159, "id": 26, "ws": true}, {"text": "the", "start": 160, "end": 163, "id": 27, "ws": true}, {"text": "antitumor", "start": 164, "end": 173, "id": 28, "ws": true}, {"text": "drugs", "start": 174, "end": 179, "id": 29, "ws": true}, {"text": ",", "start": 180, "end": 181, "id": 30, "ws": true}, {"text": "cyclophosphamide", "start": 182, "end": 198, "id": 31, "ws": true}, {"text": "and", "start": 199, "end": 202, "id": 32, "ws": true}, {"text": "doxorubicin", "start": 203, "end": 214, "id": 33, "ws": true}, {"text": ",", "start": 215, "end": 216, "id": 34, "ws": true}, {"text": "in", "start": 217, "end": 219, "id": 35, "ws": true}, {"text": "vitro", "start": 220, "end": 225, "id": 36, "ws": true}, {"text": "and", "start": 226, "end": 229, "id": 37, "ws": true}, {"text": "in", "start": 230, "end": 232, "id": 38, "ws": true}, {"text": "vivo", "start": 233, "end": 237, "id": 39, "ws": true}, {"text": ".", "start": 238, "end": 239, "id": 40, "ws": false}], "spans": [{"start": 182, "end": 198, "token_start": 31, "token_end": 31, "label": "DRUG"}, {"start": 203, "end": 214, "token_start": 33, "token_end": 33, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/21469013/", "_input_hash": 1631768353, "_task_hash": -923842770, "_session_id": "drug_drug_pilot_shared2b-maytal", "_view_id": "blocks", "relations": [{"head": 20, "child": 31, "head_span": {"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": null}, "child_span": {"start": 182, "end": 198, "token_start": 31, "token_end": 31, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}, {"head": 20, "child": 33, "head_span": {"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": null}, "child_span": {"start": 203, "end": 214, "token_start": 33, "token_end": 33, "label": "DRUG"}, "color": "#ffd882", "label": "POS2"}], "radio": ["POS11", "POS21"], "answer": "accept"}
{"text": "More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of docetaxel , platinum , and fluorouracil ( TPF ) for treating metastatic SCCE .", "paragraph": "<h3><u>Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.</u></h3> <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>urgently</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>esophagus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TPF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This phase I/II trial (n = 12/39) was conducted in our institute from April 2005 to June 2008. Progression-free survival (PFS) and overall survival were analyzed by the Kaplan-Meier method. ### results The recommended dose of <b style='color:Tomato;'><i>docetaxel</i></b> was determined to be 50 mg/m in phase I. In phase II with a mean follow-up period of 13.3 months, the objective response rate was 66.6%, a median survival period of 13 months and PFS of 7 months was achieved, and the 1-year survival and PFS rates were 52.9% and 19.6%, respectively. Grade 3/4 toxicities of leukopenia, neutropenia, and anorexia were observed in 53.8%, 43.6%, and 25.6%, respectively. ### conclusions A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens. Randomized phase III trials of the TPF regimen are warranted and urgently required.", "tokens": [{"text": "More", "start": 0, "end": 4, "id": 0, "ws": true}, {"text": "effective", "start": 5, "end": 14, "id": 1, "ws": true}, {"text": "regimens", "start": 15, "end": 23, "id": 2, "ws": true}, {"text": "are", "start": 24, "end": 27, "id": 3, "ws": true}, {"text": "urgently", "start": 28, "end": 36, "id": 4, "ws": true}, {"text": "needed", "start": 37, "end": 43, "id": 5, "ws": true}, {"text": "for", "start": 44, "end": 47, "id": 6, "ws": true}, {"text": "squamous", "start": 48, "end": 56, "id": 7, "ws": true}, {"text": "cell", "start": 57, "end": 61, "id": 8, "ws": true}, {"text": "carcinoma", "start": 62, "end": 71, "id": 9, "ws": true}, {"text": "of", "start": 72, "end": 74, "id": 10, "ws": true}, {"text": "esophagus", "start": 75, "end": 84, "id": 11, "ws": true}, {"text": "(", "start": 85, "end": 86, "id": 12, "ws": true}, {"text": "SCCE", "start": 87, "end": 91, "id": 13, "ws": true}, {"text": ")", "start": 92, "end": 93, "id": 14, "ws": true}, {"text": ",", "start": 94, "end": 95, "id": 15, "ws": true}, {"text": "therefore", "start": 96, "end": 105, "id": 16, "ws": true}, {"text": ",", "start": 106, "end": 107, "id": 17, "ws": true}, {"text": "we", "start": 108, "end": 110, "id": 18, "ws": true}, {"text": "conducted", "start": 111, "end": 120, "id": 19, "ws": true}, {"text": "a", "start": 121, "end": 122, "id": 20, "ws": true}, {"text": "phase", "start": 123, "end": 128, "id": 21, "ws": true}, {"text": "I/II", "start": 129, "end": 133, "id": 22, "ws": true}, {"text": "trial", "start": 134, "end": 139, "id": 23, "ws": true}, {"text": "of", "start": 140, "end": 142, "id": 24, "ws": true}, {"text": "a", "start": 143, "end": 144, "id": 25, "ws": true}, {"text": "combination", "start": 145, "end": 156, "id": 26, "ws": true}, {"text": "of", "start": 157, "end": 159, "id": 27, "ws": true}, {"text": "docetaxel", "start": 160, "end": 169, "id": 28, "ws": true}, {"text": ",", "start": 170, "end": 171, "id": 29, "ws": true}, {"text": "platinum", "start": 172, "end": 180, "id": 30, "ws": true}, {"text": ",", "start": 181, "end": 182, "id": 31, "ws": true}, {"text": "and", "start": 183, "end": 186, "id": 32, "ws": true}, {"text": "fluorouracil", "start": 187, "end": 199, "id": 33, "ws": true}, {"text": "(", "start": 200, "end": 201, "id": 34, "ws": true}, {"text": "TPF", "start": 202, "end": 205, "id": 35, "ws": true}, {"text": ")", "start": 206, "end": 207, "id": 36, "ws": true}, {"text": "for", "start": 208, "end": 211, "id": 37, "ws": true}, {"text": "treating", "start": 212, "end": 220, "id": 38, "ws": true}, {"text": "metastatic", "start": 221, "end": 231, "id": 39, "ws": true}, {"text": "SCCE", "start": 232, "end": 236, "id": 40, "ws": true}, {"text": ".", "start": 237, "end": 238, "id": 41, "ws": false}], "spans": [{"start": 160, "end": 169, "token_start": 28, "token_end": 28, "label": "DRUG"}, {"start": 187, "end": 199, "token_start": 33, "token_end": 33, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/19898259/", "_input_hash": -830932666, "_task_hash": 1318102472, "_session_id": "drug_drug_pilot_shared2b-maytal", "_view_id": "blocks", "relations": [{"head": 28, "child": 30, "head_span": {"start": 160, "end": 169, "token_start": 28, "token_end": 28, "label": "DRUG"}, "child_span": {"start": 172, "end": 180, "token_start": 30, "token_end": 30, "label": null}, "color": "#c5bdf4", "label": "POS1"}, {"head": 33, "child": 30, "head_span": {"start": 187, "end": 199, "token_start": 33, "token_end": 33, "label": "DRUG"}, "child_span": {"start": 172, "end": 180, "token_start": 30, "token_end": 30, "label": null}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "We determined the effects of diclofenac sodium , octreotide , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice .", "paragraph": "<h3><u>Diclofenac Sodium Treatment Ameliorates Extrapancreatic Organ Injuries in a Murine Model of Acute Pancreatitis Induced by Caerulein.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>determined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>diclofenac</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>extrapancreatic</i></b> <b style='color:DodgerBlue;'><i>organ</i></b> <b style='color:DodgerBlue;'><i>injuries</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>caerulein-induced</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>pancreatitis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A total of 58 BALB-C male mice (25\u2009g) were divided into seven groups and used to create a caerulein-induced acute pancreatitis model. <b style='color:Tomato;'><i>diclofenac</i></b> sodium, <b style='color:Tomato;'><i>octreotide</i></b>, and their combination were given for treatment of caerulin-induced acute pancreatitis in mice. At the end of the experiment, the lung, liver, kidney, and stomach were removed for histopathologic assessment. ### results Histopathologic investigation revealed a statistically significant difference between the groups in mean congestion, edema, tubular injury, perirenal fat tissue inflammation, and tubular stasis scores in kidney tissue ( ### conclusion <b style='color:Tomato;'><i>diclofenac</i></b> sodium alone ameliorates lung edema due to caerulin-induced acute pancreatitis.", "tokens": [{"text": "We", "start": 0, "end": 2, "id": 0, "ws": true}, {"text": "determined", "start": 3, "end": 13, "id": 1, "ws": true}, {"text": "the", "start": 14, "end": 17, "id": 2, "ws": true}, {"text": "effects", "start": 18, "end": 25, "id": 3, "ws": true}, {"text": "of", "start": 26, "end": 28, "id": 4, "ws": true}, {"text": "diclofenac", "start": 29, "end": 39, "id": 5, "ws": true}, {"text": "sodium", "start": 40, "end": 46, "id": 6, "ws": true}, {"text": ",", "start": 47, "end": 48, "id": 7, "ws": true}, {"text": "octreotide", "start": 49, "end": 59, "id": 8, "ws": true}, {"text": ",", "start": 60, "end": 61, "id": 9, "ws": true}, {"text": "and", "start": 62, "end": 65, "id": 10, "ws": true}, {"text": "their", "start": 66, "end": 71, "id": 11, "ws": true}, {"text": "combination", "start": 72, "end": 83, "id": 12, "ws": true}, {"text": "on", "start": 84, "end": 86, "id": 13, "ws": true}, {"text": "extrapancreatic", "start": 87, "end": 102, "id": 14, "ws": true}, {"text": "organ", "start": 103, "end": 108, "id": 15, "ws": true}, {"text": "injuries", "start": 109, "end": 117, "id": 16, "ws": true}, {"text": "in", "start": 118, "end": 120, "id": 17, "ws": true}, {"text": "caerulein-induced", "start": 121, "end": 138, "id": 18, "ws": true}, {"text": "acute", "start": 139, "end": 144, "id": 19, "ws": true}, {"text": "pancreatitis", "start": 145, "end": 157, "id": 20, "ws": true}, {"text": "in", "start": 158, "end": 160, "id": 21, "ws": true}, {"text": "mice", "start": 161, "end": 165, "id": 22, "ws": true}, {"text": ".", "start": 166, "end": 167, "id": 23, "ws": false}], "spans": [{"start": 29, "end": 39, "token_start": 5, "token_end": 5, "label": "DRUG"}, {"start": 49, "end": 59, "token_start": 8, "token_end": 8, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/30515205/", "_input_hash": 526527182, "_task_hash": 526499652, "_session_id": "drug_drug_pilot_shared2b-maytal", "_view_id": "blocks", "relations": [{"head": 5, "child": 8, "head_span": {"start": 29, "end": 39, "token_start": 5, "token_end": 5, "label": "DRUG"}, "child_span": {"start": 49, "end": 59, "token_start": 8, "token_end": 8, "label": "DRUG"}, "color": "#c2f2f6", "label": "NEG1"}], "radio": ["NEG11"], "answer": "accept"}
{"text": "Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib ( MLN9708 ) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant .", "paragraph": "<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>Ib</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Oral</i></b> <b style='color:DodgerBlue;'><i>Proteasome</i></b> <b style='color:DodgerBlue;'><i>Inhibitor</i></b> <b style='color:MediumOrchid;'><i>Ixazomib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MLN9708</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Advanced</i></b> <b style='color:DodgerBlue;'><i>ER+</i></b> <b style='color:DodgerBlue;'><i>Breast</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>Progressing</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### background <b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### methods This is a single-center phase Ib study with a 3+3 design of <b style='color:Tomato;'><i>fulvestrant</i></b> and the proteasome inhibitor <b style='color:Tomato;'><i>ixazomib</i></b> (MLN9708) in patients with advanced ER+ breast cancer that was progressing on <b style='color:Tomato;'><i>fulvestrant</i></b>. A dose-escalation design allowed establishment of the <b style='color:Tomato;'><i>ixazomib</i></b> maximum tolerated dose (MTD). Secondary objectives included progression-free survival, pharmacokinetics, and tumor molecular analyses. ### results Among nine evaluable subjects, treatment was well-tolerated without dose-limiting toxicities The MTD of <b style='color:Tomato;'><i>ixazomib</i></b> was 4 mg in combination with <b style='color:Tomato;'><i>fulvestrant</i></b>. Plasma concentrations of the active form of <b style='color:Tomato;'><i>ixazomib</i></b> (MLN2238) in the 4-mg dose cohort had a median (range) Cmax of 155 (122-171) ng/mL; Tmax of 1 (1-1.5) h; terminal elimination half-life of 66.6 (57.3-102.6) hr after initial dose; AUC of 5,025 (4,160-5,345) ng*h/mL. One partial response was observed, and median progression-free survival was 51\u2009days (range 47-137). ### conclusion This drug combination has a favorable safety profile and anti-tumor activity in patients with <b style='color:Tomato;'><i>fulvestrant</i></b>-resistant advanced ER+ breast cancer that justifies future testing.", "tokens": [{"text": "Phase", "start": 0, "end": 5, "id": 0, "ws": true}, {"text": "Ib", "start": 6, "end": 8, "id": 1, "ws": true}, {"text": "Study", "start": 9, "end": 14, "id": 2, "ws": true}, {"text": "of", "start": 15, "end": 17, "id": 3, "ws": true}, {"text": "the", "start": 18, "end": 21, "id": 4, "ws": true}, {"text": "Oral", "start": 22, "end": 26, "id": 5, "ws": true}, {"text": "Proteasome", "start": 27, "end": 37, "id": 6, "ws": true}, {"text": "Inhibitor", "start": 38, "end": 47, "id": 7, "ws": true}, {"text": "Ixazomib", "start": 48, "end": 56, "id": 8, "ws": true}, {"text": "(", "start": 57, "end": 58, "id": 9, "ws": true}, {"text": "MLN9708", "start": 59, "end": 66, "id": 10, "ws": true}, {"text": ")", "start": 67, "end": 68, "id": 11, "ws": true}, {"text": "and", "start": 69, "end": 72, "id": 12, "ws": true}, {"text": "Fulvestrant", "start": 73, "end": 84, "id": 13, "ws": true}, {"text": "in", "start": 85, "end": 87, "id": 14, "ws": true}, {"text": "Advanced", "start": 88, "end": 96, "id": 15, "ws": true}, {"text": "ER+", "start": 97, "end": 100, "id": 16, "ws": true}, {"text": "Breast", "start": 101, "end": 107, "id": 17, "ws": true}, {"text": "Cancer", "start": 108, "end": 114, "id": 18, "ws": true}, {"text": "Progressing", "start": 115, "end": 126, "id": 19, "ws": true}, {"text": "on", "start": 127, "end": 129, "id": 20, "ws": true}, {"text": "Fulvestrant", "start": 130, "end": 141, "id": 21, "ws": true}, {"text": ".", "start": 142, "end": 143, "id": 22, "ws": false}], "spans": [{"start": 48, "end": 56, "token_start": 8, "token_end": 8, "label": "DRUG"}, {"start": 73, "end": 84, "token_start": 13, "token_end": 13, "label": "DRUG"}, {"start": 130, "end": 141, "token_start": 21, "token_end": 21, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/33641211/", "_input_hash": -1014334224, "_task_hash": 1740062343, "_session_id": "drug_drug_pilot_shared2b-shaked", "_view_id": "blocks", "relations": [{"head": 8, "child": 13, "head_span": {"start": 48, "end": 56, "token_start": 8, "token_end": 8, "label": "DRUG"}, "child_span": {"start": 73, "end": 84, "token_start": 13, "token_end": 13, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}, {"head": 8, "child": 21, "head_span": {"start": 48, "end": 56, "token_start": 8, "token_end": 8, "label": "DRUG"}, "child_span": {"start": 130, "end": 141, "token_start": 21, "token_end": 21, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Pharmacokinetic studies showed that chronic lymphocytic leukemia involving more than 80 % of the bone marrow at study start was associated with lower trough concentrations of alemtuzumab and rituximab , and that higher trough serum concentrations of alemtuzumab were associated with complete bone marrow clearance .", "paragraph": "<h3><u>A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.</u></h3>This study assessed the safety and preliminary efficacy of escalated dose subcutaneous <b style='color:Tomato;'><i>alemtuzumab</i></b> in combination with <b style='color:Tomato;'><i>rituximab</i></b> in chronic lymphocytic leukemia. Twenty-eight patients with relapsed refractory chronic lymphocytic leukemia were treated on four dosing cohorts of weekly <b style='color:Tomato;'><i>rituximab</i></b> at 375 mg/m(2) and <b style='color:Tomato;'><i>alemtuzumab</i></b> doses that started at 30 mg three times per week and escalated to weekly dosing over four weeks, culminating with 90 mg weekly. One dose limiting toxicity of a <b style='color:Tomato;'><i>rituximab</i></b> infusion reaction was seen in cohort 2, but the regimen was otherwise well tolerated without evidence of differential toxicity by cohort. The overall response rate by National Cancer Institute-Working Group criteria was 61%, and the rate of complete bone marrow response was 43%, most of whom were negative for minimal residual disease. The addition of CT scan evaluation per International Workshop on Chronic Lymphocytic Leukemia 2008 criteria reduced the overall response rate to 14%. Median overall survival was 35 months, with 12 patients able to proceed to stem cell transplantation. <b style='color:DodgerBlue;'><i>Pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>lymphocytic</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>involving</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>start</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>clearance</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We conclude that escalated subcutaneous doses of <b style='color:Tomato;'><i>alemtuzumab</i></b> given weekly are well tolerated and result in excellent bone marrow clearance of chronic lymphocytic leukemia, helping patients to proceed to stem cell transplantation. This study is registered at ClinicalTrials.gov (Identifier:00330252).", "tokens": [{"text": "Pharmacokinetic", "start": 0, "end": 15, "id": 0, "ws": true}, {"text": "studies", "start": 16, "end": 23, "id": 1, "ws": true}, {"text": "showed", "start": 24, "end": 30, "id": 2, "ws": true}, {"text": "that", "start": 31, "end": 35, "id": 3, "ws": true}, {"text": "chronic", "start": 36, "end": 43, "id": 4, "ws": true}, {"text": "lymphocytic", "start": 44, "end": 55, "id": 5, "ws": true}, {"text": "leukemia", "start": 56, "end": 64, "id": 6, "ws": true}, {"text": "involving", "start": 65, "end": 74, "id": 7, "ws": true}, {"text": "more", "start": 75, "end": 79, "id": 8, "ws": true}, {"text": "than", "start": 80, "end": 84, "id": 9, "ws": true}, {"text": "80", "start": 85, "end": 87, "id": 10, "ws": true}, {"text": "%", "start": 88, "end": 89, "id": 11, "ws": true}, {"text": "of", "start": 90, "end": 92, "id": 12, "ws": true}, {"text": "the", "start": 93, "end": 96, "id": 13, "ws": true}, {"text": "bone", "start": 97, "end": 101, "id": 14, "ws": true}, {"text": "marrow", "start": 102, "end": 108, "id": 15, "ws": true}, {"text": "at", "start": 109, "end": 111, "id": 16, "ws": true}, {"text": "study", "start": 112, "end": 117, "id": 17, "ws": true}, {"text": "start", "start": 118, "end": 123, "id": 18, "ws": true}, {"text": "was", "start": 124, "end": 127, "id": 19, "ws": true}, {"text": "associated", "start": 128, "end": 138, "id": 20, "ws": true}, {"text": "with", "start": 139, "end": 143, "id": 21, "ws": true}, {"text": "lower", "start": 144, "end": 149, "id": 22, "ws": true}, {"text": "trough", "start": 150, "end": 156, "id": 23, "ws": true}, {"text": "concentrations", "start": 157, "end": 171, "id": 24, "ws": true}, {"text": "of", "start": 172, "end": 174, "id": 25, "ws": true}, {"text": "alemtuzumab", "start": 175, "end": 186, "id": 26, "ws": true}, {"text": "and", "start": 187, "end": 190, "id": 27, "ws": true}, {"text": "rituximab", "start": 191, "end": 200, "id": 28, "ws": true}, {"text": ",", "start": 201, "end": 202, "id": 29, "ws": true}, {"text": "and", "start": 203, "end": 206, "id": 30, "ws": true}, {"text": "that", "start": 207, "end": 211, "id": 31, "ws": true}, {"text": "higher", "start": 212, "end": 218, "id": 32, "ws": true}, {"text": "trough", "start": 219, "end": 225, "id": 33, "ws": true}, {"text": "serum", "start": 226, "end": 231, "id": 34, "ws": true}, {"text": "concentrations", "start": 232, "end": 246, "id": 35, "ws": true}, {"text": "of", "start": 247, "end": 249, "id": 36, "ws": true}, {"text": "alemtuzumab", "start": 250, "end": 261, "id": 37, "ws": true}, {"text": "were", "start": 262, "end": 266, "id": 38, "ws": true}, {"text": "associated", "start": 267, "end": 277, "id": 39, "ws": true}, {"text": "with", "start": 278, "end": 282, "id": 40, "ws": true}, {"text": "complete", "start": 283, "end": 291, "id": 41, "ws": true}, {"text": "bone", "start": 292, "end": 296, "id": 42, "ws": true}, {"text": "marrow", "start": 297, "end": 303, "id": 43, "ws": true}, {"text": "clearance", "start": 304, "end": 313, "id": 44, "ws": true}, {"text": ".", "start": 314, "end": 315, "id": 45, "ws": false}], "spans": [{"start": 175, "end": 186, "token_start": 26, "token_end": 26, "label": "DRUG"}, {"start": 191, "end": 200, "token_start": 28, "token_end": 28, "label": "DRUG"}, {"start": 250, "end": 261, "token_start": 37, "token_end": 37, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/23645694/", "_input_hash": -1128840740, "_task_hash": -278706627, "_session_id": "drug_drug_pilot_shared2b-shaked", "_view_id": "blocks", "relations": [{"head": 26, "child": 28, "head_span": {"start": 175, "end": 186, "token_start": 26, "token_end": 26, "label": "DRUG"}, "child_span": {"start": 191, "end": 200, "token_start": 28, "token_end": 28, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with bevacizumab ( 5 mg/kg body weight i.v . every 21 days ) and oral capecitabine ( 950 mg/m(2 ) twice daily for 14 days followed by 7 days of rest ) in 2006 - 2008 .", "paragraph": "<h3><u>Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.</u></h3>No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended <b style='color:Tomato;'><i>mitotane</i></b> as monotherapy or combined with <b style='color:Tomato;'><i>etoposide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b> and cisplatin or with <b style='color:Tomato;'><i>streptozotocin</i></b> as first-line systemic therapy. However, there is no evidence for any therapy beneficial in patients failing these therapies. Therefore, we evaluated the effects of the anti-VEGF antibody <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> as salvage therapy in ACC. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>registered</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>German</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>Registry</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>offered</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>body</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>950</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>rest</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>2006</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2008</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Evaluation of tumour response was performed by imaging according to response evaluation criteria in solid tumours every 12 weeks. ### results Ten patients were treated with <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b>. None of them experienced any objective response or stable disease. Two patients had to stop therapy after few weeks due to hand-foot syndrome, and three patients died on progressive disease within 12 weeks. Other adverse events were mild (grade I-II). Median survival after treatment initiation was 124 days. ### conclusions <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> has no activity in patients with very advanced ACC. Hence, this regimen cannot be recommended as a salvage therapy.", "tokens": [{"text": "Patients", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "registered", "start": 9, "end": 19, "id": 1, "ws": true}, {"text": "with", "start": 20, "end": 24, "id": 2, "ws": true}, {"text": "the", "start": 25, "end": 28, "id": 3, "ws": true}, {"text": "German", "start": 29, "end": 35, "id": 4, "ws": true}, {"text": "ACC", "start": 36, "end": 39, "id": 5, "ws": true}, {"text": "Registry", "start": 40, "end": 48, "id": 6, "ws": true}, {"text": "with", "start": 49, "end": 53, "id": 7, "ws": true}, {"text": "refractory", "start": 54, "end": 64, "id": 8, "ws": true}, {"text": "ACC", "start": 65, "end": 68, "id": 9, "ws": true}, {"text": "progressing", "start": 69, "end": 80, "id": 10, "ws": true}, {"text": "after", "start": 81, "end": 86, "id": 11, "ws": true}, {"text": "cytotoxic", "start": 87, "end": 96, "id": 12, "ws": true}, {"text": "therapies", "start": 97, "end": 106, "id": 13, "ws": true}, {"text": "were", "start": 107, "end": 111, "id": 14, "ws": true}, {"text": "offered", "start": 112, "end": 119, "id": 15, "ws": true}, {"text": "treatment", "start": 120, "end": 129, "id": 16, "ws": true}, {"text": "with", "start": 130, "end": 134, "id": 17, "ws": true}, {"text": "bevacizumab", "start": 135, "end": 146, "id": 18, "ws": true}, {"text": "(", "start": 147, "end": 148, "id": 19, "ws": true}, {"text": "5", "start": 149, "end": 150, "id": 20, "ws": true}, {"text": "mg/kg", "start": 151, "end": 156, "id": 21, "ws": true}, {"text": "body", "start": 157, "end": 161, "id": 22, "ws": true}, {"text": "weight", "start": 162, "end": 168, "id": 23, "ws": true}, {"text": "i.v", "start": 169, "end": 172, "id": 24, "ws": true}, {"text": ".", "start": 173, "end": 174, "id": 25, "ws": true}, {"text": "every", "start": 175, "end": 180, "id": 26, "ws": true}, {"text": "21", "start": 181, "end": 183, "id": 27, "ws": true}, {"text": "days", "start": 184, "end": 188, "id": 28, "ws": true}, {"text": ")", "start": 189, "end": 190, "id": 29, "ws": true}, {"text": "and", "start": 191, "end": 194, "id": 30, "ws": true}, {"text": "oral", "start": 195, "end": 199, "id": 31, "ws": true}, {"text": "capecitabine", "start": 200, "end": 212, "id": 32, "ws": true}, {"text": "(", "start": 213, "end": 214, "id": 33, "ws": true}, {"text": "950", "start": 215, "end": 218, "id": 34, "ws": true}, {"text": "mg/m(2", "start": 219, "end": 225, "id": 35, "ws": true}, {"text": ")", "start": 226, "end": 227, "id": 36, "ws": true}, {"text": "twice", "start": 228, "end": 233, "id": 37, "ws": true}, {"text": "daily", "start": 234, "end": 239, "id": 38, "ws": true}, {"text": "for", "start": 240, "end": 243, "id": 39, "ws": true}, {"text": "14", "start": 244, "end": 246, "id": 40, "ws": true}, {"text": "days", "start": 247, "end": 251, "id": 41, "ws": true}, {"text": "followed", "start": 252, "end": 260, "id": 42, "ws": true}, {"text": "by", "start": 261, "end": 263, "id": 43, "ws": true}, {"text": "7", "start": 264, "end": 265, "id": 44, "ws": true}, {"text": "days", "start": 266, "end": 270, "id": 45, "ws": true}, {"text": "of", "start": 271, "end": 273, "id": 46, "ws": true}, {"text": "rest", "start": 274, "end": 278, "id": 47, "ws": true}, {"text": ")", "start": 279, "end": 280, "id": 48, "ws": true}, {"text": "in", "start": 281, "end": 283, "id": 49, "ws": true}, {"text": "2006", "start": 284, "end": 288, "id": 50, "ws": true}, {"text": "-", "start": 289, "end": 290, "id": 51, "ws": true}, {"text": "2008", "start": 291, "end": 295, "id": 52, "ws": true}, {"text": ".", "start": 296, "end": 297, "id": 53, "ws": false}], "spans": [{"start": 135, "end": 146, "token_start": 18, "token_end": 18, "label": "DRUG"}, {"start": 200, "end": 212, "token_start": 32, "token_end": 32, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/19903796/", "_input_hash": 1011764762, "_task_hash": -827463686, "_session_id": "drug_drug_pilot_shared2b-shaked", "_view_id": "blocks", "relations": [{"head": 18, "child": 32, "head_span": {"start": 135, "end": 146, "token_start": 18, "token_end": 18, "label": "DRUG"}, "child_span": {"start": 200, "end": 212, "token_start": 32, "token_end": 32, "label": "DRUG"}, "color": "#c2f2f6", "label": "NEG1"}], "radio": ["NEG11"], "answer": "accept"}
{"text": "Patients who had pathologically been proven to have measurable lesions were treated with paclitaxel ( 200 mg/m(2 ) for 3 h ) and carboplatin [ area under the concentration-time curve ( AUC = 6 ) ] on day 1 and in 21 day cycles .", "paragraph": "<h3><u>Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.</u></h3>The combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> has been used to treat patients with many types of tumor, including gastric cancer. We evaluated the efficacy and safety of this combination in advanced gastric cancer patients previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>pathologically</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>proven</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>measurable</i></b> <b style='color:DodgerBlue;'><i>lesions</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results A partial response was achieved in 10 of 45 patients [22%, 95% confidence interval (CI), 10-34]. Of the 32 patients previously treated with cisplatin, four (13%) achieved partial response, whereas, of the 13 patients previously treated with heptaplatin, six (46%) achieved partial response. In all patients, the median time to progression was 14 weeks (95% CI, 10-18), and the median overall survival was 32 weeks (95% CI, 26-38). The most common grade 3/4 adverse events were neutropenia (40% of patients) and neuropathy (2.2%). Two patients developed neutropenic fever. However, there were no treatment-related deaths. ### conclusions Combination chemotherapy with <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> is feasible in patients with advanced gastric cancer who were previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum.", "tokens": [{"text": "Patients", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "who", "start": 9, "end": 12, "id": 1, "ws": true}, {"text": "had", "start": 13, "end": 16, "id": 2, "ws": true}, {"text": "pathologically", "start": 17, "end": 31, "id": 3, "ws": true}, {"text": "been", "start": 32, "end": 36, "id": 4, "ws": true}, {"text": "proven", "start": 37, "end": 43, "id": 5, "ws": true}, {"text": "to", "start": 44, "end": 46, "id": 6, "ws": true}, {"text": "have", "start": 47, "end": 51, "id": 7, "ws": true}, {"text": "measurable", "start": 52, "end": 62, "id": 8, "ws": true}, {"text": "lesions", "start": 63, "end": 70, "id": 9, "ws": true}, {"text": "were", "start": 71, "end": 75, "id": 10, "ws": true}, {"text": "treated", "start": 76, "end": 83, "id": 11, "ws": true}, {"text": "with", "start": 84, "end": 88, "id": 12, "ws": true}, {"text": "paclitaxel", "start": 89, "end": 99, "id": 13, "ws": true}, {"text": "(", "start": 100, "end": 101, "id": 14, "ws": true}, {"text": "200", "start": 102, "end": 105, "id": 15, "ws": true}, {"text": "mg/m(2", "start": 106, "end": 112, "id": 16, "ws": true}, {"text": ")", "start": 113, "end": 114, "id": 17, "ws": true}, {"text": "for", "start": 115, "end": 118, "id": 18, "ws": true}, {"text": "3", "start": 119, "end": 120, "id": 19, "ws": true}, {"text": "h", "start": 121, "end": 122, "id": 20, "ws": true}, {"text": ")", "start": 123, "end": 124, "id": 21, "ws": true}, {"text": "and", "start": 125, "end": 128, "id": 22, "ws": true}, {"text": "carboplatin", "start": 129, "end": 140, "id": 23, "ws": true}, {"text": "[", "start": 141, "end": 142, "id": 24, "ws": true}, {"text": "area", "start": 143, "end": 147, "id": 25, "ws": true}, {"text": "under", "start": 148, "end": 153, "id": 26, "ws": true}, {"text": "the", "start": 154, "end": 157, "id": 27, "ws": true}, {"text": "concentration-time", "start": 158, "end": 176, "id": 28, "ws": true}, {"text": "curve", "start": 177, "end": 182, "id": 29, "ws": true}, {"text": "(", "start": 183, "end": 184, "id": 30, "ws": true}, {"text": "AUC", "start": 185, "end": 188, "id": 31, "ws": true}, {"text": "=", "start": 189, "end": 190, "id": 32, "ws": true}, {"text": "6", "start": 191, "end": 192, "id": 33, "ws": true}, {"text": ")", "start": 193, "end": 194, "id": 34, "ws": true}, {"text": "]", "start": 195, "end": 196, "id": 35, "ws": true}, {"text": "on", "start": 197, "end": 199, "id": 36, "ws": true}, {"text": "day", "start": 200, "end": 203, "id": 37, "ws": true}, {"text": "1", "start": 204, "end": 205, "id": 38, "ws": true}, {"text": "and", "start": 206, "end": 209, "id": 39, "ws": true}, {"text": "in", "start": 210, "end": 212, "id": 40, "ws": true}, {"text": "21", "start": 213, "end": 215, "id": 41, "ws": true}, {"text": "day", "start": 216, "end": 219, "id": 42, "ws": true}, {"text": "cycles", "start": 220, "end": 226, "id": 43, "ws": true}, {"text": ".", "start": 227, "end": 228, "id": 44, "ws": false}], "spans": [{"start": 89, "end": 99, "token_start": 13, "token_end": 13, "label": "DRUG"}, {"start": 129, "end": 140, "token_start": 23, "token_end": 23, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/15886269/", "_input_hash": 980401099, "_task_hash": -2112546825, "_session_id": "drug_drug_pilot_shared2b-shaked", "_view_id": "blocks", "relations": [{"head": 13, "child": 23, "head_span": {"start": 89, "end": 99, "token_start": 13, "token_end": 13, "label": "DRUG"}, "child_span": {"start": 129, "end": 140, "token_start": 23, "token_end": 23, "label": "DRUG"}, "color": "#96e8ce", "label": "COMB1"}], "radio": [], "answer": "accept"}
{"text": "Eligible patients received ramucirumab ( 10mg/kg ) + dacarbazine ( 1000 mg/m(2 ) ) ( Arm A ) or ramucirumab only ( 10mg/kg ) ( Arm B ) every 3 weeks .", "paragraph": "<h3><u>A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.</u></h3>To evaluate the efficacy and safety of <b style='color:Tomato;'><i>ramucirumab</i></b> (IMC-1121B; LY3009806), a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2, alone and in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> in chemotherapy-na\u00efve patients with metastatic melanoma (MM). ### methods <b style='color:DodgerBlue;'><i>Eligible</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end-point was progression-free survival (PFS); secondary end-points included overall survival (OS), overall response and safety. ### findings Of 106 randomised patients, 102 received study treatment (Arm A, N=52; Arm B, N=50). Baseline characteristics were similar in both arms. Median PFS was 2.6 months (Arm A) and 1.7 months (Arm B); median 6-month PFS rates were 30.7% and 17.9% and 12-month PFS rates were 23.7% and 15.6%, respectively. In Arm A, 9 (17.3%) patients had partial response (PR) and 19 (36.5%), stable disease (SD); PR and SD in Arm B were 2 (4.0%) and 21 (42.0%), respectively. Median OS was 8.7 months in Arm A and 11.1 months in Arm B. Patients in both arms tolerated the treatment with limited Grade 3/4 toxicities. ### interpretation <b style='color:Tomato;'><i>ramucirumab</i></b> alone or in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> was associated with an acceptable safety profile in patients with MM. Although the study was not powered for comparison between treatment arms, PFS appeared greater with combination therapy. Sustained disease control was observed on both study arm.", "tokens": [{"text": "Eligible", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "patients", "start": 9, "end": 17, "id": 1, "ws": true}, {"text": "received", "start": 18, "end": 26, "id": 2, "ws": true}, {"text": "ramucirumab", "start": 27, "end": 38, "id": 3, "ws": true}, {"text": "(", "start": 39, "end": 40, "id": 4, "ws": true}, {"text": "10mg/kg", "start": 41, "end": 48, "id": 5, "ws": true}, {"text": ")", "start": 49, "end": 50, "id": 6, "ws": true}, {"text": "+", "start": 51, "end": 52, "id": 7, "ws": true}, {"text": "dacarbazine", "start": 53, "end": 64, "id": 8, "ws": true}, {"text": "(", "start": 65, "end": 66, "id": 9, "ws": true}, {"text": "1000", "start": 67, "end": 71, "id": 10, "ws": true}, {"text": "mg/m(2", "start": 72, "end": 78, "id": 11, "ws": true}, {"text": ")", "start": 79, "end": 80, "id": 12, "ws": true}, {"text": ")", "start": 81, "end": 82, "id": 13, "ws": true}, {"text": "(", "start": 83, "end": 84, "id": 14, "ws": true}, {"text": "Arm", "start": 85, "end": 88, "id": 15, "ws": true}, {"text": "A", "start": 89, "end": 90, "id": 16, "ws": true}, {"text": ")", "start": 91, "end": 92, "id": 17, "ws": true}, {"text": "or", "start": 93, "end": 95, "id": 18, "ws": true}, {"text": "ramucirumab", "start": 96, "end": 107, "id": 19, "ws": true}, {"text": "only", "start": 108, "end": 112, "id": 20, "ws": true}, {"text": "(", "start": 113, "end": 114, "id": 21, "ws": true}, {"text": "10mg/kg", "start": 115, "end": 122, "id": 22, "ws": true}, {"text": ")", "start": 123, "end": 124, "id": 23, "ws": true}, {"text": "(", "start": 125, "end": 126, "id": 24, "ws": true}, {"text": "Arm", "start": 127, "end": 130, "id": 25, "ws": true}, {"text": "B", "start": 131, "end": 132, "id": 26, "ws": true}, {"text": ")", "start": 133, "end": 134, "id": 27, "ws": true}, {"text": "every", "start": 135, "end": 140, "id": 28, "ws": true}, {"text": "3", "start": 141, "end": 142, "id": 29, "ws": true}, {"text": "weeks", "start": 143, "end": 148, "id": 30, "ws": true}, {"text": ".", "start": 149, "end": 150, "id": 31, "ws": false}], "spans": [{"start": 27, "end": 38, "token_start": 3, "token_end": 3, "label": "DRUG"}, {"start": 53, "end": 64, "token_start": 8, "token_end": 8, "label": "DRUG"}, {"start": 96, "end": 107, "token_start": 19, "token_end": 19, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/24930625/", "_input_hash": 633570856, "_task_hash": -1516010704, "_session_id": "drug_drug_pilot_shared2b-shaked", "_view_id": "blocks", "relations": [{"head": 3, "child": 8, "head_span": {"start": 27, "end": 38, "token_start": 3, "token_end": 3, "label": "DRUG"}, "child_span": {"start": 53, "end": 64, "token_start": 8, "token_end": 8, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "The aim of this study was to investigate the mutagenic and antigenotoxic effects of different doses of the flavonoid , apigenin , alone and in combination with the antitumor drugs , cyclophosphamide and doxorubicin , in vitro and in vivo .", "paragraph": "<h3><u>The effect of apigenin on cyclophosphamide and doxorubicin genotoxicity in vitro and in vivo.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mutagenic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>antigenotoxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>flavonoid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>apigenin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Using bacterial reverse mutation inhibition in vitro, with and without metabolic activation, the effect of apigenin (10-400 \u03bcg/plate) was studied on genotoxicity induced by <b style='color:Tomato;'><i>cyclophosphamide</i></b> (800 \u03bcg/plate) and by <b style='color:Tomato;'><i>doxorubicin</i></b> (0.2 \u03bcg/plate). Subsequent to a dose-finding study in vivo, CD1 mice were treated with either <b style='color:Tomato;'><i>cyclophosphamide</i></b> (40 mg/kg, i.p.) or <b style='color:Tomato;'><i>doxorubicin</i></b> (5 mg/kg, i.p.) with or without co-administration of apigenin (1-100 mg/kg, p.o.). Micronuclei were determined microscopically in blood smears and glutathione peroxidase (GPX), superoxide dismutase (SOD) and total antioxidative status (TAS) in whole blood, erythrocytes and plasma, respectively. Apigenin decreased <b style='color:Tomato;'><i>doxorubicin</i></b>-induced, but not <b style='color:Tomato;'><i>cyclophosphamide</i></b>-induced mutagenicity in vitro. In vivo, apigenin caused a statistically significant decrease in micronucleus frequency in response to <b style='color:Tomato;'><i>cyclophosphamide</i></b>, possibly due to active flavonoid metabolite formation or inhibition of <b style='color:Tomato;'><i>cyclophosphamide</i></b> metabolic activation. In animals treated with apigenin and <b style='color:Tomato;'><i>doxorubicin</i></b>, a significant decrease in micronucleus frequency was not observed, probably due to interindividual variability. No changes in GPX, SOD or TAS were observed in response to either cytotoxic agents or the flavonoid, possibly due to limited metabolic transformation of the drugs at the doses used. The results of the present study provide further evidence for the chemo-preventative properties of apigenin.", "tokens": [{"text": "The", "start": 0, "end": 3, "id": 0, "ws": true}, {"text": "aim", "start": 4, "end": 7, "id": 1, "ws": true}, {"text": "of", "start": 8, "end": 10, "id": 2, "ws": true}, {"text": "this", "start": 11, "end": 15, "id": 3, "ws": true}, {"text": "study", "start": 16, "end": 21, "id": 4, "ws": true}, {"text": "was", "start": 22, "end": 25, "id": 5, "ws": true}, {"text": "to", "start": 26, "end": 28, "id": 6, "ws": true}, {"text": "investigate", "start": 29, "end": 40, "id": 7, "ws": true}, {"text": "the", "start": 41, "end": 44, "id": 8, "ws": true}, {"text": "mutagenic", "start": 45, "end": 54, "id": 9, "ws": true}, {"text": "and", "start": 55, "end": 58, "id": 10, "ws": true}, {"text": "antigenotoxic", "start": 59, "end": 72, "id": 11, "ws": true}, {"text": "effects", "start": 73, "end": 80, "id": 12, "ws": true}, {"text": "of", "start": 81, "end": 83, "id": 13, "ws": true}, {"text": "different", "start": 84, "end": 93, "id": 14, "ws": true}, {"text": "doses", "start": 94, "end": 99, "id": 15, "ws": true}, {"text": "of", "start": 100, "end": 102, "id": 16, "ws": true}, {"text": "the", "start": 103, "end": 106, "id": 17, "ws": true}, {"text": "flavonoid", "start": 107, "end": 116, "id": 18, "ws": true}, {"text": ",", "start": 117, "end": 118, "id": 19, "ws": true}, {"text": "apigenin", "start": 119, "end": 127, "id": 20, "ws": true}, {"text": ",", "start": 128, "end": 129, "id": 21, "ws": true}, {"text": "alone", "start": 130, "end": 135, "id": 22, "ws": true}, {"text": "and", "start": 136, "end": 139, "id": 23, "ws": true}, {"text": "in", "start": 140, "end": 142, "id": 24, "ws": true}, {"text": "combination", "start": 143, "end": 154, "id": 25, "ws": true}, {"text": "with", "start": 155, "end": 159, "id": 26, "ws": true}, {"text": "the", "start": 160, "end": 163, "id": 27, "ws": true}, {"text": "antitumor", "start": 164, "end": 173, "id": 28, "ws": true}, {"text": "drugs", "start": 174, "end": 179, "id": 29, "ws": true}, {"text": ",", "start": 180, "end": 181, "id": 30, "ws": true}, {"text": "cyclophosphamide", "start": 182, "end": 198, "id": 31, "ws": true}, {"text": "and", "start": 199, "end": 202, "id": 32, "ws": true}, {"text": "doxorubicin", "start": 203, "end": 214, "id": 33, "ws": true}, {"text": ",", "start": 215, "end": 216, "id": 34, "ws": true}, {"text": "in", "start": 217, "end": 219, "id": 35, "ws": true}, {"text": "vitro", "start": 220, "end": 225, "id": 36, "ws": true}, {"text": "and", "start": 226, "end": 229, "id": 37, "ws": true}, {"text": "in", "start": 230, "end": 232, "id": 38, "ws": true}, {"text": "vivo", "start": 233, "end": 237, "id": 39, "ws": true}, {"text": ".", "start": 238, "end": 239, "id": 40, "ws": false}], "spans": [{"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": "DRUG"}, {"start": 182, "end": 198, "token_start": 31, "token_end": 31, "label": "DRUG"}, {"start": 203, "end": 214, "token_start": 33, "token_end": 33, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/21469013/", "_input_hash": 1631768353, "_task_hash": -923842770, "_session_id": "drug_drug_pilot_shared2b-shaked", "_view_id": "blocks", "relations": [{"head": 20, "child": 31, "head_span": {"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": "DRUG"}, "child_span": {"start": 182, "end": 198, "token_start": 31, "token_end": 31, "label": "DRUG"}, "color": "#96e8ce", "label": "COMB1"}, {"head": 20, "child": 33, "head_span": {"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": "DRUG"}, "child_span": {"start": 203, "end": 214, "token_start": 33, "token_end": 33, "label": "DRUG"}, "color": "#ffd1b2", "label": "COMB2"}], "radio": [], "answer": "accept"}
{"text": "More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of docetaxel , platinum , and fluorouracil ( TPF ) for treating metastatic SCCE .", "paragraph": "<h3><u>Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.</u></h3> <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>urgently</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>esophagus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TPF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This phase I/II trial (n = 12/39) was conducted in our institute from April 2005 to June 2008. Progression-free survival (PFS) and overall survival were analyzed by the Kaplan-Meier method. ### results The recommended dose of <b style='color:Tomato;'><i>docetaxel</i></b> was determined to be 50 mg/m in phase I. In phase II with a mean follow-up period of 13.3 months, the objective response rate was 66.6%, a median survival period of 13 months and PFS of 7 months was achieved, and the 1-year survival and PFS rates were 52.9% and 19.6%, respectively. Grade 3/4 toxicities of leukopenia, neutropenia, and anorexia were observed in 53.8%, 43.6%, and 25.6%, respectively. ### conclusions A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens. Randomized phase III trials of the TPF regimen are warranted and urgently required.", "tokens": [{"text": "More", "start": 0, "end": 4, "id": 0, "ws": true}, {"text": "effective", "start": 5, "end": 14, "id": 1, "ws": true}, {"text": "regimens", "start": 15, "end": 23, "id": 2, "ws": true}, {"text": "are", "start": 24, "end": 27, "id": 3, "ws": true}, {"text": "urgently", "start": 28, "end": 36, "id": 4, "ws": true}, {"text": "needed", "start": 37, "end": 43, "id": 5, "ws": true}, {"text": "for", "start": 44, "end": 47, "id": 6, "ws": true}, {"text": "squamous", "start": 48, "end": 56, "id": 7, "ws": true}, {"text": "cell", "start": 57, "end": 61, "id": 8, "ws": true}, {"text": "carcinoma", "start": 62, "end": 71, "id": 9, "ws": true}, {"text": "of", "start": 72, "end": 74, "id": 10, "ws": true}, {"text": "esophagus", "start": 75, "end": 84, "id": 11, "ws": true}, {"text": "(", "start": 85, "end": 86, "id": 12, "ws": true}, {"text": "SCCE", "start": 87, "end": 91, "id": 13, "ws": true}, {"text": ")", "start": 92, "end": 93, "id": 14, "ws": true}, {"text": ",", "start": 94, "end": 95, "id": 15, "ws": true}, {"text": "therefore", "start": 96, "end": 105, "id": 16, "ws": true}, {"text": ",", "start": 106, "end": 107, "id": 17, "ws": true}, {"text": "we", "start": 108, "end": 110, "id": 18, "ws": true}, {"text": "conducted", "start": 111, "end": 120, "id": 19, "ws": true}, {"text": "a", "start": 121, "end": 122, "id": 20, "ws": true}, {"text": "phase", "start": 123, "end": 128, "id": 21, "ws": true}, {"text": "I/II", "start": 129, "end": 133, "id": 22, "ws": true}, {"text": "trial", "start": 134, "end": 139, "id": 23, "ws": true}, {"text": "of", "start": 140, "end": 142, "id": 24, "ws": true}, {"text": "a", "start": 143, "end": 144, "id": 25, "ws": true}, {"text": "combination", "start": 145, "end": 156, "id": 26, "ws": true}, {"text": "of", "start": 157, "end": 159, "id": 27, "ws": true}, {"text": "docetaxel", "start": 160, "end": 169, "id": 28, "ws": true}, {"text": ",", "start": 170, "end": 171, "id": 29, "ws": true}, {"text": "platinum", "start": 172, "end": 180, "id": 30, "ws": true}, {"text": ",", "start": 181, "end": 182, "id": 31, "ws": true}, {"text": "and", "start": 183, "end": 186, "id": 32, "ws": true}, {"text": "fluorouracil", "start": 187, "end": 199, "id": 33, "ws": true}, {"text": "(", "start": 200, "end": 201, "id": 34, "ws": true}, {"text": "TPF", "start": 202, "end": 205, "id": 35, "ws": true}, {"text": ")", "start": 206, "end": 207, "id": 36, "ws": true}, {"text": "for", "start": 208, "end": 211, "id": 37, "ws": true}, {"text": "treating", "start": 212, "end": 220, "id": 38, "ws": true}, {"text": "metastatic", "start": 221, "end": 231, "id": 39, "ws": true}, {"text": "SCCE", "start": 232, "end": 236, "id": 40, "ws": true}, {"text": ".", "start": 237, "end": 238, "id": 41, "ws": false}], "spans": [{"start": 160, "end": 169, "token_start": 28, "token_end": 28, "label": "DRUG"}, {"start": 172, "end": 180, "token_start": 30, "token_end": 30, "label": "DRUG"}, {"start": 187, "end": 199, "token_start": 33, "token_end": 33, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/19898259/", "_input_hash": -830932666, "_task_hash": 1318102472, "_session_id": "drug_drug_pilot_shared2b-shaked", "_view_id": "blocks", "relations": [{"head": 28, "child": 30, "head_span": {"start": 160, "end": 169, "token_start": 28, "token_end": 28, "label": "DRUG"}, "child_span": {"start": 172, "end": 180, "token_start": 30, "token_end": 30, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}, {"head": 30, "child": 33, "head_span": {"start": 172, "end": 180, "token_start": 30, "token_end": 30, "label": "DRUG"}, "child_span": {"start": 187, "end": 199, "token_start": 33, "token_end": 33, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "We determined the effects of diclofenac sodium , octreotide , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice .", "paragraph": "<h3><u>Diclofenac Sodium Treatment Ameliorates Extrapancreatic Organ Injuries in a Murine Model of Acute Pancreatitis Induced by Caerulein.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>determined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>diclofenac</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>extrapancreatic</i></b> <b style='color:DodgerBlue;'><i>organ</i></b> <b style='color:DodgerBlue;'><i>injuries</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>caerulein-induced</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>pancreatitis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A total of 58 BALB-C male mice (25\u2009g) were divided into seven groups and used to create a caerulein-induced acute pancreatitis model. <b style='color:Tomato;'><i>diclofenac</i></b> sodium, <b style='color:Tomato;'><i>octreotide</i></b>, and their combination were given for treatment of caerulin-induced acute pancreatitis in mice. At the end of the experiment, the lung, liver, kidney, and stomach were removed for histopathologic assessment. ### results Histopathologic investigation revealed a statistically significant difference between the groups in mean congestion, edema, tubular injury, perirenal fat tissue inflammation, and tubular stasis scores in kidney tissue ( ### conclusion <b style='color:Tomato;'><i>diclofenac</i></b> sodium alone ameliorates lung edema due to caerulin-induced acute pancreatitis.", "tokens": [{"text": "We", "start": 0, "end": 2, "id": 0, "ws": true}, {"text": "determined", "start": 3, "end": 13, "id": 1, "ws": true}, {"text": "the", "start": 14, "end": 17, "id": 2, "ws": true}, {"text": "effects", "start": 18, "end": 25, "id": 3, "ws": true}, {"text": "of", "start": 26, "end": 28, "id": 4, "ws": true}, {"text": "diclofenac", "start": 29, "end": 39, "id": 5, "ws": true}, {"text": "sodium", "start": 40, "end": 46, "id": 6, "ws": true}, {"text": ",", "start": 47, "end": 48, "id": 7, "ws": true}, {"text": "octreotide", "start": 49, "end": 59, "id": 8, "ws": true}, {"text": ",", "start": 60, "end": 61, "id": 9, "ws": true}, {"text": "and", "start": 62, "end": 65, "id": 10, "ws": true}, {"text": "their", "start": 66, "end": 71, "id": 11, "ws": true}, {"text": "combination", "start": 72, "end": 83, "id": 12, "ws": true}, {"text": "on", "start": 84, "end": 86, "id": 13, "ws": true}, {"text": "extrapancreatic", "start": 87, "end": 102, "id": 14, "ws": true}, {"text": "organ", "start": 103, "end": 108, "id": 15, "ws": true}, {"text": "injuries", "start": 109, "end": 117, "id": 16, "ws": true}, {"text": "in", "start": 118, "end": 120, "id": 17, "ws": true}, {"text": "caerulein-induced", "start": 121, "end": 138, "id": 18, "ws": true}, {"text": "acute", "start": 139, "end": 144, "id": 19, "ws": true}, {"text": "pancreatitis", "start": 145, "end": 157, "id": 20, "ws": true}, {"text": "in", "start": 158, "end": 160, "id": 21, "ws": true}, {"text": "mice", "start": 161, "end": 165, "id": 22, "ws": true}, {"text": ".", "start": 166, "end": 167, "id": 23, "ws": false}], "spans": [{"start": 29, "end": 46, "token_start": 5, "token_end": 6, "label": "DRUG"}, {"start": 49, "end": 59, "token_start": 8, "token_end": 8, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/30515205/", "_input_hash": 526527182, "_task_hash": 526499652, "_session_id": "drug_drug_pilot_shared2b-shaked", "_view_id": "blocks", "relations": [{"head": 6, "child": 8, "head_span": {"start": 29, "end": 46, "token_start": 5, "token_end": 6, "label": "DRUG"}, "child_span": {"start": 49, "end": 59, "token_start": 8, "token_end": 8, "label": "DRUG"}, "color": "#96e8ce", "label": "COMB1"}], "radio": [], "answer": "accept"}
{"text": "Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with bevacizumab ( 5 mg/kg body weight i.v . every 21 days ) and oral capecitabine ( 950 mg/m(2 ) twice daily for 14 days followed by 7 days of rest ) in 2006 - 2008 .", "paragraph": "<h3><u>Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.</u></h3>No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended <b style='color:Tomato;'><i>mitotane</i></b> as monotherapy or combined with <b style='color:Tomato;'><i>etoposide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b> and cisplatin or with <b style='color:Tomato;'><i>streptozotocin</i></b> as first-line systemic therapy. However, there is no evidence for any therapy beneficial in patients failing these therapies. Therefore, we evaluated the effects of the anti-VEGF antibody <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> as salvage therapy in ACC. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>registered</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>German</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>Registry</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>offered</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>body</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>950</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>rest</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>2006</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2008</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Evaluation of tumour response was performed by imaging according to response evaluation criteria in solid tumours every 12 weeks. ### results Ten patients were treated with <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b>. None of them experienced any objective response or stable disease. Two patients had to stop therapy after few weeks due to hand-foot syndrome, and three patients died on progressive disease within 12 weeks. Other adverse events were mild (grade I-II). Median survival after treatment initiation was 124 days. ### conclusions <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> has no activity in patients with very advanced ACC. Hence, this regimen cannot be recommended as a salvage therapy.", "tokens": [{"text": "Patients", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "registered", "start": 9, "end": 19, "id": 1, "ws": true}, {"text": "with", "start": 20, "end": 24, "id": 2, "ws": true}, {"text": "the", "start": 25, "end": 28, "id": 3, "ws": true}, {"text": "German", "start": 29, "end": 35, "id": 4, "ws": true}, {"text": "ACC", "start": 36, "end": 39, "id": 5, "ws": true}, {"text": "Registry", "start": 40, "end": 48, "id": 6, "ws": true}, {"text": "with", "start": 49, "end": 53, "id": 7, "ws": true}, {"text": "refractory", "start": 54, "end": 64, "id": 8, "ws": true}, {"text": "ACC", "start": 65, "end": 68, "id": 9, "ws": true}, {"text": "progressing", "start": 69, "end": 80, "id": 10, "ws": true}, {"text": "after", "start": 81, "end": 86, "id": 11, "ws": true}, {"text": "cytotoxic", "start": 87, "end": 96, "id": 12, "ws": true}, {"text": "therapies", "start": 97, "end": 106, "id": 13, "ws": true}, {"text": "were", "start": 107, "end": 111, "id": 14, "ws": true}, {"text": "offered", "start": 112, "end": 119, "id": 15, "ws": true}, {"text": "treatment", "start": 120, "end": 129, "id": 16, "ws": true}, {"text": "with", "start": 130, "end": 134, "id": 17, "ws": true}, {"text": "bevacizumab", "start": 135, "end": 146, "id": 18, "ws": true}, {"text": "(", "start": 147, "end": 148, "id": 19, "ws": true}, {"text": "5", "start": 149, "end": 150, "id": 20, "ws": true}, {"text": "mg/kg", "start": 151, "end": 156, "id": 21, "ws": true}, {"text": "body", "start": 157, "end": 161, "id": 22, "ws": true}, {"text": "weight", "start": 162, "end": 168, "id": 23, "ws": true}, {"text": "i.v", "start": 169, "end": 172, "id": 24, "ws": true}, {"text": ".", "start": 173, "end": 174, "id": 25, "ws": true}, {"text": "every", "start": 175, "end": 180, "id": 26, "ws": true}, {"text": "21", "start": 181, "end": 183, "id": 27, "ws": true}, {"text": "days", "start": 184, "end": 188, "id": 28, "ws": true}, {"text": ")", "start": 189, "end": 190, "id": 29, "ws": true}, {"text": "and", "start": 191, "end": 194, "id": 30, "ws": true}, {"text": "oral", "start": 195, "end": 199, "id": 31, "ws": true}, {"text": "capecitabine", "start": 200, "end": 212, "id": 32, "ws": true}, {"text": "(", "start": 213, "end": 214, "id": 33, "ws": true}, {"text": "950", "start": 215, "end": 218, "id": 34, "ws": true}, {"text": "mg/m(2", "start": 219, "end": 225, "id": 35, "ws": true}, {"text": ")", "start": 226, "end": 227, "id": 36, "ws": true}, {"text": "twice", "start": 228, "end": 233, "id": 37, "ws": true}, {"text": "daily", "start": 234, "end": 239, "id": 38, "ws": true}, {"text": "for", "start": 240, "end": 243, "id": 39, "ws": true}, {"text": "14", "start": 244, "end": 246, "id": 40, "ws": true}, {"text": "days", "start": 247, "end": 251, "id": 41, "ws": true}, {"text": "followed", "start": 252, "end": 260, "id": 42, "ws": true}, {"text": "by", "start": 261, "end": 263, "id": 43, "ws": true}, {"text": "7", "start": 264, "end": 265, "id": 44, "ws": true}, {"text": "days", "start": 266, "end": 270, "id": 45, "ws": true}, {"text": "of", "start": 271, "end": 273, "id": 46, "ws": true}, {"text": "rest", "start": 274, "end": 278, "id": 47, "ws": true}, {"text": ")", "start": 279, "end": 280, "id": 48, "ws": true}, {"text": "in", "start": 281, "end": 283, "id": 49, "ws": true}, {"text": "2006", "start": 284, "end": 288, "id": 50, "ws": true}, {"text": "-", "start": 289, "end": 290, "id": 51, "ws": true}, {"text": "2008", "start": 291, "end": 295, "id": 52, "ws": true}, {"text": ".", "start": 296, "end": 297, "id": 53, "ws": false}], "spans": [{"start": 135, "end": 146, "token_start": 18, "token_end": 18, "label": "DRUG"}, {"start": 200, "end": 212, "token_start": 32, "token_end": 32, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/19903796/", "_input_hash": 1011764762, "_task_hash": -827463686, "_session_id": "drug_drug_pilot_shared2b-yosi", "_view_id": "blocks", "relations": [{"head": 18, "child": 32, "head_span": {"start": 135, "end": 146, "token_start": 18, "token_end": 18, "label": "DRUG"}, "child_span": {"start": 200, "end": 212, "token_start": 32, "token_end": 32, "label": "DRUG"}, "color": "#c2f2f6", "label": "NEG1"}], "radio": ["NEG11"], "answer": "accept"}
{"text": "Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib ( MLN9708 ) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant .", "paragraph": "<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>Ib</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Oral</i></b> <b style='color:DodgerBlue;'><i>Proteasome</i></b> <b style='color:DodgerBlue;'><i>Inhibitor</i></b> <b style='color:MediumOrchid;'><i>Ixazomib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MLN9708</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Advanced</i></b> <b style='color:DodgerBlue;'><i>ER+</i></b> <b style='color:DodgerBlue;'><i>Breast</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>Progressing</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### background <b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### methods This is a single-center phase Ib study with a 3+3 design of <b style='color:Tomato;'><i>fulvestrant</i></b> and the proteasome inhibitor <b style='color:Tomato;'><i>ixazomib</i></b> (MLN9708) in patients with advanced ER+ breast cancer that was progressing on <b style='color:Tomato;'><i>fulvestrant</i></b>. A dose-escalation design allowed establishment of the <b style='color:Tomato;'><i>ixazomib</i></b> maximum tolerated dose (MTD). Secondary objectives included progression-free survival, pharmacokinetics, and tumor molecular analyses. ### results Among nine evaluable subjects, treatment was well-tolerated without dose-limiting toxicities The MTD of <b style='color:Tomato;'><i>ixazomib</i></b> was 4 mg in combination with <b style='color:Tomato;'><i>fulvestrant</i></b>. Plasma concentrations of the active form of <b style='color:Tomato;'><i>ixazomib</i></b> (MLN2238) in the 4-mg dose cohort had a median (range) Cmax of 155 (122-171) ng/mL; Tmax of 1 (1-1.5) h; terminal elimination half-life of 66.6 (57.3-102.6) hr after initial dose; AUC of 5,025 (4,160-5,345) ng*h/mL. One partial response was observed, and median progression-free survival was 51\u2009days (range 47-137). ### conclusion This drug combination has a favorable safety profile and anti-tumor activity in patients with <b style='color:Tomato;'><i>fulvestrant</i></b>-resistant advanced ER+ breast cancer that justifies future testing.", "tokens": [{"text": "Phase", "start": 0, "end": 5, "id": 0, "ws": true}, {"text": "Ib", "start": 6, "end": 8, "id": 1, "ws": true}, {"text": "Study", "start": 9, "end": 14, "id": 2, "ws": true}, {"text": "of", "start": 15, "end": 17, "id": 3, "ws": true}, {"text": "the", "start": 18, "end": 21, "id": 4, "ws": true}, {"text": "Oral", "start": 22, "end": 26, "id": 5, "ws": true}, {"text": "Proteasome", "start": 27, "end": 37, "id": 6, "ws": true}, {"text": "Inhibitor", "start": 38, "end": 47, "id": 7, "ws": true}, {"text": "Ixazomib", "start": 48, "end": 56, "id": 8, "ws": true}, {"text": "(", "start": 57, "end": 58, "id": 9, "ws": true}, {"text": "MLN9708", "start": 59, "end": 66, "id": 10, "ws": true}, {"text": ")", "start": 67, "end": 68, "id": 11, "ws": true}, {"text": "and", "start": 69, "end": 72, "id": 12, "ws": true}, {"text": "Fulvestrant", "start": 73, "end": 84, "id": 13, "ws": true}, {"text": "in", "start": 85, "end": 87, "id": 14, "ws": true}, {"text": "Advanced", "start": 88, "end": 96, "id": 15, "ws": true}, {"text": "ER+", "start": 97, "end": 100, "id": 16, "ws": true}, {"text": "Breast", "start": 101, "end": 107, "id": 17, "ws": true}, {"text": "Cancer", "start": 108, "end": 114, "id": 18, "ws": true}, {"text": "Progressing", "start": 115, "end": 126, "id": 19, "ws": true}, {"text": "on", "start": 127, "end": 129, "id": 20, "ws": true}, {"text": "Fulvestrant", "start": 130, "end": 141, "id": 21, "ws": true}, {"text": ".", "start": 142, "end": 143, "id": 22, "ws": false}], "spans": [{"start": 48, "end": 56, "token_start": 8, "token_end": 8, "label": "DRUG"}, {"start": 73, "end": 84, "token_start": 13, "token_end": 13, "label": "DRUG"}, {"start": 130, "end": 141, "token_start": 21, "token_end": 21, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/33641211/", "_input_hash": -1014334224, "_task_hash": 1740062343, "_session_id": "drug_drug_pilot_shared2b-yosi", "_view_id": "blocks", "relations": [{"head": 8, "child": 13, "head_span": {"start": 48, "end": 56, "token_start": 8, "token_end": 8, "label": "DRUG"}, "child_span": {"start": 73, "end": 84, "token_start": 13, "token_end": 13, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Pharmacokinetic studies showed that chronic lymphocytic leukemia involving more than 80 % of the bone marrow at study start was associated with lower trough concentrations of alemtuzumab and rituximab , and that higher trough serum concentrations of alemtuzumab were associated with complete bone marrow clearance .", "paragraph": "<h3><u>A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.</u></h3>This study assessed the safety and preliminary efficacy of escalated dose subcutaneous <b style='color:Tomato;'><i>alemtuzumab</i></b> in combination with <b style='color:Tomato;'><i>rituximab</i></b> in chronic lymphocytic leukemia. Twenty-eight patients with relapsed refractory chronic lymphocytic leukemia were treated on four dosing cohorts of weekly <b style='color:Tomato;'><i>rituximab</i></b> at 375 mg/m(2) and <b style='color:Tomato;'><i>alemtuzumab</i></b> doses that started at 30 mg three times per week and escalated to weekly dosing over four weeks, culminating with 90 mg weekly. One dose limiting toxicity of a <b style='color:Tomato;'><i>rituximab</i></b> infusion reaction was seen in cohort 2, but the regimen was otherwise well tolerated without evidence of differential toxicity by cohort. The overall response rate by National Cancer Institute-Working Group criteria was 61%, and the rate of complete bone marrow response was 43%, most of whom were negative for minimal residual disease. The addition of CT scan evaluation per International Workshop on Chronic Lymphocytic Leukemia 2008 criteria reduced the overall response rate to 14%. Median overall survival was 35 months, with 12 patients able to proceed to stem cell transplantation. <b style='color:DodgerBlue;'><i>Pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>lymphocytic</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>involving</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>start</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>clearance</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We conclude that escalated subcutaneous doses of <b style='color:Tomato;'><i>alemtuzumab</i></b> given weekly are well tolerated and result in excellent bone marrow clearance of chronic lymphocytic leukemia, helping patients to proceed to stem cell transplantation. This study is registered at ClinicalTrials.gov (Identifier:00330252).", "tokens": [{"text": "Pharmacokinetic", "start": 0, "end": 15, "id": 0, "ws": true}, {"text": "studies", "start": 16, "end": 23, "id": 1, "ws": true}, {"text": "showed", "start": 24, "end": 30, "id": 2, "ws": true}, {"text": "that", "start": 31, "end": 35, "id": 3, "ws": true}, {"text": "chronic", "start": 36, "end": 43, "id": 4, "ws": true}, {"text": "lymphocytic", "start": 44, "end": 55, "id": 5, "ws": true}, {"text": "leukemia", "start": 56, "end": 64, "id": 6, "ws": true}, {"text": "involving", "start": 65, "end": 74, "id": 7, "ws": true}, {"text": "more", "start": 75, "end": 79, "id": 8, "ws": true}, {"text": "than", "start": 80, "end": 84, "id": 9, "ws": true}, {"text": "80", "start": 85, "end": 87, "id": 10, "ws": true}, {"text": "%", "start": 88, "end": 89, "id": 11, "ws": true}, {"text": "of", "start": 90, "end": 92, "id": 12, "ws": true}, {"text": "the", "start": 93, "end": 96, "id": 13, "ws": true}, {"text": "bone", "start": 97, "end": 101, "id": 14, "ws": true}, {"text": "marrow", "start": 102, "end": 108, "id": 15, "ws": true}, {"text": "at", "start": 109, "end": 111, "id": 16, "ws": true}, {"text": "study", "start": 112, "end": 117, "id": 17, "ws": true}, {"text": "start", "start": 118, "end": 123, "id": 18, "ws": true}, {"text": "was", "start": 124, "end": 127, "id": 19, "ws": true}, {"text": "associated", "start": 128, "end": 138, "id": 20, "ws": true}, {"text": "with", "start": 139, "end": 143, "id": 21, "ws": true}, {"text": "lower", "start": 144, "end": 149, "id": 22, "ws": true}, {"text": "trough", "start": 150, "end": 156, "id": 23, "ws": true}, {"text": "concentrations", "start": 157, "end": 171, "id": 24, "ws": true}, {"text": "of", "start": 172, "end": 174, "id": 25, "ws": true}, {"text": "alemtuzumab", "start": 175, "end": 186, "id": 26, "ws": true}, {"text": "and", "start": 187, "end": 190, "id": 27, "ws": true}, {"text": "rituximab", "start": 191, "end": 200, "id": 28, "ws": true}, {"text": ",", "start": 201, "end": 202, "id": 29, "ws": true}, {"text": "and", "start": 203, "end": 206, "id": 30, "ws": true}, {"text": "that", "start": 207, "end": 211, "id": 31, "ws": true}, {"text": "higher", "start": 212, "end": 218, "id": 32, "ws": true}, {"text": "trough", "start": 219, "end": 225, "id": 33, "ws": true}, {"text": "serum", "start": 226, "end": 231, "id": 34, "ws": true}, {"text": "concentrations", "start": 232, "end": 246, "id": 35, "ws": true}, {"text": "of", "start": 247, "end": 249, "id": 36, "ws": true}, {"text": "alemtuzumab", "start": 250, "end": 261, "id": 37, "ws": true}, {"text": "were", "start": 262, "end": 266, "id": 38, "ws": true}, {"text": "associated", "start": 267, "end": 277, "id": 39, "ws": true}, {"text": "with", "start": 278, "end": 282, "id": 40, "ws": true}, {"text": "complete", "start": 283, "end": 291, "id": 41, "ws": true}, {"text": "bone", "start": 292, "end": 296, "id": 42, "ws": true}, {"text": "marrow", "start": 297, "end": 303, "id": 43, "ws": true}, {"text": "clearance", "start": 304, "end": 313, "id": 44, "ws": true}, {"text": ".", "start": 314, "end": 315, "id": 45, "ws": false}], "spans": [{"start": 175, "end": 186, "token_start": 26, "token_end": 26, "label": "DRUG"}, {"start": 191, "end": 200, "token_start": 28, "token_end": 28, "label": "DRUG"}, {"start": 250, "end": 261, "token_start": 37, "token_end": 37, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/23645694/", "_input_hash": -1128840740, "_task_hash": -278706627, "_session_id": "drug_drug_pilot_shared2b-yosi", "_view_id": "blocks", "relations": [{"head": 26, "child": 28, "head_span": {"start": 175, "end": 186, "token_start": 26, "token_end": 26, "label": "DRUG"}, "child_span": {"start": 191, "end": 200, "token_start": 28, "token_end": 28, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Patients who had pathologically been proven to have measurable lesions were treated with paclitaxel ( 200 mg/m(2 ) for 3 h ) and carboplatin [ area under the concentration-time curve ( AUC = 6 ) ] on day 1 and in 21 day cycles .", "paragraph": "<h3><u>Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.</u></h3>The combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> has been used to treat patients with many types of tumor, including gastric cancer. We evaluated the efficacy and safety of this combination in advanced gastric cancer patients previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>pathologically</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>proven</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>measurable</i></b> <b style='color:DodgerBlue;'><i>lesions</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results A partial response was achieved in 10 of 45 patients [22%, 95% confidence interval (CI), 10-34]. Of the 32 patients previously treated with cisplatin, four (13%) achieved partial response, whereas, of the 13 patients previously treated with heptaplatin, six (46%) achieved partial response. In all patients, the median time to progression was 14 weeks (95% CI, 10-18), and the median overall survival was 32 weeks (95% CI, 26-38). The most common grade 3/4 adverse events were neutropenia (40% of patients) and neuropathy (2.2%). Two patients developed neutropenic fever. However, there were no treatment-related deaths. ### conclusions Combination chemotherapy with <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> is feasible in patients with advanced gastric cancer who were previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum.", "tokens": [{"text": "Patients", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "who", "start": 9, "end": 12, "id": 1, "ws": true}, {"text": "had", "start": 13, "end": 16, "id": 2, "ws": true}, {"text": "pathologically", "start": 17, "end": 31, "id": 3, "ws": true}, {"text": "been", "start": 32, "end": 36, "id": 4, "ws": true}, {"text": "proven", "start": 37, "end": 43, "id": 5, "ws": true}, {"text": "to", "start": 44, "end": 46, "id": 6, "ws": true}, {"text": "have", "start": 47, "end": 51, "id": 7, "ws": true}, {"text": "measurable", "start": 52, "end": 62, "id": 8, "ws": true}, {"text": "lesions", "start": 63, "end": 70, "id": 9, "ws": true}, {"text": "were", "start": 71, "end": 75, "id": 10, "ws": true}, {"text": "treated", "start": 76, "end": 83, "id": 11, "ws": true}, {"text": "with", "start": 84, "end": 88, "id": 12, "ws": true}, {"text": "paclitaxel", "start": 89, "end": 99, "id": 13, "ws": true}, {"text": "(", "start": 100, "end": 101, "id": 14, "ws": true}, {"text": "200", "start": 102, "end": 105, "id": 15, "ws": true}, {"text": "mg/m(2", "start": 106, "end": 112, "id": 16, "ws": true}, {"text": ")", "start": 113, "end": 114, "id": 17, "ws": true}, {"text": "for", "start": 115, "end": 118, "id": 18, "ws": true}, {"text": "3", "start": 119, "end": 120, "id": 19, "ws": true}, {"text": "h", "start": 121, "end": 122, "id": 20, "ws": true}, {"text": ")", "start": 123, "end": 124, "id": 21, "ws": true}, {"text": "and", "start": 125, "end": 128, "id": 22, "ws": true}, {"text": "carboplatin", "start": 129, "end": 140, "id": 23, "ws": true}, {"text": "[", "start": 141, "end": 142, "id": 24, "ws": true}, {"text": "area", "start": 143, "end": 147, "id": 25, "ws": true}, {"text": "under", "start": 148, "end": 153, "id": 26, "ws": true}, {"text": "the", "start": 154, "end": 157, "id": 27, "ws": true}, {"text": "concentration-time", "start": 158, "end": 176, "id": 28, "ws": true}, {"text": "curve", "start": 177, "end": 182, "id": 29, "ws": true}, {"text": "(", "start": 183, "end": 184, "id": 30, "ws": true}, {"text": "AUC", "start": 185, "end": 188, "id": 31, "ws": true}, {"text": "=", "start": 189, "end": 190, "id": 32, "ws": true}, {"text": "6", "start": 191, "end": 192, "id": 33, "ws": true}, {"text": ")", "start": 193, "end": 194, "id": 34, "ws": true}, {"text": "]", "start": 195, "end": 196, "id": 35, "ws": true}, {"text": "on", "start": 197, "end": 199, "id": 36, "ws": true}, {"text": "day", "start": 200, "end": 203, "id": 37, "ws": true}, {"text": "1", "start": 204, "end": 205, "id": 38, "ws": true}, {"text": "and", "start": 206, "end": 209, "id": 39, "ws": true}, {"text": "in", "start": 210, "end": 212, "id": 40, "ws": true}, {"text": "21", "start": 213, "end": 215, "id": 41, "ws": true}, {"text": "day", "start": 216, "end": 219, "id": 42, "ws": true}, {"text": "cycles", "start": 220, "end": 226, "id": 43, "ws": true}, {"text": ".", "start": 227, "end": 228, "id": 44, "ws": false}], "spans": [{"start": 89, "end": 99, "token_start": 13, "token_end": 13, "label": "DRUG"}, {"start": 129, "end": 140, "token_start": 23, "token_end": 23, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/15886269/", "_input_hash": 980401099, "_task_hash": -2112546825, "_session_id": "drug_drug_pilot_shared2b-yosi", "_view_id": "blocks", "relations": [{"head": 13, "child": 23, "head_span": {"start": 89, "end": 99, "token_start": 13, "token_end": 13, "label": "DRUG"}, "child_span": {"start": 129, "end": 140, "token_start": 23, "token_end": 23, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "Eligible patients received ramucirumab ( 10mg/kg ) + dacarbazine ( 1000 mg/m(2 ) ) ( Arm A ) or ramucirumab only ( 10mg/kg ) ( Arm B ) every 3 weeks .", "paragraph": "<h3><u>A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.</u></h3>To evaluate the efficacy and safety of <b style='color:Tomato;'><i>ramucirumab</i></b> (IMC-1121B; LY3009806), a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2, alone and in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> in chemotherapy-na\u00efve patients with metastatic melanoma (MM). ### methods <b style='color:DodgerBlue;'><i>Eligible</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end-point was progression-free survival (PFS); secondary end-points included overall survival (OS), overall response and safety. ### findings Of 106 randomised patients, 102 received study treatment (Arm A, N=52; Arm B, N=50). Baseline characteristics were similar in both arms. Median PFS was 2.6 months (Arm A) and 1.7 months (Arm B); median 6-month PFS rates were 30.7% and 17.9% and 12-month PFS rates were 23.7% and 15.6%, respectively. In Arm A, 9 (17.3%) patients had partial response (PR) and 19 (36.5%), stable disease (SD); PR and SD in Arm B were 2 (4.0%) and 21 (42.0%), respectively. Median OS was 8.7 months in Arm A and 11.1 months in Arm B. Patients in both arms tolerated the treatment with limited Grade 3/4 toxicities. ### interpretation <b style='color:Tomato;'><i>ramucirumab</i></b> alone or in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> was associated with an acceptable safety profile in patients with MM. Although the study was not powered for comparison between treatment arms, PFS appeared greater with combination therapy. Sustained disease control was observed on both study arm.", "tokens": [{"text": "Eligible", "start": 0, "end": 8, "id": 0, "ws": true}, {"text": "patients", "start": 9, "end": 17, "id": 1, "ws": true}, {"text": "received", "start": 18, "end": 26, "id": 2, "ws": true}, {"text": "ramucirumab", "start": 27, "end": 38, "id": 3, "ws": true}, {"text": "(", "start": 39, "end": 40, "id": 4, "ws": true}, {"text": "10mg/kg", "start": 41, "end": 48, "id": 5, "ws": true}, {"text": ")", "start": 49, "end": 50, "id": 6, "ws": true}, {"text": "+", "start": 51, "end": 52, "id": 7, "ws": true}, {"text": "dacarbazine", "start": 53, "end": 64, "id": 8, "ws": true}, {"text": "(", "start": 65, "end": 66, "id": 9, "ws": true}, {"text": "1000", "start": 67, "end": 71, "id": 10, "ws": true}, {"text": "mg/m(2", "start": 72, "end": 78, "id": 11, "ws": true}, {"text": ")", "start": 79, "end": 80, "id": 12, "ws": true}, {"text": ")", "start": 81, "end": 82, "id": 13, "ws": true}, {"text": "(", "start": 83, "end": 84, "id": 14, "ws": true}, {"text": "Arm", "start": 85, "end": 88, "id": 15, "ws": true}, {"text": "A", "start": 89, "end": 90, "id": 16, "ws": true}, {"text": ")", "start": 91, "end": 92, "id": 17, "ws": true}, {"text": "or", "start": 93, "end": 95, "id": 18, "ws": true}, {"text": "ramucirumab", "start": 96, "end": 107, "id": 19, "ws": true}, {"text": "only", "start": 108, "end": 112, "id": 20, "ws": true}, {"text": "(", "start": 113, "end": 114, "id": 21, "ws": true}, {"text": "10mg/kg", "start": 115, "end": 122, "id": 22, "ws": true}, {"text": ")", "start": 123, "end": 124, "id": 23, "ws": true}, {"text": "(", "start": 125, "end": 126, "id": 24, "ws": true}, {"text": "Arm", "start": 127, "end": 130, "id": 25, "ws": true}, {"text": "B", "start": 131, "end": 132, "id": 26, "ws": true}, {"text": ")", "start": 133, "end": 134, "id": 27, "ws": true}, {"text": "every", "start": 135, "end": 140, "id": 28, "ws": true}, {"text": "3", "start": 141, "end": 142, "id": 29, "ws": true}, {"text": "weeks", "start": 143, "end": 148, "id": 30, "ws": true}, {"text": ".", "start": 149, "end": 150, "id": 31, "ws": false}], "spans": [{"start": 27, "end": 38, "token_start": 3, "token_end": 3, "label": "DRUG"}, {"start": 53, "end": 64, "token_start": 8, "token_end": 8, "label": "DRUG"}, {"start": 96, "end": 107, "token_start": 19, "token_end": 19, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/24930625/", "_input_hash": 633570856, "_task_hash": -1516010704, "_session_id": "drug_drug_pilot_shared2b-yosi", "_view_id": "blocks", "relations": [{"head": 3, "child": 8, "head_span": {"start": 27, "end": 38, "token_start": 3, "token_end": 3, "label": "DRUG"}, "child_span": {"start": 53, "end": 64, "token_start": 8, "token_end": 8, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "The aim of this study was to investigate the mutagenic and antigenotoxic effects of different doses of the flavonoid , apigenin , alone and in combination with the antitumor drugs , cyclophosphamide and doxorubicin , in vitro and in vivo .", "paragraph": "<h3><u>The effect of apigenin on cyclophosphamide and doxorubicin genotoxicity in vitro and in vivo.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mutagenic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>antigenotoxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>flavonoid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>apigenin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Using bacterial reverse mutation inhibition in vitro, with and without metabolic activation, the effect of apigenin (10-400 \u03bcg/plate) was studied on genotoxicity induced by <b style='color:Tomato;'><i>cyclophosphamide</i></b> (800 \u03bcg/plate) and by <b style='color:Tomato;'><i>doxorubicin</i></b> (0.2 \u03bcg/plate). Subsequent to a dose-finding study in vivo, CD1 mice were treated with either <b style='color:Tomato;'><i>cyclophosphamide</i></b> (40 mg/kg, i.p.) or <b style='color:Tomato;'><i>doxorubicin</i></b> (5 mg/kg, i.p.) with or without co-administration of apigenin (1-100 mg/kg, p.o.). Micronuclei were determined microscopically in blood smears and glutathione peroxidase (GPX), superoxide dismutase (SOD) and total antioxidative status (TAS) in whole blood, erythrocytes and plasma, respectively. Apigenin decreased <b style='color:Tomato;'><i>doxorubicin</i></b>-induced, but not <b style='color:Tomato;'><i>cyclophosphamide</i></b>-induced mutagenicity in vitro. In vivo, apigenin caused a statistically significant decrease in micronucleus frequency in response to <b style='color:Tomato;'><i>cyclophosphamide</i></b>, possibly due to active flavonoid metabolite formation or inhibition of <b style='color:Tomato;'><i>cyclophosphamide</i></b> metabolic activation. In animals treated with apigenin and <b style='color:Tomato;'><i>doxorubicin</i></b>, a significant decrease in micronucleus frequency was not observed, probably due to interindividual variability. No changes in GPX, SOD or TAS were observed in response to either cytotoxic agents or the flavonoid, possibly due to limited metabolic transformation of the drugs at the doses used. The results of the present study provide further evidence for the chemo-preventative properties of apigenin.", "tokens": [{"text": "The", "start": 0, "end": 3, "id": 0, "ws": true}, {"text": "aim", "start": 4, "end": 7, "id": 1, "ws": true}, {"text": "of", "start": 8, "end": 10, "id": 2, "ws": true}, {"text": "this", "start": 11, "end": 15, "id": 3, "ws": true}, {"text": "study", "start": 16, "end": 21, "id": 4, "ws": true}, {"text": "was", "start": 22, "end": 25, "id": 5, "ws": true}, {"text": "to", "start": 26, "end": 28, "id": 6, "ws": true}, {"text": "investigate", "start": 29, "end": 40, "id": 7, "ws": true}, {"text": "the", "start": 41, "end": 44, "id": 8, "ws": true}, {"text": "mutagenic", "start": 45, "end": 54, "id": 9, "ws": true}, {"text": "and", "start": 55, "end": 58, "id": 10, "ws": true}, {"text": "antigenotoxic", "start": 59, "end": 72, "id": 11, "ws": true}, {"text": "effects", "start": 73, "end": 80, "id": 12, "ws": true}, {"text": "of", "start": 81, "end": 83, "id": 13, "ws": true}, {"text": "different", "start": 84, "end": 93, "id": 14, "ws": true}, {"text": "doses", "start": 94, "end": 99, "id": 15, "ws": true}, {"text": "of", "start": 100, "end": 102, "id": 16, "ws": true}, {"text": "the", "start": 103, "end": 106, "id": 17, "ws": true}, {"text": "flavonoid", "start": 107, "end": 116, "id": 18, "ws": true}, {"text": ",", "start": 117, "end": 118, "id": 19, "ws": true}, {"text": "apigenin", "start": 119, "end": 127, "id": 20, "ws": true}, {"text": ",", "start": 128, "end": 129, "id": 21, "ws": true}, {"text": "alone", "start": 130, "end": 135, "id": 22, "ws": true}, {"text": "and", "start": 136, "end": 139, "id": 23, "ws": true}, {"text": "in", "start": 140, "end": 142, "id": 24, "ws": true}, {"text": "combination", "start": 143, "end": 154, "id": 25, "ws": true}, {"text": "with", "start": 155, "end": 159, "id": 26, "ws": true}, {"text": "the", "start": 160, "end": 163, "id": 27, "ws": true}, {"text": "antitumor", "start": 164, "end": 173, "id": 28, "ws": true}, {"text": "drugs", "start": 174, "end": 179, "id": 29, "ws": true}, {"text": ",", "start": 180, "end": 181, "id": 30, "ws": true}, {"text": "cyclophosphamide", "start": 182, "end": 198, "id": 31, "ws": true}, {"text": "and", "start": 199, "end": 202, "id": 32, "ws": true}, {"text": "doxorubicin", "start": 203, "end": 214, "id": 33, "ws": true}, {"text": ",", "start": 215, "end": 216, "id": 34, "ws": true}, {"text": "in", "start": 217, "end": 219, "id": 35, "ws": true}, {"text": "vitro", "start": 220, "end": 225, "id": 36, "ws": true}, {"text": "and", "start": 226, "end": 229, "id": 37, "ws": true}, {"text": "in", "start": 230, "end": 232, "id": 38, "ws": true}, {"text": "vivo", "start": 233, "end": 237, "id": 39, "ws": true}, {"text": ".", "start": 238, "end": 239, "id": 40, "ws": false}], "spans": [{"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": "DRUG"}, {"start": 182, "end": 198, "token_start": 31, "token_end": 31, "label": "DRUG"}, {"start": 203, "end": 214, "token_start": 33, "token_end": 33, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/21469013/", "_input_hash": 1631768353, "_task_hash": -923842770, "_session_id": "drug_drug_pilot_shared2b-yosi", "_view_id": "blocks", "relations": [{"head": 20, "child": 33, "head_span": {"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": "DRUG"}, "child_span": {"start": 203, "end": 214, "token_start": 33, "token_end": 33, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}, {"head": 20, "child": 31, "head_span": {"start": 119, "end": 127, "token_start": 20, "token_end": 20, "label": "DRUG"}, "child_span": {"start": 182, "end": 198, "token_start": 31, "token_end": 31, "label": "DRUG"}, "color": "#ffd882", "label": "POS2"}], "radio": ["POS11", "POS21"], "answer": "accept"}
{"text": "More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of docetaxel , platinum , and fluorouracil ( TPF ) for treating metastatic SCCE .", "paragraph": "<h3><u>Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.</u></h3> <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>urgently</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>esophagus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TPF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This phase I/II trial (n = 12/39) was conducted in our institute from April 2005 to June 2008. Progression-free survival (PFS) and overall survival were analyzed by the Kaplan-Meier method. ### results The recommended dose of <b style='color:Tomato;'><i>docetaxel</i></b> was determined to be 50 mg/m in phase I. In phase II with a mean follow-up period of 13.3 months, the objective response rate was 66.6%, a median survival period of 13 months and PFS of 7 months was achieved, and the 1-year survival and PFS rates were 52.9% and 19.6%, respectively. Grade 3/4 toxicities of leukopenia, neutropenia, and anorexia were observed in 53.8%, 43.6%, and 25.6%, respectively. ### conclusions A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens. Randomized phase III trials of the TPF regimen are warranted and urgently required.", "tokens": [{"text": "More", "start": 0, "end": 4, "id": 0, "ws": true}, {"text": "effective", "start": 5, "end": 14, "id": 1, "ws": true}, {"text": "regimens", "start": 15, "end": 23, "id": 2, "ws": true}, {"text": "are", "start": 24, "end": 27, "id": 3, "ws": true}, {"text": "urgently", "start": 28, "end": 36, "id": 4, "ws": true}, {"text": "needed", "start": 37, "end": 43, "id": 5, "ws": true}, {"text": "for", "start": 44, "end": 47, "id": 6, "ws": true}, {"text": "squamous", "start": 48, "end": 56, "id": 7, "ws": true}, {"text": "cell", "start": 57, "end": 61, "id": 8, "ws": true}, {"text": "carcinoma", "start": 62, "end": 71, "id": 9, "ws": true}, {"text": "of", "start": 72, "end": 74, "id": 10, "ws": true}, {"text": "esophagus", "start": 75, "end": 84, "id": 11, "ws": true}, {"text": "(", "start": 85, "end": 86, "id": 12, "ws": true}, {"text": "SCCE", "start": 87, "end": 91, "id": 13, "ws": true}, {"text": ")", "start": 92, "end": 93, "id": 14, "ws": true}, {"text": ",", "start": 94, "end": 95, "id": 15, "ws": true}, {"text": "therefore", "start": 96, "end": 105, "id": 16, "ws": true}, {"text": ",", "start": 106, "end": 107, "id": 17, "ws": true}, {"text": "we", "start": 108, "end": 110, "id": 18, "ws": true}, {"text": "conducted", "start": 111, "end": 120, "id": 19, "ws": true}, {"text": "a", "start": 121, "end": 122, "id": 20, "ws": true}, {"text": "phase", "start": 123, "end": 128, "id": 21, "ws": true}, {"text": "I/II", "start": 129, "end": 133, "id": 22, "ws": true}, {"text": "trial", "start": 134, "end": 139, "id": 23, "ws": true}, {"text": "of", "start": 140, "end": 142, "id": 24, "ws": true}, {"text": "a", "start": 143, "end": 144, "id": 25, "ws": true}, {"text": "combination", "start": 145, "end": 156, "id": 26, "ws": true}, {"text": "of", "start": 157, "end": 159, "id": 27, "ws": true}, {"text": "docetaxel", "start": 160, "end": 169, "id": 28, "ws": true}, {"text": ",", "start": 170, "end": 171, "id": 29, "ws": true}, {"text": "platinum", "start": 172, "end": 180, "id": 30, "ws": true}, {"text": ",", "start": 181, "end": 182, "id": 31, "ws": true}, {"text": "and", "start": 183, "end": 186, "id": 32, "ws": true}, {"text": "fluorouracil", "start": 187, "end": 199, "id": 33, "ws": true}, {"text": "(", "start": 200, "end": 201, "id": 34, "ws": true}, {"text": "TPF", "start": 202, "end": 205, "id": 35, "ws": true}, {"text": ")", "start": 206, "end": 207, "id": 36, "ws": true}, {"text": "for", "start": 208, "end": 211, "id": 37, "ws": true}, {"text": "treating", "start": 212, "end": 220, "id": 38, "ws": true}, {"text": "metastatic", "start": 221, "end": 231, "id": 39, "ws": true}, {"text": "SCCE", "start": 232, "end": 236, "id": 40, "ws": true}, {"text": ".", "start": 237, "end": 238, "id": 41, "ws": false}], "spans": [{"start": 160, "end": 169, "token_start": 28, "token_end": 28, "label": "DRUG"}, {"start": 172, "end": 180, "token_start": 30, "token_end": 30, "label": "DRUG"}, {"start": 187, "end": 199, "token_start": 33, "token_end": 33, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/19898259/", "_input_hash": -830932666, "_task_hash": 1318102472, "_session_id": "drug_drug_pilot_shared2b-yosi", "_view_id": "blocks", "relations": [{"head": 28, "child": 30, "head_span": {"start": 160, "end": 169, "token_start": 28, "token_end": 28, "label": "DRUG"}, "child_span": {"start": 172, "end": 180, "token_start": 30, "token_end": 30, "label": "DRUG"}, "color": "#c5bdf4", "label": "POS1"}], "radio": ["POS11"], "answer": "accept"}
{"text": "We determined the effects of diclofenac sodium , octreotide , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice .", "paragraph": "<h3><u>Diclofenac Sodium Treatment Ameliorates Extrapancreatic Organ Injuries in a Murine Model of Acute Pancreatitis Induced by Caerulein.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>determined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>diclofenac</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>extrapancreatic</i></b> <b style='color:DodgerBlue;'><i>organ</i></b> <b style='color:DodgerBlue;'><i>injuries</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>caerulein-induced</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>pancreatitis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A total of 58 BALB-C male mice (25\u2009g) were divided into seven groups and used to create a caerulein-induced acute pancreatitis model. <b style='color:Tomato;'><i>diclofenac</i></b> sodium, <b style='color:Tomato;'><i>octreotide</i></b>, and their combination were given for treatment of caerulin-induced acute pancreatitis in mice. At the end of the experiment, the lung, liver, kidney, and stomach were removed for histopathologic assessment. ### results Histopathologic investigation revealed a statistically significant difference between the groups in mean congestion, edema, tubular injury, perirenal fat tissue inflammation, and tubular stasis scores in kidney tissue ( ### conclusion <b style='color:Tomato;'><i>diclofenac</i></b> sodium alone ameliorates lung edema due to caerulin-induced acute pancreatitis.", "tokens": [{"text": "We", "start": 0, "end": 2, "id": 0, "ws": true}, {"text": "determined", "start": 3, "end": 13, "id": 1, "ws": true}, {"text": "the", "start": 14, "end": 17, "id": 2, "ws": true}, {"text": "effects", "start": 18, "end": 25, "id": 3, "ws": true}, {"text": "of", "start": 26, "end": 28, "id": 4, "ws": true}, {"text": "diclofenac", "start": 29, "end": 39, "id": 5, "ws": true}, {"text": "sodium", "start": 40, "end": 46, "id": 6, "ws": true}, {"text": ",", "start": 47, "end": 48, "id": 7, "ws": true}, {"text": "octreotide", "start": 49, "end": 59, "id": 8, "ws": true}, {"text": ",", "start": 60, "end": 61, "id": 9, "ws": true}, {"text": "and", "start": 62, "end": 65, "id": 10, "ws": true}, {"text": "their", "start": 66, "end": 71, "id": 11, "ws": true}, {"text": "combination", "start": 72, "end": 83, "id": 12, "ws": true}, {"text": "on", "start": 84, "end": 86, "id": 13, "ws": true}, {"text": "extrapancreatic", "start": 87, "end": 102, "id": 14, "ws": true}, {"text": "organ", "start": 103, "end": 108, "id": 15, "ws": true}, {"text": "injuries", "start": 109, "end": 117, "id": 16, "ws": true}, {"text": "in", "start": 118, "end": 120, "id": 17, "ws": true}, {"text": "caerulein-induced", "start": 121, "end": 138, "id": 18, "ws": true}, {"text": "acute", "start": 139, "end": 144, "id": 19, "ws": true}, {"text": "pancreatitis", "start": 145, "end": 157, "id": 20, "ws": true}, {"text": "in", "start": 158, "end": 160, "id": 21, "ws": true}, {"text": "mice", "start": 161, "end": 165, "id": 22, "ws": true}, {"text": ".", "start": 166, "end": 167, "id": 23, "ws": false}], "spans": [{"start": 29, "end": 39, "token_start": 5, "token_end": 5, "label": "DRUG"}, {"start": 49, "end": 59, "token_start": 8, "token_end": 8, "label": "DRUG"}], "article_link": "https://pubmed.ncbi.nlm.nih.gov/30515205/", "_input_hash": 526527182, "_task_hash": 526499652, "_session_id": "drug_drug_pilot_shared2b-yosi", "_view_id": "blocks", "relations": [{"head": 5, "child": 8, "head_span": {"start": 29, "end": 39, "token_start": 5, "token_end": 5, "label": "DRUG"}, "child_span": {"start": 49, "end": 59, "token_start": 8, "token_end": 8, "label": "DRUG"}, "color": "#96e8ce", "label": "COMB1"}], "radio": [], "answer": "accept"}
